VacCiencia

FINLAY EDICIONES

Boletín Científico

No. 19 (18-31 agosto/2025)

EN ESTE NÚMERO

VacCiencia es una publicación dirigida a investigadores y especialistas dedicados a la vacunología y temas afines, con el ojetivo de serle útil.

Usted puede realizar sugerencias sobre los contenidos y de esa forma crear una retroalimentación que nos permita acercarnos más a sus necesidades de información.

IFV INSTITUTO FINLAY DE VACUNAS

SiViFinlay

VaCyT

Un nuevo enfoque de vacuna basadas en proteínas podría permitir respuestas más rápidas a la Enfermedad X

Una nueva investigación está destinada a investigar un enfoque pionero que utiliza tecnología de marcado de proteínas en nanopartículas, lo que podría acelerar la producción de vacunas contra amenazas epidémicas y pandémicas, incluyendo una futura "Enfermedad X". El diseño de las nanopartículas también podría facilitar una administración de vacunas más potente y específica, y ayudar a reforzar la respuesta inmunitaria.

El equipo de expertos, con sede en la empresa biotecnológica privada POP Biotechnologies, Inc. (POP BIO) , recibirá hasta 1,5 millones de dólares estadounidenses de CEPI para avanzar en la investigación de la plataforma de vacunas basadas en proteínas SNAP™ (Particulación Espontánea de Antígenos en Nanoliposomas) de POP BIO.

Esta tecnología ha sido diseñada para desarrollar rápidamente los candidatos vacunales potentes en nanopartículas, a la vez que purifica antígenos. Se añaden a la vacuna fragmentos de proteínas inertes de un patógeno causante de enfermedad, conocidos como antígenos, para enseñar al sistema inmunitario a reconocerlo y defenderse.

“Los antígenos añadidos a las formulaciones de vacunas deben purificarse para garantizar su seguridad, eficacia y consistencia. Sin embargo, los métodos de purificación convencionales pueden ser costosos e implicar múltiples pasos, que suelen durar varios días, lo que ralentiza el proceso de desarrollo de la vacuna”, afirmó el Dr. Kent Kester, Director Ejecutivo de I+D de Vacunas de la Coalición para las Innovaciones en Preparación para Epidemias (CEPI).

Mediante un enfoque innovador, la tecnología patentada de SNAP utiliza una pequeña etiqueta proteica, denominada polihistidina o His6, que se adhiere a los antígenos de la vacuna (para una técnica de purificación comúnmente utilizada en la investigación básica de proteínas) y también se utiliza para integrarlos en pequeños liposomas esféricos combinados con cobalto metálico para favorecer la respuesta inmunitaria. Gracias a su excelente relación costo-beneficio, se le conoce como una de las etiquetas de afinidad proteica más utilizadas hasta la fecha.



Por su pequeño tamaño, que varía entre cuatro y diez aminoácidos, rara vez interfiere con la función de la proteína diana. Además, su baja inmunogenicidad y versatilidad en condiciones nativas y desnaturalizantes la distinguen de otras. El principio de purificación subyacente de la etiqueta His es la interacción entre los iones metálicos y el anillo imidazol de la histidina.

En comparación con los métodos de purificación tradicionales, esta técnica mejorada podría eliminar rápidamente los posibles contaminantes de los antígenos de la vacuna en tan solo 30 minutos.

“Como cada día cuenta durante un brote incipiente, un desarrollo más rápido de vacunas purificadas podría ayudar a contener con mayor rapidez una amenaza viral nueva o reemergente de rápida propagación antes de que alcance proporciones pandémicas, de acuerdo con la Misión de los 100 Días”, afirma el Dr. Kester.

El versátil diseño "*plug and play*" de SNAP también podría ser beneficioso en un brote, ya que el antígeno procedente del patógeno causante de la enfermedad podría integrarse fácil y rápidamente en la plataforma de la vacuna para un desarrollo y despliegue más rápidos de las vacunas. Con menos etapas y menos

complejas involucradas en su proceso de purificación, la tecnología SNAP también podría ser más eficiente que los métodos tradicionales de purificación de vacunas basadas en proteínas, produciendo mayores rendimientos de antígenos que ayudan a ampliar los suministros de vacunas disponibles y permiten inmunizar a más personas durante un brote.

"El uso dual de la etiqueta histidina para facilitar la purificación de proteínas y luego convertirlas de forma fácil, rápida y estable en potentes candidatos vacunales en nanopartículas ha sido fundamental para el impulso que POP BIO ha alcanzado", afirma Jonathan Lovell, cofundador de dicha compañía biotecnológica. "Es importante destacar que, cuando se utiliza la etiqueta his para anclar proteínas en la superficie de las nanopartículas SNAP, no se produce una respuesta inmunitaria significativa contra la etiqueta en sí, como se observó en pruebas clínicas en humanos".

La tecnología SNAP ya se ha probado en un ensayo a gran escala de fase III de etapa avanzada de la vacuna EuCorVac-19 contra la COVID-19, donde se obtuvieron resultados positivos de seguridad y eficacia. A principios de este año, la revista Cell Biomaterials publicó resultados positivos para una vacuna contra la gripe aviar H5N1 desarrollada con la plataforma SNAP de POP BIO en modelos preclínicos.

El proyecto, explorará primero el potencial de la tecnología para proteger contra el síndrome de fiebre grave con trombocitopenia (SFTS), una enfermedad viral transmitida por garrapatas que afecta a Asia Oriental, en ensayos preclínicos. Liderado por POP BIO, el proyecto será llevado a cabo por un equipo internacional de investigadores de la Universidad de Buffalo y la Universidad Médica SUNY Upstate en EE. UU., así como del Instituto Nacional de Enfermedades Infecciosas, dentro del Instituto Japonés para la Seguridad Sanitaria. CEPI está explorando opciones para seleccionar antígenos para las pruebas de sus socios actuales, incluyendo aquellos que utilizan IA para el diseño de antígenos.

Si el proyecto tiene éxito, la plataforma SNAP tiene el potencial de adaptarse rápidamente para desarrollar candidatos vacunales contra otros patógenos, incluyendo la Enfermedad X.

CEPI y POP BIO se comprometen a facilitar el acceso equitativo a los resultados de su colaboración, de acuerdo con la Política de Acceso Equitativo de CEPI. Los resultados del proyecto, incluyendo los datos relacionados, se publicarán en acceso abierto para beneficio de la comunidad científica mundial.

Acerca de POP Biotechnologies

POP Biotechnologies, Inc. es una empresa biotecnológica privada que desarrolla nuevas terapias y vacunas basadas en su tecnología patentada de liposomas de porfirina-fosfolípido (PoP). La plataforma PoP, con licencia exclusiva de la Fundación de Investigación de la Universidad Estatal de Nueva York (SUNY-RF), fue inventada por el cofundador, el Dr. Jonathan Lovell, en SUNY Buffalo. POP Biotechnologies opera desde la incubadora de SUNY Buffalo en el Parque de Investigación Baird.

Acerca de la tecnología SNAP™ de POP BIO

La tecnología SNAP™ (Particulación Espontánea de Antígenos Nanoliposomales) de POP BIO permite el desarrollo rápido de potentes vacunas basadas en partículas mediante el uso de un sistema de liposomas PoP modificado con cobalto (CoPoP). Esta plataforma permite la presentación estable y espontánea de antígenos proteicos y peptídicos en liposomas, lo que mejora sustancialmente la inmunogenicidad.

Fuentes:

CEPI. Disponible en https://n9.cl/6mvvg

Cube Biotech. The His-Tag: Fundamentals And Principles. Disponible en https://n9.cl/lrlfk

POP BIO. Introducing SNAP: Spontaneous Nanoliposome Antigen Particles. Disponible en https://n9.cl/9xy71

Noticias en la Web

Study Estimates COVID-19 Vaccinations Prevented More Than 2.5 Million Deaths in 2020 to 2024

Aug 18. COVID-19 vaccination during 2020 to 2024 was beneficial, but estimates are more conservative than previous calculations that focused on the first year of vaccinations, according to a study published online July 25 in JAMA Health Forum.

John P.A. Ioannidis, M.D., D.Sc., from the Stanford University School of Medicine in California, and colleagues calculated lives and life-years saved by COVID-19 vaccination worldwide from the onset of vaccination campaigns through Oct. 1, 2024, in a comparative effectiveness study.

The researchers found that more than 2.5 million deaths were averted in the main analysis (one death averted per 5,400 vaccine doses administered); 82 percent were among people vaccinated before any infection. A suggested 1.4 to 4.0 million lives were saved in sensitivity analyses. A preponderance of benefit was seen during the pre-omicron period in some sensitivity analyses. An estimated 14.8 million life-years were saved, with one life-year saved per 900 vaccine doses; the sensitivity range was 7.4 to 23.6 million life-years. Overall, 76 percent of life-years saved were among people aged 60 years or older; only 2 percent of the total was contributed by long-term care residents. Very small contributions to the total benefit were seen for children and adolescents and young adults aged 20 to 29 years (0.01 and 0.07 percent of lives saved, respectively; 0.1 and 0.3 percent of life-years saved, respectively).

“These estimates are substantially more conservative than previous calculations that focused mainly on the first year of vaccination, but clearly demonstrate an important overall benefit from COVID-19 vaccination over the period 2020-2024,” coauthor Stefania Boccia, D.Sc., Ph.D., from the Università Cattolica del Sacro Cuore in Rome, said in a statement.

Most life-years saved were among people aged 60 years or older; estimates are more conservative than those that focused on the first year of vaccination.

Fuente: Hematology Advisor. Disponible en https://n9.cl/ftbr7v

Vaccine line project delays impact SKAN’s bottom line

Aug 21. SKAN Group has come out with its financial results for the first half of 2025.

The Switzerland-based company is a provider of isolators, cleanroom devices, and decontamination processes, primarily focused on the aseptic production of biopharmaceutical substances.

The company stated that H1 was marked by “two contrasting developments”

The two developments concern a very strong order intake, contrasted by weak net sales.

The strong order intake was attributed to filling lines for ADCs (antibody drug conjugates), which SKAN said

were in particularly high demand.

These modern oncology drugs require complex, large-scale aseptic-toxic systems with the highest quality and safety requirements.

SKAN's success rate for tenders for these products was over 40%.

This success delivered order intake at 20.2% above 2024, with the order backlog reaching a record level of CHF 386.4m.

So orders were coming in, but why were sales so low in comparison to 2024.

In terms of incoming money, SKAN attributed the weak performance to project delays. This means that final payments on these can not be taken, so do not contribute to H1. These payments can often be about 20% of total project revenue.

Specifically, these project delays centre around vaccine lines. "This development is primarily attributable to the global shift in vaccine-related demand and strategic priorities by some pharmaceutical companies," SKAN stated. "Several lines ordered during the COVID phase are only slowly being put into operation."

SKAN does believe that it will be able to compensate for these temporary shortfalls in the second half of the year due to its full order books and pipeline.

Other influencing factors in the company's operations this year, were acquisitions and tariffs.

July saw two important majority share acquisitions for SKAN; Metronik and ABC Transfer. These acquisitions focus on digitalisation and aseptic transfer, respectively. Both of these will add significant value to the company's offering in the pharmaceutical industry.

Current developments in US customs policy also represent a challenge to businesses with operations in the US. "[The tariffs] confirm the strategic relevance of the plan to expand the SKAN site in the US and establish local production."

SKAN added that suitable options are currently being evaluated for this US expansion.

Fuente: CLEANROOM TECHNOLOGY. Disponible en https://n9.cl/8fef9

Japan's Takeda weighs India for global trials to speed up drug launches

Aug 22. Japanese drugmaker Takeda Pharmaceutical is exploring conducting global clinical trials in India to speed up the launch of its innovative therapies in the country, its India head told Reuters. The move comes as India's clinical trials market expands, driven by diverse patient pools, cost efficiency, and a rapidly growing hospital network. Grand View Research projects the market to exceed Rs. 17,456 crore (US$ 2 billion) by 2030. General manager of Takeda India, Ms. Annapurna Das, said the company is evaluating opportunities to leverage India's clinical trial ecosystem and is open to partnerships with local academia, healthcare providers, and technology firms to advance innovation. Takeda's goal is to integrate India's research and development ecosystem into its global pipeline while expanding patient access to therapies in oncology, neuroscience, gastrointestinal health, and inflammation.

Takeda plans to launch several key therapies in India over the next two to three years, including a lung cancer

drug this year and a dengue vaccine in partnership with local manufacturer Biological E., awaiting approval from India's drug regulator. The company recently established an innovation centre in Bengaluru, expanding from just over 500 to 750 employees, specialising in artificial intelligence (AI), data science, engineering, and design to support its global digital transformation. This strategic focus on India underscores Takeda's long-term commitment to the country as a growth market. It reflects the increasing role of India in global pharmaceutical research and innovation.

Fuente: India Brand Equity Foundation IBEF. Disponible en https://n9.cl/zx0la

Sanofi's New Vaccine Trial: A Potential Game-Changer for Infant Health

Aug 22. Sanofi is currently conducting a Phase 3 clinical trial to evaluate the safety and effectiveness of a new 21-valent pneumococcal conjugate vaccine (PCV21) in healthy infants and toddlers. The study, officially titled A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group, 2-arm Study to Investigate the Safety and Immunogenicity of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers, aims to determine if PCV21 can safely produce antibodies when administered alongside routine pediatric vaccines.

The trial involves two groups: one receiving the experimental PCV21 vaccine and the other receiving the active comparator, the 15-valent pneumococcal vaccine (Vaxneuvance). Both vaccines are administered via intramuscular injection at specified intervals, with additional routine vaccines given concurrently.

This interventional study follows a randomized, parallel assignment model with quadruple masking to ensure unbiased results. The primary goal is prevention, focusing on the vaccine's ability to generate an immune response.

Key dates for the study include its start on May 22, 2025, with the most recent update submitted on August 19, 2025. These dates are crucial as they mark the progression and current status of the trial.

The outcome of this study could significantly impact Sanofi's market position, potentially boosting investor confidence and stock performance if results are favorable. It also positions Sanofi competitively within the vaccine industry, particularly against other pneumococcal vaccine producers.

The study is ongoing, with further details available on the ClinicalTrials portal.

Fuente: TIP RANKS. Disponible en https://n9.cl/y8lau

Equipo científico chileno está entre los más productivos en avances contra el virus sincitial

22 ago. El virus respiratorio sincitial (VRS) es la principal causa de infecciones agudas respiratorias en niños menores de 2 años en el mundo. Una reciente publicación científica de *Frontiers* hizo una revisión sistemática y un análisis bibliométrico de los últimos cinco años, para determinar las características, puntos críticos y fronteras de la producción científica mundial.

El profesor Alexis Kalergis, director del Instituto Milenio en Inmunología e Inmunoterapia (IMII), -equipo que actualmente está desarrollando la primera vacuna chilena contra el VRS- aparece en los top 10 de autores más productivos en este campo de investigación del mundo. El grupo de científicos que está desarrollando la primera vacuna chilena contra el virus respiratorio sincicial, que lidera el académico, contribuyó un número

importante de publicaciones de alto impacto en los últimos 5 años, que han fortalecido conocimiento fundamental sobre el VRS.

Este reporte denominado “Puntos críticos de investigación y tendencias mundiales del virus respiratorio sincitial en los últimos años”, de los autores Xiaoli Tao, Zhuping Ma, Hongxia Yuan, Wei Zhao, Jingyu Liu, Jing Tian, del Centro de Innovación Colaborativa para la Prevención y el Control de Zoonosis, y de la División de Enfermedades Infecciosas del Primer Hospital Afiliado de la Universidad Médica de Jinzhou, China, destacaron los avances donde se recuperó la versión del Science Citation Index Expanded (SCI-Expanded) de la Web of Science Core Collection (WoSCC) para publicaciones e información de registros publicados entre 2020 y 2024.

“Recibimos con mucho agradecimiento y humildad este reconocimiento, el cual es compartido junto a un extenso grupo de colaboradora(e)s y científica(o)s jóvenes que, como equipo, aspiramos a que desde la ciencia que desarrollamos en la universidad podamos impactar positivamente a la sociedad”, manifestó el académico UC. En el reporte se utilizó un paquete de software bibliométrico para analizar los indicadores bibliométricos, y las tendencias de investigación y los puntos críticos del VRS se visualizaron mediante VOSviewer y Citespace. Se evaluó la influencia de los artículos con el Global Citation Score (GCS). Se buscaron un total de 7.238 artículos y comentarios.

“Este equipo ha demostrado que, a través de la investigación científica básica, fundamental, aplicada y clínica, y su difusión, podemos aportar al desarrollo de políticas públicas en la búsqueda de una mejor calidad de vida para nuestra población, a nivel nacional e internacional. La importancia que reviste el reconocimiento que se nos hace como grupo es destacar el aporte científico que realizamos desde nuestro país hacia el mundo y que se basa en la calidad de las publicaciones y el impacto de nuestra investigación científica en varias disciplinas, lo que además reconoce el gran potencial científico que tiene nuestro país”, agregó el experto.

Estados Unidos es el país más productivo en el campo de la investigación sobre el VRS y también el país con la cooperación más estrecha con otros países e instituciones. La revista más influyente en este campo es “VIRUSES BASEL”, con 246 publicaciones.

El análisis de cocitación de referencias mostró que los temas relacionados con el VRS con mayor enfoque son: "pandemia de COVID-19"; "prefusión del virus respiratorio sincitial"; "academia estadounidense" y "vacuna proteica". De 2020 a 2024, los análisis de grupos y ráfagas de palabras clave mostraron que "Virus Respiratorio Sincicial", "Infección" y "Niños"; "Coinfección viral", "antivirus" y "vacunas" son actualmente focos de investigación. El área de investigación en este campo se distribuye principalmente entre "Inmunología", "Pediatría", "Farmacia”, “Farmacéutica" y "Bioquímica Biología Molecular".

Fuente: Pontificia Universidad Católica de Chile. Disponible en https://n9.cl/8s685y

Evolving Perspectives on Pneumococcal Vaccination Across Adult

Aug 25. Community-acquired pneumonia is one of the leading infectious causes of hospital admission; further, it is associated with high rates of morbidity and mortality. *Streptococcus pneumoniae* remains the most common bacterial cause of pneumonia, accounting for approximately 227,000 hospitalizations annually and an estimated 25% mortality rate within 1 year of hospitalization. Additional compli-cations of pneumococcal disease can range from non-invasive syndromes (acute otitis media, sinusitis) to invasive pneumococcal disease (IPD), including meningitis and bacteremia.

Prevention of pneumococcal disease through routine vaccination has led to substantial declines in IPD, particularly in serotypes covered in the pneumococcal conjugate vaccines (PCV). Since 2010, the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) has recommended the routine use of the 13-valent pneumococcal vaccine (PCV-13) for all children aged 14 to 59 months. This recommendation has led to direct declines in PCV-13 serotype pneumococcal disease in children and an indirect decline in adults, highlighting the importance of vaccination efforts to protect at-risk patients. Adults at highest risk of IPD include those older than 50 years, those aged 19 to 49 years who smoke or have certain comorbidities (eg, heart disease, diabetes, chronic obstructive pulmonary disease), and immuno-compromised individuals. Additionally, racial disparities in pneumococcal disease continue to dispro-portionately affect certain groups, with IPD rates higher in non-Hispanic Black and non-Hispanic American Indian or Alaska Native adults compared to the general population.

To mitigate IPD caused by non–PCV-13 serotypes, several new pneumococcal vaccines have been approved for the prevention of IPD, including a 15-valent (PCV-15), 20-valent (PCV-20), and 21-valent (PCV-21) pneumococcal vaccine. Based on the CDC's Active Bacterial Core Surveillance, approximately 54% to 62% and 77% to 85% of IPD cases between 2018-2022 were due to pneumococcal vaccine serotypes contained in PCV-20 and PCV-21, respectively. Unfortunately, overall risk-based pneumococcal vaccination coverage among adults remains low, with only 22% of adults aged 19 to 64 years who have risk factors receiving at least 1 dose of pneumococcal vaccine. Rates of vaccination additionally differ by race and health care accessibility, with vaccination rates generally lower among Black or Hispanic adults and those without a usual place to receive health care.

Expanding Protection: ACIP's Latest Adult Pneumococcal Vaccine Recommendation

As of October 23, 2024, the ACIP expanded the recommended use of a PCV from the previous recommendation of adults 65 years or older to include all PCV-naïve adults 50 years and older. The recommend-ation for PCV in adults aged 19 to 49 years with risk factors remains unchanged.12,15 Available vaccine options include PCV-15 (Vaxneuvance; Merck), PCV-20 (Prevnar 20; Pfizer), and PCV-21 (Capvaxive; Merck). The 3 PCVs offer protection against different pneumococcal serotypes. If PCV-15 is selected, administration of pneumococcal polysaccharide vaccine (PPSV-23) is recommended at least 1 year later (or at least 8 weeks later if the patient is immunocompromised) to confer protection against 8 additional serotypes not covered in PCV-15.15,17 If PCV-20 or PCV-21 is used, a follow-up PPSV-23 dose is not needed, as these 2 vaccines confer broader protection of prevalent serotypes compared to PCV-15.

Of note, PCV-20 confers protection against the same 15 serotypes as PCV-15 plus 5 additional serotypes. Although PCV-21 offers more broad protection against 11 serotypes not prevalent in PCV-15 or PCV-20, it does not include serotype 4; this is an important consideration in regions such as the western United States, where this serotype remains highly prevalent among adults younger than 65 years who smoke, are homeless, use injectable drugs, or have underlying conditions (eg, alcoholism, chronic lung disease). Vaccine selection should take into account local serotype distribution and individual patient risk factors. Individuals who previously started the pneumococcal vaccine series with PCV-13 or PPSV-23 should receive an updated PCV vaccine; timing and product selection will vary depending on the initial vaccine received.

The expansion of the recommendation for PCV administration to adults at least 50 years of age aims to reduce disease burden in patients aged 50 to 64 years, increase access to preventative care in patients at high risk for IPD, and reduce racial disparities seen in IPD. The shift in recommendation for the administration of expanded serotype vaccines (eg, PCV-20, PCV-21, or PCV-15 plus PPSV-23 instead of PCV-13) is designed to combat the substantial burden of non–PCV-13 serotypes that account for 42% and 75% of IPD in children and adults, respectively.18 The expanded age recommendation attempts to ensure that patients at moderate to high risk for IPD are readily identified and able to access vaccines. Previous data suggested that over 80% of patients aged 50 to 64 years who were hospitalized with pneumococcal pneumonia had at least 1 risk factor (eg, heart disease, lung disease, liver disease, diabetes) that put them at higher risk of IPD. According to 2022 Behavioral Risk Factor Surveillance System Data, among the general population, an estimated 32% to 54% of adults aged 50 to 64 years qualify for a risk-based pneumococcal vaccine, although only an estimated 37% of eligible adults aged 50 to 64 years were vaccinated. Rates of vaccination were higher in patients older than 65 years who were identified based on an age cutoff instead of a risk-based system, suggesting that a streamlined age-based approach may be easier to follow.

In addition to capturing patients at high risk based on comorbidities, previous data suggested that peak rates of IPD occur at a younger age (55-59 years) in Black males, highlighting a population that previously would not have been identified as candidates for pneumococcal vaccination using comorbidity-based risk assessment. By simplifying the PCV recommendation to include adults older than 50 years, patients who would benefit most from pneumococcal vaccination may be more readily identified, which may help reduce pneumococcal-associated morbidity and mortality and improve public health.

Clinical Considerations for Pharmacists

Pharmacists can play a key role in preventing pneumococcal infection by administering pneumococcal vaccines in the community and health care settings. Identifying patients eligible for pneumococcal vaccination should involve stepwise decision-making. Key factors to consider include age, underlying medical conditions, and vaccine history.

For adults at least 50 years of age or aged 19 to 49 years with risk factors (alcoholism, chronic heart disease, chronic liver disease, chronic lung disease, cigarette smoking, or diabetes) who have not previously received a pneumococcal vaccine, PCV-15, PCV-20, or PCV-21 should be administered. If PCV-15 is administered, an additional dose of PPSV-23 is required in at least 1 year, making this approach less preferable for patients with limited health care access. For special populations (eg, patients with an immunocompromising condition, cochlear implants, or cerebrospinal fluid leaks) who have not previous received a pneumococcal vaccine, PCV-15, PCV-20, or PCV-21 may be administered, although PCV-15 should be followed by PPSV-23 in 8 weeks or more, compared to at least 1 year in non-immunocompromised patients.

Additional considerations for selection between pneumococcal vaccines, particularly PCV-20 and PCV-21, include the patient's geographic location, as serotype protection differs between vaccines. For areas where more than 30% of IPD is caused by serotype 4, PCV-20 or PCV-15 followed by PPSV-23 at least 1 year later is preferred, as PCV-21 lacks serotype 4 protection. For all other areas, both vaccines are viable options, although PCV-21 offers broader coverage of more serotypes compared to PCV-20. Streamlined vaccine recommend-ations may make vaccinations more readily offered and available during routine pharmacist interactions.

For patients who previously started the pneumococcal vaccine series, the timing and selection of vaccine will differ depending on the prior vaccine schedule. For adults who previously were given PPSV-23 only, a single dose of PCV-15, PCV-20, or PCV-21 should be administered at least 1 year after the last PPSV-23 dose. For adults who previously were given PCV-13 only, a single dose of PCV-20 or PCV-21 is recommended at least 1 year after PCV-13, and PPSV-23 is no longer needed. For adults who were given PCV-13 and PPSV-23 (1 or 2 doses), a single dose of PCV-20 or PCV-21 may be recommended 5 years or longer after the last pneumococcal vaccine depending on age, risk factors, and shared clinical decision-making.

Fuente: Drug Topics. Disponible en https://n9.cl/e099zk

Vaccine Integrity Project Fills Information Gap

Aug 26. This fall, guidance for protection against the flu, COVID, and other respiratory infections remains consistent with previous years, with no new safety signals, based on evidence reviewed by the Vaccine Integrity Project and presented in an online webinar.

The Vaccine Integrity Project (VIP) was created by the University of Minnesota's Center for Infectious Disease Research and Policy (CIDRAP) to provide evidence on vaccine safety and effectiveness as a resource for clinicians and for medical societies.

Overall, the experts found that vaccination against COVID, respiratory syncytial virus (RSV), and influenza yielded similar or better outcomes compared to no vaccination. Additionally, the VIP experts found no sufficient evidence of new safety signals to justify the CDC's rescinding of the previous recommendation to vaccinate pregnant women and healthy children against COVID this season, said CIDRAP director Michael Osterholm, PhD, MPH, in a press release.

The VIP is a response to the gaps left by federal changes that have altered the dissemination of evidence-based scientific information, according to CIDRAP. In advance of the upcoming respiratory virus season, the VIP presented its first live-streamed webinar on August 19 with data on influenza, COVID, and RSV vaccines, focusing on indications for pregnant women, children, and immunocompromised individuals.

For the presentation, a team of 24 infectious disease experts and epidemiologists reviewed data from 1406 full-text articles published within the last few years and identified 590 for detailed examination. Jake Scott, MD, of Stanford University, established the VIP's credentials by reviewing their strict research criteria and outlined the specific safety events analyzed for three vaccines of interest: COVID vaccines, RSV vaccines and antibodies, and influenza vaccines.

Pregnancy Protection

Some infections, such as influenza, are more severe during pregnancy and in fact may increase the risk of adverse outcomes, including preterm birth and stillbirth, said Caitlin Dugdale, MD, an infectious diseases physician at Massachusetts General Hospital and assistant professor of medicine at Harvard Medical School, Boston. Dugdale presented the VIP's evidence base for vaccines in pregnancy.

The researchers focused on safety and effectiveness of COVID, RSV, and influenza, and found no studies with new epidemiologic trends related to RSV or influenza; the one study involving epidemiology of COVID showed a 7% incidence of long COVID among vaccinated pregnant patients compared to a 12% incidence among unvaccinated pregnant patients. As for COVID vaccine safety, no concerns were identified for outcomes of miscarriage, stillbirth, or congenital anomalies with either the Pfizer or Moderna vaccines, she said.

Considerations for Children

Harleen Marwah, MD, a pediatrician at Mass General Brigham for Children, presented the evidence review for the flu, COVID, and RSV vaccines in children.

Children are especially vulnerable to respiratory infections because they are in critical stages of development, Marwah said. The VIP experts reviewed data on myocarditis and Guillain-Barré syndrome associated with COVID vaccination. The studies of myocarditis were consistent with previous research, and new data showed that risk decreased with subsequent booster doses, she said. Similarly, pediatric studies of co-administered COVID mRNA vaccines and flu vaccines showed no increased risk of serious adverse events.

Immunocompromised Individuals

Michael Abers, MD, a physician scientist at Albert Einstein College of Medicine, New York City, presented the evidence base for vaccination of immunocompromised individuals against COVID, RSV, and influenza.

Vaccines work by training the immune system to more rapidly recognize pathogens, but someone with a compromised immune system may be less responsive to vaccination, Abers said in his presentation.

However, the most recent data showed that vaccines for COVID were similarly safe and effective among immunocompromised individuals and the general population. The RSV vaccine was especially effective among patients with solid organ transplants, he noted. The flu vaccine, while slightly less effective among immunocompromised individuals compared to immunocompetent individuals, was still effective, he said.

Support for Society Guidelines

The goal of the VIP webinar was to assemble information that could be shared with professional societies to make recommendations, Abers said in a discussion period.

Based on the data reviewed by the VIP, the American Academy of Pediatrics (AAP) released its own recommended childhood vaccination schedule, independent of the CDC. Other societies, including the Infectious Diseases Society of America, the American College of Obstetricians and Gynecologists, and the American Academy of Family Physicians, are expected to release independent vaccine guidelines based on the VIP evidence review.

Evidence Clinicians Need

"The work of the Vaccine Integrity Project is urgently needed because of the myriad questions [about vaccines] that have now been raised," David J. Cennimo, MD, associate professor of medicine & pediatrics at Rutgers New Jersey Medical School in Newark, told Medscape Medical News.

"Unfortunately, the past work of ACIP and CDC which has been grounded in vaccine science and public health has been destabilized, often with unfounded speculations and misinterpretation of data," said Cennimo, who is not involved in the VIP.

"I commend CIDRAP and Dr Osterholm for their steadfast leadership and commitment to protecting the nation's health," Cennimo added. "They have worked to recreate the unbiased, evidence-based research presentations that characterized the ACIP's gold standard of open debate." The medical community will need these data not only to make informed decisions, but also to support educated and informed discussions for shared decision-making with parents and families, he said.

"For instance, the safety and efficacy of COVID vaccines in children are actually supported by a plethora of data, contrary to recent reports," he said.

"As clinicians, we must become familiar with these debates as well as the incorrect messages permeating our media," Cennimo told Medscape Medical News. He expressed confidence that the AAP and other medical organizations will strengthen the vaccine message, but also expressed concerns about vaccine funding, which is tied to CDC recommendations.

Fuente: Medscape. Disponible en https://n9.cl/z6gh5

ImmunoPrecise Advances AI Discovered and Developed Universal Dengue Vaccine Initiative: Moves into Preclinical Antibody Generation

Aug 27. ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ("IPA" or the "Company"), a biotherapeutics company delivering advanced solutions in biologics and drug discovery today announced the next milestone in its universal dengue vaccine program. Building on its June announcements confirming the discovery and validation of a uniquely conserved dengue epitope using its LENSai™ platform powered by patented HYFT® technology, the Company has updated that they are now advancing to pre-clinical manufacturing for *in vivo* (in animal) testing and virus neutralization analysis.

The manufactured product will be used in proprietary immunization protocols at IPA's Canadian facility. These studies, conducted in a rabbit model, are designed to evaluate whether the vaccine candidate elicits robust monoclonal antibody (mAb) responses—a crucial step toward translational development.

"This is the natural next step in our journey from AI discovery to real-world validation," said Dr. Jennifer Bath, CEO of ImmunoPrecise. "We've shown that HYFT technology can identify vaccine targets that others miss — unique targets that are conserved, specific, and immunologically relevant. Now we're now moving into manufacturing and live immunization studies, where the question becomes: can this target elicit a powerful and protective antibody response? This is where discovery turns into translational reality, with dengue as the first example of what our platform can achieve across infectious diseases."

The science behind the step:

- AI Discovery → Manufacturing: HYFT-guided analysis revealed a discontiguous dengue epitope conserved across all four virus serotypes.

- Validated Safety & Immunogenicity: In silico screens confirmed immune activation potential (B- and T-cell responses), structural stability, and comprehensive safety against host proteomes.
- Now Entering Immunization Studies: The product is being synthesized and will be used in rabbit models to assess whether it elicits specific monoclonal antibodies — an essential proof point for vaccine development.

A platform approach, not just a vaccine:

This progression highlights IPA's end-to-end advantage: combining AI-native discovery with in-house wet-lab validation. With regulators like the U.S. FDA encouraging predictive, human-relevant approaches that reduce reliance on animal testing, ImmunoPrecise's in silico-to-in vivo workflow represents a forward-looking model for next-generation vaccine R&D.

By applying the same methodology across pathogens, IPA is positioning its LENSai/HYFT platform as a versatile discovery engine — not only for dengue, but also for other infectious diseases and immuno-oncology targets.

About ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) is a biotherapeutics company focused on the discovery and development of next-generation biologics. The Company combines scientific expertise with proprietary technologies—such as its LENSai™ platform—to accelerate drug discovery and improve decision-making across complex biological systems. IPA supports global partners in advancing novel therapeutics, diagnostics, and translational research. For more information, visit www.ipatherapeutics.com

Fuente: MORNING STAR. Disponible en https://n9.cl/wjqggt

Boosting mRNA Vaccines with Cutting-Edge Technology

Aug 27. Messenger RNA (mRNA) vaccines revolutionized public health during the COVID-19 pandemic, representing a groundbreaking shift away from traditional vaccine design. Unlike conventional vaccines that introduce weakened or inactivated viruses to train the immune system, mRNA vaccines operate on a genetic blueprint level. They deliver encoded instructions directly into human cells, enabling these cells to produce viral proteins that then trigger an immune response. This innovative method allowed Pfizer-BioNTech and Moderna to rapidly develop highly effective COVID-19 vaccines, setting the stage for a new era in vaccinology.

Building on this success, researchers at Yale University have now unveiled a novel technological advance that enhances the immunogenic power and effectiveness of mRNA vaccine platforms.

This breakthrough, recently detailed in the prestigious journal Nature Biomedical Engineering, promises to significantly broaden the potential applications of mRNA vaccines beyond infectious diseases like COVID-19, extending to challenging conditions such as cancer and autoimmune disorders. The team, led by Sidi Chen, associate professor of genetics and neurosurgery, sought to understand why mRNA vaccines, despite their triumphant pandemic debut, often underperformed in clinical trials for other diseases.

A critical bottleneck identified by the researchers lies in the behavior of antigens — the molecular flags

presented by infected or abnormal cells that alert the immune system. For an antigen to be effectively recognized and to induce a robust immune response, it must be displayed on the surface of cells. However, Chen and his team discovered that many antigens generated through mRNA vaccines remain trapped inside the cell's interior, inaccessible to immune surveillance. This intracellular sequestration critically limits the vaccine's capacity to provoke a protective immune response, hindering its efficacy against a range of diseases.

To overcome this challenge, Yale scientists engineered a sophisticated molecular vaccine platform (MVP) that effectively upgrades the delivery and presentation of vaccine-derived antigens. Their approach involves fusing what they refer to as a "cell-GPS" module to the proteins produced by mRNA instructions. This GPS-like component comprises natural membrane-associated elements such as signal peptides and transmembrane anchors, which are essential in normal biological processes for directing proteins to their correct cellular locations — namely, the cell membrane.

Signal peptides are short amino acid sequences that act like postal codes, guiding the nascent proteins through cellular trafficking pathways to ensure they reach the surface. Transmembrane anchors secure these proteins to the extracellular membrane, stabilizing their position where immune cells can detect them. Incorporation of these elements into the vaccine design guarantees that the antigens will be displayed robustly on the cell surface, vastly improving immune visibility and subsequent activation of both antibody- and T cell-mediated responses.

In rigorous laboratory experiments, this MVP framework was tested across multiple disease models including mpox virus (formerly monkeypox), human papillomavirus (HPV), and the varicella-zoster virus responsible for shingles. Remarkably, the enhanced antigen expression translated into significantly amplified immune responses: elevated levels of neutralizing antibodies, greater activation of cytotoxic T lymphocytes, and improved overall immunogenicity. These results underscore the platform's versatility and its potential to redefine mRNA vaccine effectiveness against a spectrum of viral infections and potentially malignant conditions.

The implications of this research extend far beyond virology. By ensuring precise antigen localization, the MVP technology addresses one of the principal limitations that have constrained the broader adoption of mRNA vaccines in oncology and immunology. Diseases such as cancer and autoimmune disorders, which require a finely tuned immune activation profile, may profoundly benefit from this targeted approach. Chen emphasizes that this innovation represents a foundational step toward expanding the versatility of mRNA-based immunotherapies.

Moreover, the platform's modular nature allows for rapid adaptation to different antigens and disease targets, a crucial advantage in the battle against emerging pathogens and evolving health threats. This flexibility is particularly vital given the increasing incidences of viral mutations and the complexity of tumor-associated antigens. By integrating natural cellular machinery into vaccine design, the researchers have crafted a robust system that harmonizes synthetic biology with immunological precision.

The study also benefits from a collaborative environment at Yale, involving interdisciplinary expertise from immunobiology, molecular biophysics, and therapeutic radiology. Co-senior authors Carolina Lucas and Daniel DiMaio contribute insights from their respective fields, enriching the study's multi-faceted approach to solving complex biological challenges. Their combined efforts highlight the importance of integrating diverse scientific perspectives to overcome hurdles in next-generation vaccine development.

As the scientific community intensifies the push for more effective immunization strategies, the MVP platform constitutes a critical advance in mRNA vaccine science. It not only revitalizes interest in mRNA technology for diseases that have eluded effective vaccination but also inspires confidence in the adaptability of this platform for future biomedical applications. The fusion of natural protein trafficking elements with lipid nanoparticle mRNA delivery opens new avenues for precision immunotherapy, with the promise to uplift global health outcomes.

Looking ahead, clinical translation of this innovative vaccine platform will require extensive validation in human trials to confirm safety, immunogenicity, and efficacy. Nonetheless, the promising preclinical results afford optimism. With improved antigen presentation capability, vaccines developed through MVP technology could lead to a new generation of preventive and therapeutic measures against a broad array of infectious agents and immune-related diseases.

This breakthrough exemplifies how fundamental insights into cellular biology can be harnessed to refine and expand the capabilities of revolutionary technologies like mRNA vaccinology. The research team plans to further explore applications of their platform, aiming to tackle formidable health challenges including HIV and autoimmune conditions. Their work not only furthers scientific understanding but also paves the way for tangible innovations in medicine poised to transform disease prevention and treatment worldwide.

Fuente: Bioengineer.org. Disponible en https://n9.cl/wzkjt

La OPS llama a reforzar vacunación y vigilancia ante la propagación de resistencia de la tosferina a los antibióticos en las Américas

27 ago. Frente al resurgimiento de la tosferina en varios países de la región y la aparición y propagación de cepas resistentes a los antibióticos, la Organización Panamericana de la Salud (OPS) reiteró la importancia de fortalecer la vacunación y los sistemas de vigilancia. La preocupación fue compartida durante una reunión reciente con la Red Latinoamericana y del Caribe de Vigilancia de la Resistencia a los Antimicrobianos (ReLAVRA+), en la que se discutieron los hallazgos más recientes y las estrategias de respuesta frente a esta enfermedad altamente contagiosa.


iStock/Vadym Terelyuk
Imagen

"La vacunación, la vigilancia y el uso responsable de los antibióticos son fundamentales para evitar que la tosferina vuelva a convertirse en una amenaza grave de salud pública", afirmó Pilar Ramón-Pardo, jefa del Programa Especial de Resistencia Antimicrobiana de la OPS. "Aún estamos a tiempo de contener este problema, pero necesitamos actuar: aumentar la cobertura vacunal, fortalecer la detección temprana y mejorar nuestra capacidad de respuesta ante brotes", añadió.

Uno de los principales desafíos es que el tratamiento habitual se basa en antibióticos del grupo de los macrólidos, como la azitromicina, claritromicina y eritromicina. Sin embargo, mutaciones genéticas en la bacteria, particularmente en el gen 23S rRNA, están reduciendo la eficacia de estos medicamentos, dificultando el tratamiento de pacientes y la prevención en contactos cercanos.

Durante la pandemia de COVID-19, el uso extensivo e inadecuado de antibióticos como la azitromicina pudo haber contribuido a la aparición de cepas resistentes de Bordetella pertussis. Desde 2024, se han reportado casos en Brasil, Estados Unidos, México y Perú. Su detección fue posible gracias al fortalecimiento de los sistemas de vigilancia y diagnóstico, que incluyen el uso de pruebas moleculares y métodos estandarizados en laboratorios de referencia. Este avance, apoyado por alianzas internacionales, ha sido clave para identificar y contener estos casos.

Dado el uso generalizado de estos antibióticos y la alta movilidad internacional, existe el riesgo de una propagación más amplia si no se refuerza la respuesta sanitaria.

La resistencia a los antimicrobianos (RAM) ocurre cuando las bacterias desarrollan mecanismos para evadir el efecto de los medicamentos, volviéndolos ineficaces. En el caso de la tosferina, esto puede limitar las opciones de tratamiento, dificultar el control de brotes, y aumentar el riesgo de complicaciones graves, especialmente en contextos con baja cobertura vacunal.

Coberturas de vacunación en descenso

La tosferina, también conocida como coqueluche o tos convulsiva, puede prevenirse con tres dosis de la vacuna DPT en niños menores de un año, y refuerzos durante la infancia y la adolescencia. Aun así, en personas infectadas —especialmente en lactantes— puede causar cuadros graves, con riesgo de complicaciones o incluso la muerte.

La enfermedad ha resurgido con fuerza en las Américas. Mientras en 2023 se notificaron 4.139 casos, en 2024 la cifra ascendió a 43.751. En los primeros siete meses de 2025, nueve países han reportado más de 18.595 casos y 128 defunciones. Este resurgimiento está relacionado con la disminución de las tasas de vacunación y resalta la necesidad de reforzar la vigilancia activa y estandarizada.

Durante la pandemia, las coberturas regionales de la primera dosis (DTP1) y la tercera (DTP3) cayeron a mínimos históricos: 87% y 81% en 2021, respectivamente. En 2023 se observó una recuperación parcial (90% y 88%), aunque aún por debajo del 95% recomendado por la OPS y con disparidades significativas dentro de los países. Además de la vacunación infantil, la OPS también recomienda vacunar a las embarazadas —especialmente en contextos de brote— y al personal de salud que está en contacto con recién nacidos.

Laboratorios fortalecen la vigilancia

Fortalecer los laboratorios nacionales de referencia con métodos de diagnóstico confiables y estandarizados es esencial para detectar la resistencia de manera oportuna y guiar la respuesta de las autoridades de salud. Iniciativas colaborativas como la red ReLAVRA+ y la Red de Vigilancia Genómica Regional (PAHOgen) de la OPS, junto con otras alianzas estratégicas, han permitido estandarizar metodologías y ampliar la capacidad de vigilancia en varios países de la región.

Como parte de su cooperación técnica, la OPS organizó el 19 de agosto un seminario virtual de la red ReLAVRA+, que reunió a laboratorios nacionales de referencia y especialistas en microbiología de la región. Durante el encuentro, expertos de Colombia, México, Brasil y Perú compartieron hallazgos recientes, metodologías para detectar cepas resistentes y estrategias de vigilancia y respuesta.

Ante este panorama, la OPS insta a los países a fortalecer el diagnóstico, reforzar la formación técnica del personal de salud, mantener o incrementar las coberturas de vacunación, y establecer sistemas de vigilancia activos y estandarizados que permitan una respuesta ágil y eficaz frente a la resistencia a antimicrobianos.

Fuente: Organización Panamericana de la Salud OPS. Disponible en https://n9.cl/k5em4

Raina Biosciences unveils breakthrough generative AI platform for mRNA therapeutics featured in Science

Aug 28. Raina Biosciences Inc., ("Raina"), an mRNA technology and therapeutics company, today announced the publication of data from its generative AI platform in Science. The data supports Raina's pioneering approach to mRNA design using its GEMORNA platform to generate novel sequences with superior drug properties over existing mRNA discovery methods. Founded by a team with deep RNA therapeutics and AI expertise, the Company's mission is to transform the mRNA-based therapeutics landscape by accelerating drug discovery timelines and opening new therapeutic areas for mRNA with best-in-class AI-designed therapeutics.

The Science article, titled, "Deep generative models design mRNA sequences with enhanced translational capacity and stability," marks a significant landmark for optimizing novel mRNAs with enhanced expression and durability to facilitate a wide range of therapeutic mRNA applications.

The article, which was published online today by the journal *Science*, is summarized as follows:

⇒ Raina's GEMORNA platform designs superior linear and circular mRNA drug molecules with optimized expression levels and durability, addressing two major issues that have limited the effectiveness of mRNA-based therapeutics

⇒ GEMORNA is highly differentiated from prior RNA language models developed for predictive tasks through its direct design of novel sequences from a near infinite design space

⇒ GEMORNA-generated mRNAs:

- Elicited significantly higher immune response in mice compared to a leading commercially available mRNA vaccine sequence, potentially supporting mRNA therapeutic vaccine applications for diseases such as cancer
- Achieved up to a 150-fold increase in human erythropoietin (hEPO) expression compared to an optimized benchmark, potentially supporting mRNA medicines for gene therapy
- Demonstrated a 5-fold increase in CD19 CAR expression and a 2-fold improvement in durability compared to a patented benchmark, resulting in nearly 100% anti-tumor efficacy in primary human T cells, potentially supporting mRNA therapies for in vivo CAR-T

"Raina's GEMORNA platform is built upon a decade of the team's foundational work in synthetic biology and artificial intelligence," said Jicong Cao, Ph.D., Chief Executive Officer and co-founder of Raina Biosciences, and corresponding author of the Science paper. "We are excited to work with industry-leading pharma and biotech companies to expand the usage of mRNA-based therapeutics while we prepare to build an internal pipeline."

"Raina has the potential to transform mRNA therapeutics by rapidly and reliably generating novel sequences with greater performance, precision and efficacy," said Timothy Lu, M.D., Ph.D., Raina's Chairman of the Board and former MIT faculty member. "The GEMORNA platform could be a sea change for biopharma companies pursuing mRNA-based medicines beyond traditional infectious disease vaccines ranging from neoantigen cancer vaccines, in vivo CARs, to gene editing or gene therapy applications."

Based in Boston, Raina Biosciences is a spinout company from the Massachusetts Institute of Technology

(MIT), founded by leaders in mRNA and AI with a strong track record in the biotech industry. Jicong Cao, Ph.D. (co-founder, Chief Executive Officer) is a former mRNA researcher at MIT and co-founder of Bota Biosciences. He Zhang, Ph.D. (co-founder, Chief Technology Officer and first author of the Science paper) was previously a Senior Staff Scientist at Baidu Research. Timothy Lu, M.D., Ph.D., Raina's co-founder and Chairman of the Board, is a serial biotech entrepreneur having co-founded a number of biotechnology and biopharmaceutical companies, and served on the MIT faculty from 2010–2022. Joel Edwards, Chief Corporate Development Officer, brings over 25 years of leadership in corporate strategy and deal-making across biotech, including his tenure as Vice President of Corporate Strategy at Ionis Pharmaceuticals. Raina is also supported by its key scientific advisor Jeff Coller, Ph.D., Bloomberg Distinguished Professor and Inaugural Director of the RNA Innovation Center at Johns Hopkins University. Raina closed an angel round of $5.7 million upon company formation.

About Raina Biosciences

Raina is pioneering the world's first and leading generative AI platform for mRNA-based therapeutics. Using its proprietary platform, GEMORNA, Raina navigates new frontiers in mRNA engineering to design sequences with optimal profiles for expression, durability, and stability. Raina is partnering with leading pharma and biotech companies to create next generation and best-in-class mRNA-based therapeutics.

Fuente: EurekAlert. Disponible en https://n9.cl/9yooj

Biotecnológica mixta Cuba-Vietnam elevará producción de fármacos

29 ago. La producción conjunta de medicamentos esenciales para Cuba y Vietnam, así como exportar a naciones de Asia y el mundo figura entre los objetivos esenciales de la empresa mixta Genfarma, destacó este viernes BioCubafarma en un comunicado.

Establecida en Vietnam, fue creada tras la firma del acuerdo constitutivo el pasado 19 de mayo de 2025 entre BCF S.A. (de BioCubaFarma) y la empresa vietnamita Genfarma Holdings, destacó la institución cubana en un comunicado.

En ocasión de la visita de la presidenta de BioCubaFarma Mayda Mauri a esa nación asiática la empresa resaltó que Genfarma representa un modelo de cooperación en el sector biofarmacéutico que presenta, además, entre sus objetivos, la transferencia tecnológica para llevar tecnología médica cubana de vanguardia a Vietnam, con una clara vocación internacional.

Este aspecto es fundamental para la sostenibilidad económica del proyecto y para cumplir con su objetivo de generar ingresos que serían utilizados en el desarrollo de la industria y la producción de medicamentos para la población cubana, subraya el comunicado.

La visita de la presidenta Mayda Mauri Pérez a la empresa mixta en Vietnam representa un paso significativo en la materialización de este proyecto estratégico para ambos países.

Esta iniciativa no sólo fortalece los lazos históricos entre Cuba y Vietnam, sino que establece un modelo innovador de cooperación sur-sur en el sector de la biotecnología farmacéutica, con potencial para impactar positivamente en la salud de ambos pueblos y de la región asiática.

La concreción exitosa de esta empresa mixta demostrará cómo naciones hermanadas pueden desarrollar proyectos mutuamente beneficiosos que aprovechen las capacidades científicas y tecnológicas para el bienestar de sus poblaciones, destacó el texto.

Mega-empresa de casi 12 años de fundación, BioCubaFarma se consolida como entidad de ciclo cerrado que investiga, desarrolla, produce, comercializa, o sea, desde la gestación del producto, hasta que llega al paciente.

En su gestión sustentable y sostenible garantiza todo lo necesario para el cuidado de la salud de los cubanos, exporta medicamentos, medios y sistemas diagnósticos, equipos médicos, tecnologías de avanzada en la producción de medicamentos y alimentos, así como servicios de alta tecnología.

Fuente: Cuba MinRex. Disponible en https://n9.cl/frrka6

Ente africano lanzó proyecto sobre respuesta ante pandemias

29 ago. La Autoridad Intergubernamental para el Desarrollo (IGAD) lanzó en Uganda el Proyecto de Preparación y Respuesta ante Pandemias, una iniciativa que fortalecerá la vigilancia, alerta temprana y sistemas de laboratorios para mejorar la resiliencia regional.

En la estrategia de tres años participan junto al ente africano el Fondo Pandémico, la Federación Internacional de Sociedades de la Cruz Roja y de la Media Luna Roja y la Organización Mundial de la Salud colaboran en la propuesta.

La jefa de la Misión de la IGAD en Kampala, Joselyn Bigirwa, el proyecto es oportuno y esencial, dada la creciente frecuencia y complejidad de las emergencias de salud pública en el Cuerno de África.

Bigirwa precisó que está centrado en mejorar las funciones transfronterizas críticas, esenciales para salvaguardar la seguridad sanitaria regional.

Este hito subraya el compromiso de la IGAD de salvar vidas, proteger los medios de vida y promover un Cuerno de África más seguro y saludable mediante la acción colectiva, subrayó un comunicado de prensa.

La región del ente africano, integrada por Djibouti, Etiopía, Kenya, Somalia, Sudán del Sur, Sudán del Sur y Uganda, se enfrenta a riesgos persistentes de brotes de enfermedades infecciosas con importantes consecuencias para la salud pública, socioeconómica y mundial.

El texto reconoció que los sistemas sanitarios frágiles se ven continuamente tensados por las epidemias recurrentes, exacerbadas por los altos niveles de circulación transfronteriza de personas, ganado y bienes, lo que aumenta el riesgo de transmisión de enfermedades.

Al margen del lanzamiento, el secretario ejecutivo de la IGAD, Workneh Gebeyehu, entregará suministros y equipos críticos de preparación para pandemias al Ministerio de Salud de Uganda.

Fuente: Granma. Disponible en https://n9.cl/q7xq65

México y Brasil firman acuerdo para producir medicamentos y vacunas

29 ago. Las autoridades sanitarias de México y Brasil firmaron este jueves dos memorándums de entendimiento para impulsar la producción de vacunas y principios activos para desarrollar medicamentos, así como para reforzar la vigilancia epidemiológica y el combate de enfermedades como el dengue.

En un comunicado, la Secretaría de Salud destacó que el acuerdo de colaboración permitirá reforzar la producción nacional de medicamentos esenciales "para garantizar la soberanía sanitaria regional".

La firma de los acuerdos de colaboración se selló entre autoridades sanitarias de ambos países y fue encabezada por el secretario de Salud de México, David Kershenobich, y el vicepresidente de Brasil, Geraldo Alckmin.

El primero de estos acuerdos fue entre la Comisión Federal para la Protección contra Riesgos Sanitarios (Cofepris) y la Agencia Nacional de Vigilancia Sanitaria de Brasil (ANVISA).

Con ello, se busca el reconocimiento recíproco de capacidades regulatorias, lo que permitirá agilizar la homologación de registros sanitarios, facilitar ensayos clínicos y coordinar la certificación de plantas farmacéuticas, incluso en terceros países.

"El reconocimiento mutuo entre ANVISA y Cofepris permitirá acelerar la llegada de nuevas moléculas y medicamentos a la población", dijo el titular de Salud.

El segundo memorándum se celebró entre Laboratorios de Biológicos y Reactivos de México (Birmex) y la Fundación Fiocruz.

Lo anterior permitirá la cooperación en la producción de vacunas y principios activos para desarrollar "medicamentos estratégicos", incluyendo factores de coagulación, albúminas e inmunoglobulinas, vitales para los sistemas de salud de México y Brasil.

La Secretaría de Salud destacó que bajo este acuerdo también se buscará combatir el dengue y otras arbovirosis, mediante el uso de la vacuna desarrollada por el Instituto Butantan, el intercambio de métodos de control biológico y la vigilancia epidemiológica.

Crearán Comité Bilateral de Salud

Para dar seguimiento puntual a estos compromisos y con el fin de que se traduzcan en resultados concretos, se creará un Comité Bilateral de Salud México–Brasil que se reunirán cada mes.

“Celebro este encuentro entre Brasil y México, no sólo de palabra, sino porque están aquí sus delegaciones, la nuestra, y hemos logrado implementar lo que discutimos, asegurando que trascienda en verdaderos proyectos de colaboración en nuestros países. Creo que en la región latinoamericana tenemos una gran responsabilidad”, manifestó David Kershenobich.

El secretario de Salud también resaltó los programas sociales como “Salud Casa por Casa”, que prioriza la atención a personas mayores y con discapacidad, como ejemplos de políticas que pueden inspirar una mayor cooperación sanitaria regional.

“México y Brasil comparten una relación bilateral larga y profunda que está a la altura de nuestras responsabilidades como las dos economías más grandes de América Latina, bajo el liderazgo de la presidenta Claudia Sheinbaum y del presidente Luiz Inácio Lula da Silva, con una visión humanista que prioriza la salud como derecho, el desarrollo científico y tecnológico, y el impulso a la producción local para robustecer la soberanía sanitaria en un escenario geopolítico”, aseguró David Kershenobich.

Por su parte, la titular de Cofepris, Armida Zúñiga, subrayó que estos acuerdos se alinean con el Plan México, impulsado por el gobierno de la presidenta Claudia Sheinbaum.

Fuente: EL ECONOMISTA. Disponible en https://n9.cl/bi1619

FDA approves updated Covid-19 vaccines for limited groups as US cases continue to rise

Aug 31. The U.S. Food and Drug Administration approved updated COVID-19 vaccines but for a more limited group: adults age 65 and older and younger people who are at higher risk from COVID-19.

"FDA has now issued marketing authorization for those at higher risk: Moderna (6+ months), Pfizer (5+), and Novavax (12+). These vaccines are available for all patients who choose them after consulting with their doctors," US Health and Human Services Secretary Robert F. Kennedy Jr. said in a post on X.

Kennedy said in this post that he had promised "to keep vaccines available to people who want them, especially the vulnerable," but the move may limit access to COVID-19 shots for people who were routinely able to get them in the past.

It may be significantly more difficult for infants and young children to be vaccinated, although they are especially vulnerable to COVID-19. Last respiratory virus season, there were 48 COVID-19 hospitalizations for every 100,000 children under 5 – nearly seven times the rate for older children and more than twice the rate for adults under 50.

Emergency use authorizations for COVID-19 vaccines are rescinded, Kennedy said on Wednesday, which means Pfizer's COVID-19 vaccine is no longer available for children younger than 5. Moderna's vaccine is approved for children as young as 6 months, but only if they have an underlying condition that puts them at higher risk. The FDA had already approved Novavax's COVID-19 vaccine, but only for people 65 and older and those 12 and up who have at least one underlying condition that puts them at higher risk of severe illness.

"Our health care system is now solidly anti-children and anti-science. The data are clear: young children–especially infants–remain highly vulnerable to severe illness and hospitalization from COVID-19. By restricting access to safe, evidence-based vaccines, federal leaders are choosing ideology over science," Fatima Khan, co-founder of the nonprofit grassroots group Protect Their Future, which advocates for vaccine access for kids, told CNN. "Denying children a critical tool to prevent avoidable tragedies will be a lasting stain on every policymaker who allowed it to happen."

In May, Kennedy announced that the U.S. Centers for Disease Control and Prevention would no longer recommend COVID-19 vaccines for healthy children or pregnant women. The CDC's immunization schedule was updated to reflect that children would be able to get the vaccines after consulting with a health care provider — what's known as "shared decision-making." For pregnant women, there is no recommendation.

Last week, the American Academy of Pediatrics broke from the CDC to recommend COVID-19 shots for infants and young children. The American College of Obstetricians and Gynecologists also reaffirmed support for COVID-19 vaccination during pregnancy,

FDA Commissioner Dr. Marty Makary and Dr. Vinay Prasad, director of FDA's Center for Biologics Evaluation and Research, also said in May there's not enough evidence that healthy children and adults get clinically meaningful benefit from regular COVID-19 shots, and they want to see more placebo-controlled trials, particularly in adults 50 to 64, before recommending the shots for other groups.

COVID-19 levels have been on the rise for months in the U.S., with transmission increasing in most states, according to the U.S. Centers for Disease Control and Prevention. Surveillance data from WastewaterSCAN suggests that virus levels are about half of what they were during the peak of last summer's surge, but they match the peak from the summer of 2023 – and epidemiologist Caitlin Rivers noted in her newsletter that there are no signs of slowing yet, so activity will likely continue to increase in the weeks ahead. There were about 1.7 Covid hospitalizations for every 100,000 people during the first week of August, CDC data shows, with the highest rates among seniors and children under 5.

Fuente: WCVB. Disponible en https://n9.cl/75bfg

Artículos científicos publicados en Medline

Filters activated: (vaccine[Title/Abstract]) AND (("2025/08/17"[Date - Publication] : "2025/08/31"[Date - Publication])) 512 records

HPV-**Vaccine** and Reduced Odds Ratio for Oral and Oropharyngeal Cancer in Both Genders.
Katz J, Gao H, Garcia AI.J Oral Pathol Med. 2025 Aug 20. doi: 10.1111/jop.70016. Online ahead of print.PMID: 40836317

Unraveling the arc of **vaccine** progress.
Berkley S.Science. 2025 Aug 28;389(6763):eaea7053. doi: 10.1126/science.aea7053. Epub 2025 Aug 28.PMID: 40875862

Regulation of antiviral and antimicrobial innate immunity and immune evasion.
Wang L, He D, Satoh-Takayama N, Zheng C, Xing J.Cell Mol Life Sci. 2025 Aug 29;82(1):326. doi: 10.1007/s00018-025-05864-w.PMID: 40879755

Research progress of mRNA vaccines for infectious diseases.
Zhang Z, Du J, Zhang D, Han R, Wu X, Liang Y.Eur J Med Res. 2025 Aug 23;30(1):792. doi: 10.1186/s40001-025-03060-x.PMID: 40847375

COVID-19 **Vaccine**-Induced Severe Pneumonitis.
Suzuki T, Furuta H, Naganawa M, Hayashi K, Kiyotoshi H, Ohta C, Ninomiya S.Respirol Case Rep. 2025 Aug 21;13(8):e70274. doi: 10.1002/rcr2.70274. eCollection 2025 Aug.PMID: 40860748

Regulatory factors affecting sustainable **vaccine** manufacturing in Asia and the Pacific: Findings from a scoping review and semi-structured interviews.
Chan MXJ, Khoo YK, Stona AC, Joarder T, de Alwis R, Vogel S, Lim JCW, Tan-Koi WC.Vaccine. 2025 Aug 21;63:127607. doi: 10.1016/j.vaccine.2025.127607. Online ahead of print.PMID: 40845795

Chemically modified tRNA enhances the translation capacity of mRNA rich in cognate codons.
Dong L, Wang J, Xia Q.Nat Commun. 2025 Aug 22;16(1):7825. doi: 10.1038/s41467-025-62981-7.PMID: 40846860

Head and Neck Cancer Immunotherapy: Overcoming Limitations and Enhancing Efficacy.
Shibata H, Kuroki M, Kawaura R, Yamada T, Iinuma R, Ishihara H, Okuda H, Mori K, Ogawa T.Cancer Sci. 2025 Aug 23. doi: 10.1111/cas.70176. Online ahead of print.PMID: 40847645

Staphylococcus aureus: a model for bacterial cell biology and pathogenesis.
Pinho MG, Götz F, Peschel A.J Bacteriol. 2025 Aug 21;207(8):e0010625. doi: 10.1128/jb.00106-25. Epub 2025 Jul 24.PMID: 40704795

Synergically enhanced anti-tumor immunity of in vivo panCAR by circRNA **vaccine** boosting.
Wang Y, Lin L, Wang X, Li J, Pan Q, Kou H, Yin J, Gao F, Liao X, Zhang C, Yin Q, Zhao C, Li X, Lin J, Xu Y, Qiu M, Luo D, Qu L.Cell Rep Med. 2025 Aug 19;6(8):102250. doi: 10.1016/j.xcrm.2025.102250. Epub 2025 Jul 24.PMID: 40712575

Dengue Fever Vaccines: Progress and Challenges.
Rothman AL, Friberg H.Annu Rev Pharmacol Toxicol. 2025 Aug 18. doi: 10.1146/annurev-pharmtox-062124-040711. Online ahead of print.PMID: 40825354

Identification and engineering of potent bispecific antibodies that protect against herpes simplex virus recurrent disease.
Lee CV, Viadiu H, Kalamkar A, Bernstein DI, Pae A, Yu X, Wong S, Bravo FJ, Ding S, Seto E, Hung M, Yu Y, Xing W, Papalia GA, Kan W, Carr B, Thomas M, Tong L, Desai P, Jarrousse N, Mercier A, Holdorf MM, Fletcher SP, Abernathy E.Cell Rep. 2025 Aug 26;44(8):116063. doi: 10.1016/j.celrep.2025.116063. Epub 2025 Jul 26.PMID: 40716063

The pragmatic management of rabies risk in Operation DAMAN 50 (Lebanon, October 2024-February 2025): A case study for evidence-based military medicine in the field.
Gasc T, Santinelli Y, Marti J.Infect Dis Now. 2025 Aug 21;55(7):105136. doi: 10.1016/j.idnow.2025.105136. Online ahead of print.PMID: 40848848

Platelet-activating histone/antihistone IgG complexes in anti-PF4-negative thrombosis and thrombocytopenia syndrome.
Esefeld M, Handtke S, Kaiser R, Nicolai L, Di Fina L, Rossaro D, Wesche J, Rath J, Wienrich AC, Hoffmann T, Harasser L, Feistritzer C, Loacker L, Lotfi K, Holmström M, Antovic J, Steil L, Völker U, Ulm L, Becker K, Hübner NO, Greinacher A, Thiele T.Blood Adv. 2025 Aug 26;9(16):4323-4335. doi: 10.1182/bloodadvances.2024015076.PMID: 40179418

Overcoming cancer immunotherapy barriers *via* nanomaterial-mediated pyroptosis.
Xie J, Peng B, Xiao Y, Chen X, Zhang X, Chen D, Song L, Xu M, Liao W, Zhang X.J Mater Chem B. 2025 Aug 26. doi: 10.1039/d5tb01024a. Online ahead of print.PMID: 40856020

Evaluation of immunogenicity of mumps **vaccine** strains in cotton rat (Sigmodon hispidus) model.
Ito T, Yamaji Y, Sawada A, Nakayama T.Vaccine. 2025 Aug 21;63:127640. doi: 10.1016/j.vaccine.2025.127640. Online ahead of print.PMID: 40845792

Sublingual and Buccal Delivery: A Historical and Scientific Prescriptive.
Bahraminejad S, Almoazen H.Pharmaceutics. 2025 Aug 20;17(8):1073. doi: 10.3390/pharmaceutics17081073.PMID: 40871092

Nonamyloid-beta active immunization for the treatment of Alzheimer's disease.
Triplett O, Varda N, Decourt B, Sabbagh MN.Expert Opin Investig Drugs. 2025 Aug 21. doi: 10.1080/13543784.2025.2551352. Online ahead of print.PMID: 40842219

Metavac-RSV mucosal bivalent **vaccine** candidate protects cotton rats against pneumoviruses and is produced using serum-free cell culture in bioreactor.
Chupin C, Brun P, Ray M, Mialon C, Reitano M, Traversier A, Laurent E, Goumaidi A, Fouret J, Paul S, Boukhvalova M, Yim K, Blanco J, Hamelin ME, Boivin G, Rosa-Calatrava M, Dubois J.NPJ Vaccines. 2025 Aug 22;10(1):202. doi: 10.1038/s41541-025-01231-9.PMID: 40846848

Mucosal immunity and vaccination strategies: current insights and future perspectives.
Zhang Z, Hong W, Zhang Y, Li X, Que H, Wei X.Mol Biomed. 2025 Aug 20;6(1):57. doi: 10.1186/s43556-025-00301-7.PMID: 40830509

An adjuvant database for preclinical evaluation of vaccines and immunotherapeutics.
Natsume-Kitatani Y, Kobiyama K, Igarashi Y, Aoshi T, Nakatsu N, Tripathi LP, Ito J, Nyström-Persson J, Kosugi Y, Allendes Osorio RS, Nagao C, Temizoz B, Kuroda E, Standley DM, Kiyono H, Nakanishi K, Uematsu S, Hamaguchi I, Yasutomi Y, Kunisawa J, Yamasaki S, Coban C, Yamada H, Mizuguchi K, Ishii

KJ.Cell Chem Biol. 2025 Aug 21;32(8):1075-1088.e3. doi: 10.1016/j.chembiol.2025.07.005. Epub 2025 Aug 11.PMID: 40795871

[Advances in phage immunoprecipitation sequencing technology].
Zhu Y, Zhu W, Lai Y, Zhang M, Li W.Sheng Wu Gong Cheng Xue Bao. 2025 Aug 25;41(8):2987-3007. doi: 10.13345/j.cjb.250221.PMID: 40873306

Current status of severe fever with thrombocytopenia syndrome in China (Review).
Sun H, Hu Q, Lu S, Yang Y, Zhang L, Long J, Jin Y, Yang H, Chen S, Duan G.Int J Mol Med. 2025 Nov;56(5):169. doi: 10.3892/ijmm.2025.5610. Epub 2025 Aug 24.PMID: 40849814

Decrypting the Immune Symphony for RNA Vaccines.
Weidensee B, Sahu I.Vaccines (Basel). 2025 Aug 20;13(8):882. doi: 10.3390/vaccines13080882.PMID: 40872966

Genetic and molecular basis for low efficacy of **vaccine** strains against canine distemper virus in Brazil.
de Souza KSS, Lopes JM, Ribeiro RMR, Lescano CH, de Oliveira DA, Aguilar CM, Silva JC, Pires de Oliveira I.Vaccine. 2025 Aug 22;62:127621. doi: 10.1016/j.vaccine.2025.127621. Online ahead of print.PMID: 40848685

Immunogenicity evaluation of semisynthetic alpha-(1 3)-D,D-heptoglycan conjugates for Helicobacter pylori **vaccine** development.
Zou X, Xiao L, Tian G, Qin C, Hu J, Yin J.Carbohydr Res. 2025 Aug 19;557:109650. doi: 10.1016/j.carres.2025.109650. Online ahead of print.PMID: 40845492

Safety and Efficacy of Plant-Produced Trivalent Virus-Like Particle **Vaccine** Candidate Against Bluetongue Disease.
Mlingo TAM, O'Kenndedy MM, Matsiela M, Nkomo N, Coetzee P, Rametse T, Mutowembwa P, Heath L, Mokoena N.Plant Biotechnol J. 2025 Aug 23. doi: 10.1111/pbi.70316. Online ahead of print.PMID: 40847622

Is There a Norovirus **Vaccine** on the Horizon?
Schweitzer K.JAMA. 2025 Aug 26;334(8):656-658. doi: 10.1001/jama.2025.10673.PMID: 40711782

A modular **vaccine** platform for optimized lipid nanoparticle mRNA immunogenicity.
Fang Z, Monteiro VS, Oh C, Janabi KA, Romero L, Ahsan N, Yang L, Peng L, DiMaio D, Lucas C, Chen S.Nat Biomed Eng. 2025 Aug 25. doi: 10.1038/s41551-025-01478-6. Online ahead of print.PMID: 40855125

Adherence to national and international **vaccine** information sources and future pandemic preparedness among Iranian adults in the post-COVID-19 era.
Askarian M, Ahmadkhani A, Mousavi S, Muhajarine N, Sadeghi A, Zarei S, Hatam N, Taherifard E.BMC Public Health. 2025 Aug 20;25(1):2859. doi: 10.1186/s12889-025-24161-6.PMID: 40836327

Piercing the future of vaccination: the revolutionary role of microneedle-based systems in healthcare advancements.
Koçer AT, Durasi E, Kuscu E, Amasya H, Maden H, Ay HF, Calik H, Memis H, Çoksu İ, Surgit N, Gündüz O, Arayıcı PP, Cakir R, Ozturk RY, Yuka SA, Bedir T, Chifiriuc MC, Marinaș IC, Narayan R, Üstündağ CB.Vaccine. 2025 Aug 19;63:127612. doi: 10.1016/j.vaccine.2025.127612. Online ahead of print.PMID: 40834549

Targeted CRISPR screens reveal genes essential for Cryptosporidium survival in the host intestine.
Watson LC, Sala KA, Bernitz N, Baumgärtel L, Pallett MA, Marzook NB, Straker LC, Peng D, Collinson L, Sateriale A.Nat Commun. 2025 Aug 20;16(1):7749. doi: 10.1038/s41467-025-63012-1.PMID: 40835841

Third exposure to COVID-19 infection or vaccination differentially impacts T cell responses.
Ahimbisibwe G, Greenwood D, Wilkinson KA, Gahir J, Townsley H, Miah M, Bawumia P, Chaloner C, Levi D, Hobson P, Riddell A, Hobbs A, Dowgier G, Penn R, Sanderson T, Stevenson-Leggett P, Daley O, Bazire J, Harvey R, Fowler AS, Smith C, Miranda M, O'Reilly N, Warchal S, Ambrose K, Strange A, Kelly G, Kjar S; Legacy Investigators; Williams B, Libri V, Gamblin S, Gandhi S, Swanton C, Bauer DL, Wilkinson RJ, Carr EJ, Wall EC.J Infect. 2025 Aug 21;91(3):106598. doi: 10.1016/j.jinf.2025.106598. Online ahead of print.PMID: 40848990

Review of Toxoplasmosis: What We Still Need to Do.
Farhab M, Aziz MW, Shaukat A, Cao MX, Hou Z, Huang SY, Li L, Yuan YG.Vet Sci. 2025 Aug 18;12(8):772. doi: 10.3390/vetsci12080772.PMID: 40872723

The Search for a Respiratory Syncytial Virus **Vaccine**.
Wright PF.NEJM Evid. 2025 Sep;4(9):EVIDe2500194. doi: 10.1056/EVIDe2500194. Epub 2025 Aug 26.PMID: 40856553

Human papillomavirus vaccination uptake among men who have sex with men living with HIV.
Moran C, Garcia-Iglesias J, Kerr C.Sex Transm Infect. 2025 Aug 28;101(6):414-421. doi: 10.1136/sextrans-2024-056361.PMID: 40015961

Determinants of **vaccine** hesitancy among healthcare workers in an international multicenter study within the EuCARE project.
Drobniewski F, Ashmi M, Kusuma D, Ahmad R, Naumovas D, Juozapaitė D, Toscano C, Perea E, Abecasis AB, Viveiros M, Pereira JPV, Jensen BO, Bardeck N, de Morais Caporali JF, Pinto JA, Incardona F, Parczewski M, Serwin K.Sci Rep. 2025 Aug 28;15(1):31703. doi: 10.1038/s41598-025-17507-y.PMID: 40877401

Mucosal COVID-19 vaccines in clinical development.
Tscherne A, Sun W, Liu STH, Krammer F.Vaccine. 2025 Aug 22;63:127602. doi: 10.1016/j.vaccine.2025.127602. Online ahead of print.PMID: 40848675

Vaccine hesitancy and decision regret among nurses in oncology settings in Italy: a cluster-based profile analysis.
Caruso R, Perrone PM, Arrigoni C, Arcidiacono MA, Belloni S, Brera AS, Caponetti S, Conte G, Cremona G, Dabbene M, Guberti M, Piredda A, Magon A, Castaldi S.Sci Rep. 2025 Aug 21;15(1):30813. doi: 10.1038/s41598-025-16759-y.PMID: 40841428

Live-Attenuated Intranasal RSV **Vaccine** in Infants and Toddlers.
Idoko OT, Vargas SL, Bueso A, Rivera D, Edward H, Simon M, Banooni P, Berger S, Janicot S, Vercasson C, Pallardy S, Nteene R, Adhikarla H, Gerchman E, Gasparotto M, Gallichan S, Rivas E, Buchholz UJ, Collins PL, Sesay S, Gurunathan S, De Bruijn I, Dhingra MS.NEJM Evid. 2025 Sep;4(9):EVIDoa2500026. doi: 10.1056/EVIDoa2500026. Epub 2025 Aug 26.PMID: 40856556

A novel nanoparticle **vaccine**, based on S1-CTD, elicits robust protective immune responses against porcine deltacoronavirus.
He Q, Zou Y, Yu B, Yuan Q, Meng C, Du C, Wang Z, Lian J, Luo S, Cao S, Yang W, Li D, Lei H, Zhan Y, Zhou W, Yang Y, Wang N.J Virol. 2025 Aug 21:e0067425. doi: 10.1128/jvi.00674-25. Online ahead of print.PMID: 40838789

Tick-Borne Encephalitis (TBE) **Vaccine** in the National Immunisation Programme-For Whom, When and Where?
Askling HH, Zavadska D.Acta Paediatr. 2025 Aug 26. doi: 10.1111/apa.70280. Online ahead of print.PMID: 40856098

Political **vaccine** hesitancy: not new but growing problem.
MacDonald NE, Dubé È, Graham JE.Vaccine. 2025 Aug 22;63:127643. doi: 10.1016/j.vaccine.2025.127643. Online ahead of print.PMID: 40848674

HIV broadly neutralizing antibody precursors to the Apex epitope induced in nonhuman primates.
Ma KM, Sutton HJ, Pratap PP, Steichen JM, Carnathan D, Quinn J, Kalyuzhniy O, Liguori A, Agrawal S, Baboo S, Madden P, Cottrell CA, Willis JR, Lee JH, Landais E, Hu X, Ramezani-Rad P, Ozorowski G, Lewis VR, Diedrich JK, Zhou X, Altheide TK, Phelps N, Georgeson E, Alavi NB, Lu D, Eskandarzadeh S, Kubitz M, Adachi Y, Mullen TM, Silva M, Melo MB, Himansu S, Irvine DJ, Burton DR, Yates JR 3rd, Paulson JC, Sok D, Wilson IA, Silvestri G, Ward AB, Crotty S, Schief WR.Sci Immunol. 2025 Aug 22;10(110):eadt6660. doi: 10.1126/sciimmunol.adt6660. Epub 2025 Aug 22.PMID: 40845127

Investigating the link between COVID-19 misinformation exposure and **vaccine** hesitancy through perceptions of efficacy and unsafety.
Yu N, Li J, Wang W, Miller AN.J Public Health (Oxf). 2025 Aug 29;47(3):594-601. doi: 10.1093/pubmed/fdaf069.PMID: 40568755

Molecular pathogenesis of *Haemophilus ducreyi* infection in human volunteers.
Spinola SM, Fortney KR, Ofner S, Gebregziabher N, Brothwell JA, Katz BP.Microbiol Mol Biol Rev. 2025 Aug 22:e0005524. doi: 10.1128/mmbr.00055-24. Online ahead of print.PMID: 40844291

Advances of mRNA vaccines in genitourinary cancers.
Shen YM, Wan FN, Xu H, Yu L, Huang SL, Ye DW, Dai B.Biochim Biophys Acta Rev Cancer. 2025 Aug 20;1880(5):189427. doi: 10.1016/j.bbcan.2025.189427. Online ahead of print.PMID: 40846251

Resurgence of pertussis: whopping the '100-day cough'.
Christie CDC.Curr Opin Pediatr. 2025 Aug 21. doi: 10.1097/MOP.0000000000001486. Online ahead of print.PMID: 40842393

Structural and genetic basis of HIV-1 envelope V2 apex recognition by rhesus broadly neutralizing antibodies.
Roark RS, Habib R, Gorman J, Li H, Connell AJ, Bonsignori M, Guo Y, Hogarty MP, Olia AS, Sowers KJ, Zhang B, Bibollet-Ruche F, Bylund T, Callaghan S, Carey JW, Cerutti G, Harris DR, He W, Lewis E, Liu T, Mason RD, Qiao Y, Park Y, Rando JM, Singh A, Wolff JJ, Lei QP, Louder MK, Andrabi R, Doria-Rose NA, Saunders KO, Seaman MS, Haynes BF, Kulp DW, Mascola JR, Roederer M, Pierson TC, Sheng Z, Hahn BH, Shaw GM, Kwong PD, Shapiro L.J Exp Med. 2025 Oct 6;222(10):e20250638. doi: 10.1084/jem.20250638. Epub 2025 Aug 18.PMID: 40824240

Governance in Crisis: A Mixed-Methods Analysis of Global Health Governance During COVID-19.

Abdel-Motaal KA, Chun S.Int J Environ Res Public Health. 2025 Aug 20;22(8):1305. doi: 10.3390/ijerph22081305.PMID: 40869890

Approaches to overcome the current treatment plateau in immunotherapy.
Di Giacomo AM, Canetta R, Connolly J, Leidner R, Zheng W, Kim Y, Ibrahim R, Lahn M, Smith M, Eggermont A, Fox BA, Maio M.Eur J Cancer. 2025 Aug 26;226:115605. doi: 10.1016/j.ejca.2025.115605. Epub 2025 Jul 6.PMID: 40639020

Self-assembled ferritin nanoparticles using SpyCatcher/SpyTag multimerization of Mycobacterium tuberculosis TB10.4 protein induce potent immunogenicity.
Guo F, Dong S, Song Y, Xiesihan G, Jiang H, Qian Z, Wang X, Wang H, Xu T.Int Immunopharmacol. 2025 Aug 28;161:115019. doi: 10.1016/j.intimp.2025.115019. Epub 2025 Jun 12.PMID: 40513336

Immunostimulatory Pickering emulsion for oral **vaccine** delivery.
Xie J, Li X, Funk GA, Song SJ, Shah U, Ahlquist CS, Kim H.Int J Pharm. 2025 Aug 20;681:125890. doi: 10.1016/j.ijpharm.2025.125890. Epub 2025 Jun 23.PMID: 40562287

Dengue virus: structure, genome, evolution and challenges to control and prevent transmission.
Umar K, Sutradhar T, Prakash P, Bavanilatha M, Hemamalani AU, Prakashini RS, Thangam T, Parthasarathy K.Antonie Van Leeuwenhoek. 2025 Aug 26;118(9):139. doi: 10.1007/s10482-025-02153-1.PMID: 40858865

Needle-Free Transdermal Patch for Influenza Vaccination.
Tanaka K, Masaki H, Minamihata K, Wakabayashi R, Kawaguchi Y, Kamiya N, Goto M.ACS Appl Bio Mater. 2025 Aug 21. doi: 10.1021/acsabm.5c01361. Online ahead of print.PMID: 40839797

SARS-CoV-2 and chronic kidney disease: challenges and future directions.
Olivier G, Luigia E.Curr Opin Immunol. 2025 Aug 18;96:102642. doi: 10.1016/j.coi.2025.102642. Online ahead of print.PMID: 40829499

Avian HEV triggered egg decline: Viral-host, immune-neuroendocrine mechanisms in layers.
Zhang B, Kuang S, He Z, Zhang J, Li S, Duan H, Ma Z, Ding J.Vet Microbiol. 2025 Aug 21;309:110687. doi: 10.1016/j.vetmic.2025.110687. Online ahead of print.PMID: 40848355

Advance Market Commitments and Their Role in Public Innovation.
Nagar S, Cacodcar A, Kesselheim AS.J Law Med Ethics. 2025 Aug 26:1-4. doi: 10.1017/jme.2025.10153. Online ahead of print.PMID: 40855182

Investigating the Relationships Between COVID-19 Cases, Public Health Interventions, **Vaccine** Coverage, and Mean Temperature in Ontario and Toronto.
Barati Chermahini M, Hoeppner V.Diseases. 2025 Aug 19;13(8):269. doi: 10.3390/diseases13080269.PMID: 40863242

Research on inner membrane complex protein 1: a novel nanovaccines against Toxoplasma gondii.
Fang Y, Zhou P, Qi W, Yu Y, Wang X, Jiang Y, Zhang L, Yu Y, Wang J, Yu Z, Liu T.BMC Vet Res. 2025 Aug 23;21(1):521. doi: 10.1186/s12917-025-04961-z.PMID: 40849645

Uptake of the Second Dose of the Measles **Vaccine** and Its Determinants Among Children Aged Less Than 5 Years: Systematic Review and Meta-Analysis.

Adisu MA, Habtie TE, Kitaw TA, Zemariam AB.JMIR Public Health Surveill. 2025 Aug 27;11:e77195. doi: 10.2196/77195.PMID: 40864500

Personalized Cancer Vaccines in the Clinical Trial Pipeline.
Iamukova L, Alferova E.Asia Pac J Clin Oncol. 2025 Aug 22. doi: 10.1111/ajco.70006. Online ahead of print.PMID: 40846676

Pathogen virulence genes: Advances, challenges and future directions in infectious disease research (Review).
Chen Y, Wu X, Xu C, Huang J, Zhang L, Qiu P, Zheng D, Chen W, Zhang S.Int J Mol Med. 2025 Nov;56(5):173. doi: 10.3892/ijmm.2025.5614. Epub 2025 Aug 24.PMID: 40849821

Quantitative Methods for Evaluating Antibody Responses to Pneumococcal Vaccines: A Scoping Review.
Hayashi Y, Domai FM, Dhoubhadel BG.Trop Med Infect Dis. 2025 Aug 21;10(8):236. doi: 10.3390/tropicalmed10080236.PMID: 40864139

Single-cell transcriptomics uncovers key immune drivers of **vaccine** efficacy in cattle.
Wilson A, Alexandre PA, Brice AM, Hine BC, Ingham A, Legrand TPRA, Royle C, Niemeyer D, Reverter A, Denman SE, Farr RJ.BMC Genomics. 2025 Aug 18;26(1):750. doi: 10.1186/s12864-025-11915-0.PMID: 40826444

Directed evolution-based discovery of ligands for in vivo restimulation of chimeric antigen receptor T cells.
Grzywa TM, Neeser A, Ramasubramanian R, Romanov A, Tannir R, Mehta NK, Cossette B, Morgan DM, Goncalves B, Sukaj I, Bergaggio E, Kadauke S, Myers RM, Paruzzo L, Ghilardi G, Cozzone A, Schuster SJ, Frey N, Zhang L, Yousefpour P, Abraham W, Suh H, Ruella M, Grupp SA, Chiarle R, Wittrup KD, Ma L, Irvine DJ.Nat Biomed Eng. 2025 Aug 25. doi: 10.1038/s41551-025-01470-0. Online ahead of print.PMID: 40855124

Effectiveness of NVX-CoV2373 and BNT162b2 COVID-19 Vaccination in South Korean Adolescents.
Gwak E, Choe SA, Kim K, Bolormaa E, Gschwend MH, Fix J, Vadivale M, Rousculp MD, Choe YJ.Pediatr Infect Dis J. 2025 Aug 27. doi: 10.1097/INF.0000000000004954. Online ahead of print.PMID: 40865116

Development and Biological Properties of a New Live Attenuated Mumps **Vaccine** Strain.
Song X, Ren X, Song Y, Yang S, Lu K, Zhang Y, Liu J.Vaccines (Basel). 2025 Aug 20;13(8):879. doi: 10.3390/vaccines13080879.PMID: 40872963

Exploring Metal-Free Click Reactions: New Frontiers in Glycochemistry and Bioconjugation.
Ramírez-López P, Suárez JR, Flores A, Hernáiz MJ.Bioconjug Chem. 2025 Aug 20;36(8):1553-1581. doi: 10.1021/acs.bioconjchem.5c00049. Epub 2025 Jul 17.PMID: 40673383

The Path Forward for **Vaccine** Policy in the United States.
Chu HY, Brewer NT, Asturias EJ, Brooks O, Cineas S, Jamieson DJ, Kamboj M, Kuchel GA, Loehr J, Lyons K, Maldonado YA, Moser CA, Schechter R, Shaw AC, Talbot HK, Zucker JR, Chen LH.N Engl J Med. 2025 Aug 21;393(8):817-822. doi: 10.1056/NEJMsb2509134. Epub 2025 Jul 30.PMID: 40737616

Best practice: Childhood immunisations-current practice, common challenges and future considerations.
Kennedy LS, Pinsker J, Bland R.Arch Dis Child Educ Pract Ed. 2025 Aug 24:edpract-2024-328397. doi: 10.1136/archdischild-2024-328397. Online ahead of print.PMID: 40850737

Trends in DTP3 Vaccination in Asia (2012-2023).
Aguinaga-Ontoso I, Guillen-Aguinaga L, Guillen-Aguinaga S, Alas-Brun R, Guillen-Aguinaga M, Aguinaga-Ontoso E, Onambele L, Guillen-Grima F.Vaccines (Basel). 2025 Aug 19;13(8):877. doi: 10.3390/vaccines13080877.PMID: 40872962

Integrated Chemoenzymatic Synthesis of the mRNA **Vaccine** Building Block N(1)-Methylpseudouridine Triphosphate.
Pfeiffer M, Krammer L, Zöhrer J, Breinbauer R, Nidetzky B.Angew Chem Int Ed Engl. 2025 Aug 18;64(34):e202506330. doi: 10.1002/anie.202506330. Epub 2025 Jul 4.PMID: 40424092

Host-intrinsic and host-extrinsic factors modulate immunity to Mtb infection, reinfection, and noncanonical vaccination routes.
Bromley JD, Simonson AW, Shalek AK, Flynn JL.Cell Rep Med. 2025 Aug 19;6(8):102286. doi: 10.1016/j.xcrm.2025.102286. Epub 2025 Aug 7.PMID: 40780201

Factors influencing healthcare workers' **vaccine** recommendations: A cross-sectional study in Zhejiang Province, China.
Zhao J, Li M, Zeng Y, Xu Y, Yao D, Wang X, Ji C.Hum Vaccin Immunother. 2025 Dec;21(1):2543166. doi: 10.1080/21645515.2025.2543166. Epub 2025 Aug 18.PMID: 40820885

Applications of artificial intelligence and nanotechnology in **vaccine** development.
Bahrami Y, Bolideei M, Mohammadzadeh S, Gahrouei RB, Mohebbi E, Haider KH, Barzigar R, Mehran MJ.Int J Pharm. 2025 Aug 29:126096. doi: 10.1016/j.ijpharm.2025.126096. Online ahead of print.PMID: 40886810

Effectiveness of Cell Culture-Based Influenza **Vaccine**, 2023-2024.
Nguyen HQ, Alonge OD, Hanson KE, Stefanski E, Petrie JG, Ambrose K, Gandhi A, Bissonnette A, Sylvester GC, Meece JK, Belongia EA.J Pediatric Infect Dis Soc. 2025 Aug 27;14(8):piaf069. doi: 10.1093/jpids/piaf069.PMID: 40736196

Immunogenicity and Safety of the COVID-19 mRNA **Vaccine** Coadministered with Influenza and 23-valent Pneumococcal Polysaccharide Vaccines.
Rezahosseini O, Stæhr Jensen JU, Rahimi HK, Jensen NE, Jørgensen CS, Fischer TK, Ostrowski SR, Lundgren J, Ostergaard L, Harboe ZB.Clin Infect Dis. 2025 Aug 18:ciaf455. doi: 10.1093/cid/ciaf455. Online ahead of print.PMID: 40826247

"I have the **vaccine** in my body": perceptions of female sex workers after enrolling in a phase IIb HIV **vaccine** and pre-exposure prophylaxis trial in urban Tanzania.
Tarimo EAM, Iseselo MK, Ambikile JS, Lukumay G, Munseri P, Bakari M, Lyamuya E, Aboud S, Kawuma R, Seeley J; PrEPVacc Team.BMC Public Health. 2025 Aug 25;25(1):2906. doi: 10.1186/s12889-025-24202-0.PMID: 40855415

Non-Viral Gene Delivery Systems: Current Advances and Therapeutic Applications.
Wang F, Liang L, Wang C, Zhang C, Ye Y, Dou L, Shi L, Zhou D, Sun X.Chem Asian J. 2025 Aug 28:e00684. doi: 10.1002/asia.202500684. Online ahead of print.PMID: 40874945

Human papillomavirus (HPV) **vaccine** effectiveness against anal HPV-16 and HPV-18 infections among young men who have sex with men visiting the sexual health center of Amsterdam (HPV4M): study protocol of an observational study.

van Veelen S, Alberts C, Hoornenborg E, Bruisten SM, Vermeij K, van der Klis F, Noordpool L, Bogaards JA, Schim van der Loeff MF.BMJ Open. 2025 Aug 26;15(8):e101634. doi: 10.1136/bmjopen-2025-101634.PMID: 40858373

Emerging threat of scrub typhus: A call for greater awareness and research.
Bhuvaneshwari V, Amsaveni R.Int Immunopharmacol. 2025 Aug 20;164:115387. doi: 10.1016/j.intimp.2025.115387. Online ahead of print.PMID: 40840137

Effectiveness of the TAK-003 dengue **vaccine** in adolescents during the 2024 outbreak in Sao Paulo, Brazil: a test-negative, case-control study.
Ranzani OT, Lazar Neto F, Mareto LK, Brumatti TS, de Oliveira RD, da Silva PV, Dos Santos ER, D' Agostini TL, De Paula RAC, Dean NE, Ko AI, Cummings DAT, Andrews JR, Hitchings MDT, Croda J.Lancet Infect Dis. 2025 Aug 19:S1473-3099(25)00382-2. doi: 10.1016/S1473-3099(25)00382-2. Online ahead of print.PMID: 40845862

Conflicts of Interest in Federal **Vaccine** Advisory Committees.
Kanter GP, Mankowitz T, Lurie P.JAMA. 2025 Aug 18:e2513245. doi: 10.1001/jama.2025.13245. Online ahead of print.PMID: 40824635

Hijacking the Host Cell for Replication: Pro-Viral Host Factors Involved in EVA71 Infection.
Wang Q, Wu X, Liu M, Li L, Wang Y, He Q, Zhang X, Liang Z, Gao F, Ma X.Int J Mol Sci. 2025 Aug 19;26(16):7992. doi: 10.3390/ijms26167992.PMID: 40869312

Supporting dialogue amongst multicultural communities: Exploring the role of **vaccine** champions.
Karras J, Harrison M, Danchin M, Kaufman J, Leask J, Petrakis D, Gore E, Seale H.Vaccine. 2025 Aug 19;63:127629. doi: 10.1016/j.vaccine.2025.127629. Online ahead of print.PMID: 40834550

Professional Responsibility for COVID-19 Vaccination in Pregnancy.
Grünebaum A, Chervenak FA.JAMA. 2025 Aug 26;334(8):665-666. doi: 10.1001/jama.2025.11328.PMID: 40560687

Identification of the seven critical residues that control ZIKV-DENV cross-reactivity to engineer a non-cross-reactive ZIKV **vaccine**.
Grinyo-Escuer A, Reddy S, Chenine AL, Whitbeck JC, Jacobsen S, Sheetz A, Doolan K, Norden DM, Frey N, Holtsberg FW, Aman MJ, Fink K, Diamond MS, Schieffelin JS, Crowe JE Jr, Davidson E, Doranz BJ.Cell Rep. 2025 Aug 26;44(8):116098. doi: 10.1016/j.celrep.2025.116098. Epub 2025 Aug 2.PMID: 40753572

Vaccine hesitation: attitudes of Turkish health worker parents towards adult and childhood immunisation.
Çelik E, Şahin ÇE, Değer MS, Altaş ZM.BMC Public Health. 2025 Aug 20;25(1):2857. doi: 10.1186/s12889-025-24100-5.PMID: 40835915

Exogenous estrogen enhances T cell activation in male primates.
Hahn PA, Escrivà-Font J, Alexander ES, Weisgrau K, Ou T, He W, O'Hagan D, Da Silva LCF, Gurley NJ, Lin L, Cameron MD, Rakasz E, Farzan M, Kurian JR, Capuano S 3rd, Consiglio CR, Martins MA.Cell Rep. 2025 Aug 22;44(9):116170. doi: 10.1016/j.celrep.2025.116170. Online ahead of print.PMID: 40849906

Evaluation of Campylobacter fetus subspecies concentrations in commercial bovine reproductive vaccines.

Dias ME, Breyer GM, De Carli S, Siqueira FM.Braz J Microbiol. 2025 Aug 21. doi: 10.1007/s42770-025-01768-w. Online ahead of print.PMID: 40839183

Vulval Squamous Cell Carcinoma: a review.
Sheern C, Levell NJ, Craig PJ, Harwood CA, Jeffrey P, Nordin A, Patel P, Sterling JC, Venables ZC.Clin Exp Dermatol. 2025 Aug 20:llaf389. doi: 10.1093/ced/llaf389. Online ahead of print.PMID: 40834239

A Cross-Sectional Study Examining **Vaccine** Uptake and Attitudes Among Parents Compared to Other Adults.
Massey PM, Chuang A, Holman EA, Silver RC, Garfin DR.Health Educ Behav. 2025 Aug 26:10901981251361433. doi: 10.1177/10901981251361433. Online ahead of print.PMID: 40856250

Structure of a SARS-CoV-2 spike S2 subunit in a pre-fusion, open conformation.
Olmedillas E, Rajamanickam RR, Avalos RD, Ana-Sosa-Batiz F, Zyla D, Zandonatti MA, Harkins SS, Shresta S, Hastie KM, Saphire EO.Cell Rep. 2025 Aug 26;44(8):116052. doi: 10.1016/j.celrep.2025.116052. Epub 2025 Jul 22.PMID: 40705599

Immunoinformatics design and experimental expression of a multi-epitope **vaccine** simultaneously targeting AAV2 and HAdV-F41 against acute hepatitis of unknown etiology.
Zeng F, Liu Q, Wang X, Zhong P, Wu P, Yang M, Wei P.Virology. 2025 Aug 18;611:110653. doi: 10.1016/j.virol.2025.110653. Online ahead of print.PMID: 40850180

Safety and efficacy of an intramuscular bivalent **vaccine** against influenza and Streptococcus pneumoniae infections in mice.
Cardoso KF, de Souza LRA, Martins DS, da Silva Santos BSÁ, de Carvalho KRA, da Silva Messias SG, de Faria Gonçalves AP, Do Nascimento Macário RR, de Jesus DJF, De Mendonça Ângelo ALP, de Paula Pereira L, Nascimento SLM, Kano FS, Alves PA, Xavier MAP, Martins-Filho OA, Russo RC, Gazzinelli RT, Miyaji EN, Garcia CC, de Magalhães Vieira Machado A, Araújo MSS.Med Microbiol Immunol. 2025 Aug 29;214(1):39. doi: 10.1007/s00430-025-00848-w.PMID: 40879808

Reverse vaccinology-based identification and in silico characterization of immunogenic membrane proteins of Salmonella Typhimurium as novel **vaccine** targets against multidrug-resistant infections.
Habiba TU, Hussain Z, Asghar F, Nawaz W.BMC Microbiol. 2025 Aug 23;25(1):542. doi: 10.1186/s12866-025-04124-y.PMID: 40849649

The role of serological testing for vaccination with a focus on immunocompromised patients: a synthesis of current evidence.
Patel C, Wang X, Giles M, Burns P, Nguyen T, Macartney K, Williams PCM.Vaccine. 2025 Aug 25;63:127659. doi: 10.1016/j.vaccine.2025.127659. Online ahead of print.PMID: 40857937

Weaving a public health network: Process and results from an evaluation of CDC's Prevention Research Centers **Vaccine** Confidence Network.
Chuvileva YE, Kuiper NM, Ramakrishnan A, Goodman K, Jeffers A, Swarna H, Gandhi P, Reed-Morrice M, Ulin B.Vaccine. 2025 Aug 21;60 Suppl 1(Suppl 1):127636. doi: 10.1016/j.vaccine.2025.127636. Online ahead of print.PMID: 40845542

Cell membrane **vaccine** delivery system: A review of the recent advances against breast cancer.
Hilles AR, Mahmood S, Widodo RT, Azemi AK, Nordin AH, Mohamad Norpi AS, Abd Jalil MF, Sofian ZM, Mohamed M, Hambali KA, Mohd Sani NI, Rashid R, Nordin ML.Int J Pharm. 2025 Aug 20;681:125849. doi: 10.1016/j.ijpharm.2025.125849. Epub 2025 Jun 14.PMID: 40516769

Parents' perspectives of the new neonatal BCG vaccination pathway in England: a qualitative study.
Bisset K, Chisnall G, Campbell CNJ, Saliba V, Mounier-Jack S, Chantler T.BMC Public Health. 2025 Aug 18;25(1):2821. doi: 10.1186/s12889-025-23859-x.PMID: 40826403

Therapeutic Vaccines for Non-Communicable Diseases: Global Progress and China's Deployment Pathways.
Huang Y, Lyu X, Kam YW.Vaccines (Basel). 2025 Aug 20;13(8):881. doi: 10.3390/vaccines13080881.PMID: 40872964

Evaluating COVID-19 vaccination policy in Québec (Canada) using a data-driven dynamic transmission model.
Torres-Florez S, Flores Anato JL, He JH, Portilla VG, Wu Y, Maheu-Giroux M, Racine É, Wagner CE.PLoS Comput Biol. 2025 Aug 25;21(8):e1013207. doi: 10.1371/journal.pcbi.1013207. Online ahead of print.PMID: 40853999

V4020 Venezuelan Equine Encephalitis **Vaccine**: Mitigating Neuroinvasion and Reversion Through Rational Design.
Centers A, Barnaby K, Goedeker S, Pignataro A, Tretyakova I, Lukashevich I, Pushko P, Chung D.Viruses. 2025 Aug 19;17(8):1136. doi: 10.3390/v17081136.PMID: 40872849

Post-marketing surveillance for the safety of the quadrivalent human papillomavirus **vaccine**: a retrospective real-world study in China.
Meng R, Ma R, Wang J, Liu P, Liu Z, He B, Liu Z, Yang Y, Zhan S.Expert Rev Vaccines. 2025 Dec;24(1):849-856. doi: 10.1080/14760584.2025.2550972. Epub 2025 Aug 30.PMID: 40848019

Utilizing the Program Impact Pathways framework for improving COVID-19 **vaccine** confidence and uptake: demonstrations of multi-sector collaboration from two geographies in Connecticut.
Beaulieu A, LaMonaca K, Higginbottom J, Foster J, Macklin B, Muhammad TC, Schwartz E, Comerford BP, Santilli A, O'Connor Duffany K, Pérez-Escamilla R.Vaccine. 2025 Aug 25;60 Suppl 1:127623. doi: 10.1016/j.vaccine.2025.127623. Online ahead of print.PMID: 40857953

A mix of views: Perspectives on pregnant women's participation in maternal **vaccine** trials.
Nalubega P, Namugumya R, Kyohere M, Seeley J, Le Doare K, Ssali A.Vaccine. 2025 Aug 31;63:127627. doi: 10.1016/j.vaccine.2025.127627. Online ahead of print.PMID: 40889445

COVID-19 hoax belief endorsement and its implications for **vaccine** uptake: Investigating the role of perceived threat.
Morstead T, Loo N, Sin NL, DeLongis A.Vaccine. 2025 Aug 19;63:127630. doi: 10.1016/j.vaccine.2025.127630. Online ahead of print.PMID: 40834548

Resiquimod-Induced Nanovaccine (RINV) for Personalized Cancer Immunotherapy.
Xu W, Luo JQ, Wang SY, Gao ZL, Luo FQ, Zhang X, Wang KS, Du J, Ji ZL, Du JZ, Wang J.Angew Chem Int Ed Engl. 2025 Aug 18;64(34):e202507902. doi: 10.1002/anie.202507902. Epub 2025 Jun 30.PMID: 40533414

Risk factors and effectiveness of vaccination for nosocomial SARS-CoV-2 acquisition throughout the SARS-CoV-2 pandemic.
Dave N, van der Werff SD, Sjöholm D, Zetterqvist J, Nauclér P.BMC Infect Dis. 2025 Aug 19;25(1):1040. doi: 10.1186/s12879-025-11349-9.PMID: 40830930

Lessons from COVID-19 **vaccine** hesitancy among healthcare workers in West Africa and strategies for future pandemic preparedness: a structured literature review.
Asasah SI, Imade EE, Enagbonma BJ.J Public Health (Oxf). 2025 Aug 29;47(3):487-498. doi: 10.1093/pubmed/fdaf071.PMID: 40580944

High-Dose Influenza **Vaccine** to Reduce Hospitalizations.
Pardo-Seco J, Rodríguez-Tenreiro-Sánchez C, Giné-Vázquez I, Mallah N, Mirás-Carballal S, Piñeiro-Sotelo M, Cribeiro-González M, Conde-Pájaro M, González-Pérez JM, Rivero-Calle I, Bello X, Razzini JL, Dacosta-Urbieta A, Salas A, Harris RC, Loiacono MM, van Aalst R, Farre JM, Dufournet M, Johansen ND, Modin D, Biering-Sørensen T, Durán-Parrondo C, Martinón-Torres F; GALFLU Trial Team.N Engl J Med. 2025 Aug 30. doi: 10.1056/NEJMoa2509834. Online ahead of print.PMID: 40888694

Preexisting yellow fever virus and West Nile virus immunity and pregnancy outcomes in a Nigerian cohort with endemic orthoflavivirus exposure.
Kim T, Herrera BB, Chaplin B, Naito-Keoho K, Ogwuche J, Sagay AS, Chang CA, Hamel DJ, Wang WK, Kanki PJ.Emerg Microbes Infect. 2025 Dec;14(1):2544720. doi: 10.1080/22221751.2025.2544720. Epub 2025 Aug 21.PMID: 40793825

Temporal trends in COVID-19 **vaccine** uptake among social housing residents compared to the general population in Ontario, Canada: A population-based panel study.
Agarwal G, Keshavarz H, Angeles R, Pirrie M, Marzanek F, Nguyen F, Brar J, Michael Paterson J.Ann Epidemiol. 2025 Aug 19;110:154-159. doi: 10.1016/j.annepidem.2025.08.024. Online ahead of print.PMID: 40840571

COVID-19 **vaccine** effectiveness and duration of protection among children and adolescents: A retrospective cohort study in 11 large cities in Japan.
Kitamura N, Tomo Y, Okuyama M, Ueda K, Matsuoka H, Morino S, Miyahara R, Yoneoka D, Takanashi S, Suzuki M.Vaccine. 2025 Aug 27;63:127656. doi: 10.1016/j.vaccine.2025.127656. Online ahead of print.PMID: 40876144

Nanofilament immunotherapy induces potent antitumor **vaccine** responses.
Neil K, Génier S, Poisson MÈ, Douchin J, Giguère H, Daniel L, Gonzalez MF, Huang S, Trinh VQ, Tai LH, Rodrigue S, Millau JF.J Immunother Cancer. 2025 Aug 31;13(8):e011331. doi: 10.1136/jitc-2024-011331.PMID: 40889802

Risk Factors for Typhoid Fever: Systematic Review.
Boakye Okyere P, Twumasi-Ankrah S, Newton S, Nkansah Darko S, Owusu Ansah M, Darko E, Agyapong F, Jeon HJ, Adu-Sarkodie Y, Marks F, Owusu-Dabo E.JMIR Public Health Surveill. 2025 Aug 28;11:e67544. doi: 10.2196/67544.PMID: 40875987

Situated efficacy: FMD vaccines in France and Britain, 1930s-1960s.
Berdah D.Med Hist. 2025 Aug 22:1-16. doi: 10.1017/mdh.2025.10016. Online ahead of print.PMID: 40842310

Cytotoxic granules and effector molecules from immune cells in tuberculosis: Mechanisms of host defense and therapeutic potential.
Qin Y, Xu J, Wang Q, Shi J.Virulence. 2025 Dec;16(1):2542466. doi: 10.1080/21505594.2025.2542466. Epub 2025 Aug 18.PMID: 40825006

Real-world safety of herpes zoster vaccines: A pharmacovigilance study based on the **vaccine** adverse event reporting system (may 2006-december 2024).
Cai H, Jia B, Song Z, Wang L, Zhao S.Vaccine. 2025 Aug 19;63:127628. doi: 10.1016/j.vaccine.2025.127628. Online ahead of print.PMID: 40834551

Humoral immune response to Covid-19 vaccination in patients with cancer - Results from the ANRS0001S COV-POPART study.
Luong Nguyen LB, Magloire L, François A, Billard D, Priou F, Arrondeau J, Linassier C, Ben Ghezala I, Gross-Goupil M, Charles J, Dohollou N, Vanhems P, Cracowski C, Leroi AM, Lainé F, Galtier F, Barthelemy K, Priet S, Gharib M, Chalouni M, Barquin A, Loubet P, de Lamballerie X, Launay O, Wittkop L, Blay JY, Spano JP; ANRS0001S COV-POPART cohort study group.Vaccine. 2025 Aug 22;63:127633. doi: 10.1016/j.vaccine.2025.127633. Online ahead of print.PMID: 40848673

Correlates of HPV vaccination intention and uptake among Asian American and Pacific Islander populations in the USA: a systematic review and meta-analysis protocol.
Mansuri S, Subedi S, Ghonaim N, Yu T, Lin CY, Chen AC.BMJ Open. 2025 Aug 19;15(8):e103947. doi: 10.1136/bmjopen-2025-103947.PMID: 40829845

Plant and probiotic-based edible vaccines for Helicobacter pylori: Research status and application prospects.
Ye S, Zhao J, Zhao S.Microb Pathog. 2025 Aug 18:107993. doi: 10.1016/j.micpath.2025.107993. Online ahead of print.PMID: 40835075

Effect of 5 % lactose and 0.1 % polysorbate 80 buffer on protein-based multivalent ETEC **vaccine** candidate MecVax stabilization and immunogenicity.
Edao B, Upadhyay I, Zhang W.Vaccine. 2025 Aug 21;63:127634. doi: 10.1016/j.vaccine.2025.127634. Online ahead of print.PMID: 40845793

Mapping **Vaccine** Sentiment by Analyzing Spanish-Language Social Media Posts and Survey-Based Public Opinion: Dual Methods Study.
Huguet-Feixa A, Ahmed W, Artigues-Barberà E, Sol J, Gomez-Arbones X, Godoy P, Ortega Bravo M.JMIR Infodemiology. 2025 Aug 29;5:e63223. doi: 10.2196/63223.PMID: 40882220

Immunogenic and Protective Properties of mRNA **Vaccine** Encoding Hemagglutinin of Avian Influenza A/H5N8 Virus, Delivered by Lipid Nanoparticles and Needle-Free Jet Injection.
Yakovlev VA, Litvinova VR, Rudometova NB, Borgoyakova MB, Tigeeva EV, Starostina EV, Ivanova KI, Gudymo AS, Danilchenko NV, Perfilyeva ON, Makarova KP, Vahitov DI, Zaitsev BN, Dmitrienko EV, Sharabrin SV, Krasnikova SI, Kisakova LA, Kisakov DN, Ilyicheva TN, Marchenko VY, Karpenko LI, Rudometov AP, Ilyichev AA.Vaccines (Basel). 2025 Aug 21;13(8):883. doi: 10.3390/vaccines13080883.PMID: 40872967

Teaching an old vector new tricks: the surprising versatility of AAV vaccines.
Winston SM, Wiggins KB, Schultz-Cherry S, Davidoff AM.J Virol. 2025 Aug 19;99(8):e0073025. doi: 10.1128/jvi.00730-25. Epub 2025 Jul 14.PMID: 40657919

Human Metapneumovirus: A Narrative Review on Emerging Strategies for Prevention and Treatment.
Principi N, Fainardi V, Esposito S.Viruses. 2025 Aug 20;17(8):1140. doi: 10.3390/v17081140.PMID: 40872853

Knowledge of human papillomavirus and self-sampling, including vaccination practices among female students in Free State, South Africa.
Tiiti TA, Aluko O, Barrett C.Cancer Causes Control. 2025 Aug 23. doi: 10.1007/s10552-025-02049-5. Online ahead of print.PMID: 40848138

A process evaluation of Ontario, Canada's 2023-24 older-adult RSV vaccination program.
Morrison R, Sarmiento J, Park J, Lim G, Renda C, Whelan M, McGeer A, Harris T, Wilson SE.Hum Vaccin Immunother. 2025 Dec;21(1):2550089. doi: 10.1080/21645515.2025.2550089. Epub 2025 Aug 25.PMID: 40853184

Human tonsil organoids reveal innate pathways modulating humoral and cellular responses to ChAdOx1.
Pudjohartono MF, Powell K, Barnes E, Klenerman P, Provine NM.PLoS Pathog. 2025 Aug 22;21(8):e1013432. doi: 10.1371/journal.ppat.1013432. eCollection 2025 Aug.PMID: 40845053

Developing community-based surveillance systems for **vaccine**-preventable diseases: lessons learned from Indonesia.
Sitorukmi G, Rusadi CP, Lazuardi L, Prasetyo S, Putri LP.Glob Health Action. 2025 Dec;18(1):2548083. doi: 10.1080/16549716.2025.2548083. Epub 2025 Aug 28.PMID: 40873390

Characterizing influenza A virus lineages and clinically relevant mutations through high-coverage wastewater sequencing.
John A, Kang S, Fuhrmann L, Topolsky I, Kent C, Quick J, Stadler T, Julian TR, Beerenwinkel N.Water Res. 2025 Aug 21;287(Pt B):124453. doi: 10.1016/j.watres.2025.124453. Online ahead of print.PMID: 40865342

Highly scalable prefusion-stabilized RSV F **vaccine** with enhanced immunogenicity and robust protection.
Huang Q, Lang Q, Li Y, Wang F, Han X, Luo L, Duan X, Cao X, Wang Y, Bai Y, Song Y, Xu Y, Bian L, Gao C, Zhao L, Yan J.Nat Commun. 2025 Aug 21;16(1):7805. doi: 10.1038/s41467-025-63084-z.PMID: 40841372

Political Polarization During Disease Outbreaks: A Meta-Analysis of Archival Survey Data From Polio to COVID-19.
McMurtry CL, Cheu R.Am J Public Health. 2025 Aug 28:e1-e13. doi: 10.2105/AJPH.2025.308226. Online ahead of print.PMID: 40875966

Genetic characteristics of rotavirus a in Shenzhen and Zhuhai, China, 2020-2023.
Hu M, Lin Y, Zhang R, Wang X, He Y, Huang H, Wang B, Liu W, Li K, Fu J, Zhao X, Aimaiti B, Yang W, Song H, Ren H, Hu X.BMC Genomics. 2025 Aug 18;26(1):752. doi: 10.1186/s12864-025-11953-8.PMID: 40826331

Zeolitic imidazolate frameworks enhanced transfection efficiency of mRNA loaded lipid nanoparticles.
Singh R, Bruce K, Heazlewood SY, White JF, de Vries M, Muir BW, Cao B, Mulet X, Layton D, Doherty CM.J Mater Chem B. 2025 Aug 27;13(34):10675-10683. doi: 10.1039/d4tb02101k.PMID: 40813562

Precision Vaccinology: Making Vaccines Work Better for Women and Men.
Scully EP, Morgan R, Klein SL.J Infect Dis. 2025 Aug 20:jiaf397. doi: 10.1093/infdis/jiaf397. Online ahead of print.PMID: 40833848

A QS21+ CpG-Adjuvanted Rabies Virus G Subunit **Vaccine** Elicits Superior Humoral and Moderate Cellular Immunity.

Cao H, Li H, Liu W, Luan N, Hu J, Kong M, Song J, Liu C.Vaccines (Basel). 2025 Aug 21;13(8):887. doi: 10.3390/vaccines13080887.PMID: 40872971

Lassa fever in West Africa: a systematic review and meta-analysis of attack rates, case fatality rates and risk factors.
Ogundele GO, Jolayemi KO, Bello S.BMC Public Health. 2025 Aug 27;25(1):2948. doi: 10.1186/s12889-025-24377-6.PMID: 40866826

Enhanced protective efficacy of a dendritic cell-targeting truncated F protein delivery via minicircle DNA **vaccine** against genotype VII newcastle disease virus in chickens.
Bao M, Wang W, Sun Y, Zhang Y, Gao Y, Zhang Y, Yang T, Guo Q, Zhang G, Wang M, Gong J, Tian Y, He Y, Wang J, Huang H, Wang Z, Wang C, Jiang Y.Vet Microbiol. 2025 Aug 18;309:110685. doi: 10.1016/j.vetmic.2025.110685. Online ahead of print.PMID: 40834623

Vaccine Hesitancy in Public Healthcare During Pandemics: An International Study to Inform Management Learning.
Svensson A, Nardoni M, Svalastog AL, Vidmar M, Machado H, Kopilaš V, Gajović S, Martinelli L, Todorović Z.Health Sci Rep. 2025 Aug 19;8(8):e71190. doi: 10.1002/hsr2.71190. eCollection 2025 Aug.PMID: 40837721

HepB-CpG vaccination: An alternate strategy to life long antiviral therapy in patients transplanted for chronic Hepatitis B.
Garrido-Trevino L, Gonzalez SA, Saracino G, Anderson M, Cloherty G, Fortney T, Perrillo R.Liver Transpl. 2025 Aug 20. doi: 10.1097/LVT.0000000000000714. Online ahead of print.PMID: 40833356

Public Attention to Mpox in China During the Pandemic: Qualitative Analysis of TikTok Data Using Latent Dirichlet Allocation Topic Modeling.
Luo D, Xu J, Jiang Y, Tan M, Yao Y, He L, Ma J, Dong W, Luo W, Zhou C.J Med Internet Res. 2025 Aug 21;27:e77424. doi: 10.2196/77424.PMID: 40839789

An Activated Gasdermin Mimicking Polymer for Antitumor Immunity.
Li J, Mu Y, Chen Y, Zhang X, Wang Y, Wang J, Ying J, Yang H, Zhou X, Du Y, Xu C, Ding K, Shen Y, Liu X, Zhou T, Zhou Q.ACS Nano. 2025 Aug 26;19(33):30525-30543. doi: 10.1021/acsnano.5c12189. Epub 2025 Aug 14.PMID: 40811768

A nasal **vaccine** candidate based on S2 and N proteins from SARS-CoV-2 generates a broad antibody response systemically and in the lower respiratory tract.
Lobaina Y, Chen R, Vazquez-Blomquist D, Suzarte E, Zhang M, Zhou Z, Lan Y, Guillen G, Li W, Perera Y, Hermida L.Immunol Res. 2025 Aug 27;73(1):125. doi: 10.1007/s12026-025-09675-w.PMID: 40859051

Understanding the traits underlying **vaccine**-driven virulence evolution in malaria parasites.
Jeong Y, Kamiya T, Mideo N.BMC Biol. 2025 Aug 26;23(1):267. doi: 10.1186/s12915-025-02366-w.PMID: 40859351

Functional epitope mapping of porcine reproductive and respiratory syndrome virus nsp7α and nsp7β using monoclonal antibodies and development of a feasible ELISA.
Han S, Duan H, Yang N, Wang S, Gao F, Jiang Y, Tang C, Zhou Y, Tong G, Zhao K, Li L.Int J Biol Macromol. 2025 Aug 25:147104. doi: 10.1016/j.ijbiomac.2025.147104. Online ahead of print.PMID: 40865809

Clinical and Proteomic Associations of SARS-CoV-2 Infection and COVID-19 Vaccination in Multimorbid Patients: A Cross-Sectional Observational Study.
Hudák A, Pettko-Szandtner A, Letoha A, Letoha T.Int J Mol Sci. 2025 Aug 19;26(16):8007. doi: 10.3390/ijms26168007.PMID: 40869330

Design of a multi-Epitope mRNA **vaccine** against Brucella type IV secretion system using reverse vaccinology and immunogenicity approaches.
Luo JR, Qi XX, Tian TT, Shang KY, Shi HD, Li C, Chai ZL, Ding JB, Zhu YJ, Zhang FB.Sci Rep. 2025 Aug 21;15(1):30698. doi: 10.1038/s41598-025-09509-7.PMID: 40841725

U.S. trust in physicians as key public health messengers during the H5N1 avian influenza outbreak.
Piltch-Loeb R, Gibbs SG, Lowe JJ, Gorman S, Wyka K, White TM, El-Mohandes A.Sci Rep. 2025 Aug 23;15(1):31011. doi: 10.1038/s41598-025-12304-z.PMID: 40849434

Navigating health information: Factors influencing **vaccine** decision-making and health information access in emerging adults at a no-cost **vaccine** clinic.
Stepp NA, Ky SL, Coblentz EG, Sembian S, Packee CR, Rudd TM, Koch K, DeMaria AL, Kasting ML.J Am Coll Health. 2025 Aug 18:1-8. doi: 10.1080/07448481.2025.2542408. Online ahead of print.PMID: 40825583

Primary care pediatricians' involvement in influenza vaccination campaign in Italy.
Indaco R, Leoni F, Panza C, Giorgi Rossi P.Ital J Pediatr. 2025 Aug 22;51(1):259. doi: 10.1186/s13052-025-02093-6.PMID: 40847306

High measles and rubella **vaccine** coverage and seroprevalence among Zambian children participating in a measles and rubella supplementary immunization activity.
Prosperi C, Truelove S, Carcelen AC, Chongwe G, Mwansa FD, Ndubani P, Simulundu E, Bwalya IC, Hamahuwa M, Kapungu K, Matakala KH, Musukwa G, Mutale I, Betha E, Chaavwa N, Kampamba L, Matoba J, Munachoonga P, Mufwambi W, Situtu K, Thuma PE, Sakala C, Kayeye P, Winter AK, Ferrari MJ, Moss WJ, Mutembo S.PLOS Glob Public Health. 2025 Aug 29;5(8):e0003209. doi: 10.1371/journal.pgph.0003209. eCollection 2025.PMID: 40880368

RSV **Vaccine** Effectiveness Against Hospitalization Among US Adults Aged 60 Years or Older During 2 Seasons.
Surie D, Self WH, Yuengling KA, Lauring AS, Zhu Y, Safdar B, Ginde AA, Simon SJ, Peltan ID, Brown SM, Gaglani M, Ghamande S, Columbus C, Mohr NM, Gibbs KW, Hager DN, Prekker M, Gong MN, Mohamed A, Johnson NJ, Steingrub JS, Khan A, Duggal A, Gordon AJ, Qadir N, Chang SY, Mallow C, Felzer JR, Kwon JH, Exline MC, Vaughn IA, Ramesh M, Papalambros L, Mosier JM, Harris ES, Baughman A, Cornelison SA, Blair PW, Johnson CA, Lewis NM, Ellington S, Grijalva CG, Talbot HK, Casey JD, Halasa N, Chappell JD, Rutkowski RE, Ma KC, Dawood FS; Investigating Respiratory Viruses in the Acutely Ill (IVY) Network.JAMA. 2025 Aug 30:e2515896. doi: 10.1001/jama.2025.15896. Online ahead of print.PMID: 40884491

Streamlined and accelerated nonclinical development of COVID-19 vaccines and therapeutics - an IQ consortium DruSafe survey.
Liu MM, Ralston SL.Regul Toxicol Pharmacol. 2025 Aug 21;163:105928. doi: 10.1016/j.yrtph.2025.105928. Online ahead of print.PMID: 40849041

Emerging cGAS-STING Agonist-Based Nanotherapeutics: Mechanistic Insights and Applications in Cancer Combination Therapy.
Wang Z, Wang Y, He Z, Liu C.Adv Sci (Weinh). 2025 Aug 21:e09890. doi: 10.1002/advs.202509890. Online ahead of print.PMID: 40842018

E2-based mRNA **vaccine** encapsulated in lipid nanoparticles protects pigs against classical swine fever virus.
Liu J, Xia Y, Tian C, Chen Z, Guo W, Liu Y, Wen J, Xie Z, Lin J, Li J, Chen H, Liu Y.J Virol. 2025 Aug 21:e0097825. doi: 10.1128/jvi.00978-25. Online ahead of print.PMID: 40838721

Exploring lingering COVID-19 **vaccine** hesitancy in three diverse U.S. states: Alabama, Illinois, and Texas.
Almukhtar S, McWhirter N, Mendiola A, Samuel S, Dominguez O, Boyd DP, Flores S, Gandhi P, Kazungu F, Khare M, Cuccaro P, Fernández ME, Hershow RC, Kim S, Stiehl E.Vaccine. 2025 Aug 27;60 Suppl 1:127664. doi: 10.1016/j.vaccine.2025.127664. Online ahead of print.PMID: 40876078

Knowledge of cervical cancer prevention and HPV vaccination: A survey among 961 college students in Hangzhou, China.
Zou J, Xu JY, Hua XP, Cao Z, Ye J, Li Y.Medicine (Baltimore). 2025 Aug 22;104(34):e44069. doi: 10.1097/MD.0000000000044069.PMID: 40859538

Synthesis of Chirally Chimeric Protein Nanoparticle Vaccines via Mirror-Image Spy Chemistry.
Kou S, Sun C, Chen W, Gao H, Sun F.Angew Chem Int Ed Engl. 2025 Aug 18;64(34):e202509419. doi: 10.1002/anie.202509419. Epub 2025 Jun 25.PMID: 40528680

Analysis of factors driving HPV vaccination coverage and associated cost savings in the united States.
Wang S, Muthukrishnan S, Quddus S, Manning SH, Brandt HM.BMC Public Health. 2025 Aug 19;25(1):2833. doi: 10.1186/s12889-025-23928-1.PMID: 40830855

Late initiation of pneumococcal and Haemophilus influenzae type b vaccinations.
Albers AN, Fox ER, Michels SY, Daley MF, Glanz JM, Newcomer SR.Vaccine. 2025 Aug 18;62:127611. doi: 10.1016/j.vaccine.2025.127611. Online ahead of print.PMID: 40829385

Correlates of higher trust in public health officials: results from a representative cohort of private university undergraduates.
Gollub EL, Myszkowski N, Xi M, Boyraz G, Mendelsohn JB.Vaccine. 2025 Aug 18;63:127610. doi: 10.1016/j.vaccine.2025.127610. Online ahead of print.PMID: 40829286

A novel replication-deficient FCV **vaccine** provides strong immune protection in cats.
Heng W, Zang D, Li R, Jiang Q, Liu J, Jia H, Kang H.J Virol. 2025 Aug 19;99(8):e0009325. doi: 10.1128/jvi.00093-25. Epub 2025 Jul 8.PMID: 40626663

Genomic surveillance in Morocco tracks SARS-CoV-2 variant shift from Alpha to Omicron sublineage JN1.
Bouddahab O, Aqillouch S, Charoute H, Noureddine R, El Hamouchi A, Laazaazia O, Aainouss A, Baba H, Ouladlahsen A, Pineau P, Sarih M, Maaroufi A, Lkhider M, Barakat A, Ezzikouri S.Npj Viruses. 2025 Aug 19;3(1):63. doi: 10.1038/s44298-025-00145-6.PMID: 40830238

Association between depression and three key COVID-19-related outcomes: The SHARE study.

Gao Y, Duan C, Miao T, Shen Q, Yu J, Shen S, Chen Y, Shen Y, Zhang K.Hum Vaccin Immunother. 2025 Dec;21(1):2551930. doi: 10.1080/21645515.2025.2551930. Epub 2025 Aug 26.PMID: 40859683

Two cross-neutralizing antibodies isolated from a COVID-19 convalescent via single B cell sorting.
Hu Y, Hu C, Su J, Zhu B, Liang H, Shao Y.Arch Virol. 2025 Aug 25;170(9):199. doi: 10.1007/s00705-025-06372-9.PMID: 40855237

A transformation in cholera surveillance.
Debes AK, Baumgartner ET, Williams KN, Sack DA.Lancet Infect Dis. 2025 Aug 25:S1473-3099(25)00408-6. doi: 10.1016/S1473-3099(25)00408-6. Online ahead of print.PMID: 40876468 Review.

Inadequate immune response to inactivated COVID-19 **vaccine** among older people living with HIV: a prospective cohort study.
Zhang H, Deng X, Dai R, Fu J, Ding L, Hu X, Sun P, Shu R, Chen L, Xu X.J Virol. 2025 Aug 21:e0068825. doi: 10.1128/jvi.00688-25. Online ahead of print.PMID: 40838719

Estimating prevalence and identifying predictors of zero-dose pentavalent and never-immunized children under two years of age in Kashmore and Sujawal Districts of Sindh, Pakistan: An analysis of household survey data.
Siddiqi DA, Memon M, Iftikhar S, Siddique M, Dharma VK, Ahmad A, Safdar N, Shah MT, Setayesh H, Sodhar IA, Malik FR, Chandir S.PLoS One. 2025 Aug 26;20(8):e0330281. doi: 10.1371/journal.pone.0330281. eCollection 2025.PMID: 40857277

Breaking barriers: a qualitative study on polio **vaccine** hesitancy in Herat Province, Afghanistan.
Sillab FA, Moghri J, Najar AV, Marvi A, Sana A, Naghipour M, Hooshmand E.BMC Public Health. 2025 Aug 18;25(1):2820. doi: 10.1186/s12889-025-23903-w.PMID: 40826048

Parental intent to vaccinate children with the updated 2023-2024 COVID-19 **vaccine**.
Groom HC, Kuntz JL, Varga AM, Smith N, Coto E, Cox SN, Babu TM, Briggs-Hagen M, Frivold C, Saydah S, Mularski RA, Boisvert C, Drummond M, Feldstein LR, Fortmann SP, MacMillan MP, McDonald D, Hollcroft M, Midgley CM, Plumb ID, Reich S, Schmidt MA, Yetz N, Grioni H, McCaffrey KM, Hatchie TL, Lo N, Lockwood C, Starita L, Englund JA, Weil AA, Carone M, Chu HY, Naleway AL.Vaccine. 2025 Aug 23;63:127618. doi: 10.1016/j.vaccine.2025.127618. Online ahead of print.PMID: 40850295

Communication about COVID-19 with urban American Indian and Alaska Native peoples: the role of health literacy, trust, and information source.
Boyd AD, Henderson A, Uddin A, Amiri S, MacLehose RF, Manson SM, Buchwald D.J Public Health (Oxf). 2025 Aug 29;47(3):460-468. doi: 10.1093/pubmed/fdaf050.PMID: 40342159

Psychological inoculation improves resilience to and reduces willingness to share **vaccine** misinformation.
Appel RE, Roozenbeek J, Rayburn-Reeves R, Basol M, Corbin J, Compton J, van der Linden S.Sci Rep. 2025 Aug 18;15(1):29830. doi: 10.1038/s41598-025-09462-5.PMID: 40820144

Molecular characterization of *Neospora caninum* major antigens NcSAG1 and NcSRS2.
Echeverría S, Carrión F, Soñora M, Cabrera A, Robello C.R Soc Open Sci. 2025 Aug 20;12(8):250239. doi: 10.1098/rsos.250239. eCollection 2025 Aug.PMID: 40843189

Recommendations for COVID-19 Vaccines in Infants, Children, and Adolescents: Policy Statement.

Committee on Infectious Diseases.Pediatrics. 2025 Aug 19. doi: 10.1542/peds.2025-073924. Online ahead of print.PMID: 40826495

Enhancing influenza vaccination uptake: a systematic review and meta-analysis of intervention strategies.
Wang Y, Zhang Y, Wang J, Shi N, Jin H, Jin H.Expert Rev Vaccines. 2025 Dec;24(1):17-27. doi: 10.1080/14760584.2025.2550986. Epub 2025 Aug 23.PMID: 40847913

Age- and time-dependent waning **vaccine** effectiveness of PPV23 against community-acquired pneumonia among adults aged 60 and older: A cohort study.
Wang B, Qian C, Wu Y, Yi L, Yu H, Liu X, Jiang Y, Zhang T, Zhao G.Hum Vaccin Immunother. 2025 Dec;21(1):2541508. doi: 10.1080/21645515.2025.2541508. Epub 2025 Aug 18.PMID: 40820596

Boosting the influenza **vaccine** schedule in children with cancer: a prospective open-label study.
Chiu SK, Furlong E, McKinnon EJ, Fox A, Ovando SS, Carolan L, McLean-Tooke A, Oommen J, Yeoh DK, Cheung LC, Gottardo NG, Kotecha RS.NPJ Vaccines. 2025 Aug 26;10(1):203. doi: 10.1038/s41541-025-01256-0.PMID: 40855072

HPV16 E6 and E7 expressing cancer cells suppress the antitumor immune response by upregulating KLF2-mediated IL-23 expression in macrophages.
Prins R, Fernandez DJ, Akbari O, Da Silva DM, Kast WM.J Immunother Cancer. 2025 Aug 19;13(8):e011915. doi: 10.1136/jitc-2025-011915.PMID: 40829900

Sequence variability of BamA and FadL candidate vaccinogens suggests divergent evolutionary paths of *Treponema pallidum* outer membrane proteins.
Bettin EB, Aghakhanian F, Hennelly CM, Chen W, Davenport TC, Hackl ST, Grassmann AA, Vargas-Cely F, Silva S, García-Luna JA, Ramirez LG, Jiang Y, Yang L, Zheng H, Yang B, Pospíšilová P, Šmajs D, Matoga MM, Hoffman IF, López-Medina E, Nieselt K, Moody MA, Seña AC, Salazar JC, Parr JB, Caimano MJ, Hawley KL, Radolf JD.J Bacteriol. 2025 Aug 21;207(8):e0015925. doi: 10.1128/jb.00159-25. Epub 2025 Jul 14.PMID: 40802283

Understanding the structure of measles virus and its implications for novel drug discovery.
Chen L, Kita S, Fukuhara H, Maenaka K.Expert Opin Drug Discov. 2025 Sep;20(9):1131-1140. doi: 10.1080/17460441.2025.2546888. Epub 2025 Aug 18.PMID: 40820583

RSV Prefusion F **Vaccine** for Prevention of Hospitalization in Older Adults.
Lassen MCH, Johansen ND, Christensen SH, Aliabadi N, Skaarup KG, Modin D, Claggett BL, Larsen CS, Larsen L, Wiese L, Dalager-Pedersen M, Lindholm MG, Jensen AMR, Dons M, Bernholm KF, Davidovski FS, Duus LS, Ottosen CI, Nielsen AB, Borchsenius JH, Espersen C, Köse G, Fussing FH, Køber L, Solomon SD, Jensen JUS, Martel CJ, Gessner BD, Schwarz C, Gonzalez E, Skovdal M, Moulton LH, Zhang P, Begier E, Biering-Sørensen T.N Engl J Med. 2025 Aug 30. doi: 10.1056/NEJMoa2509810. Online ahead of print.PMID: 40888695

Bivalent RSV Prefusion F Protein-Based **Vaccine** for Preventing Cardiovascular Hospitalizations in Older Adults: A Prespecified Analysis of the DAN-RSV Trial.
Lassen MCH, Johansen ND, Christensen SH, Aliabadi N, Skaarup KG, Modin D, Claggett BL, Larsen CS, Larsen L, Wiese L, Dalager-Pedersen M, Lindholm MG, Jensen AMR, Dons M, Bernholm KF, Davidovski FS, Duus LS, Ottosen CI, Nielsen AB, Borchsenius JH, Espersen C, Köse G, Fussing FH, Pareek M, Køber L, Solomon SD, Jensen JUS, Martel CJ, Gessner BD, Schwarz C, Gonzalez E, Skovdal M, Moulton LH, Zhang P, Begier E, Biering-Sørensen T.JAMA. 2025 Aug 30:e2515405. doi: 10.1001/jama.2025.15405. Online ahead of print.PMID: 40884493

Impact of acellular immunization against pertussis; comparative experience of four countries in North, Central and South America.
Avila-Aguero ML, Betancourt-Cravioto M, Trejo Varon R, Torres JP, Lucas AG, Becerra-Posada F, Espinal C.Expert Rev Vaccines. 2025 Dec;24(1):834-839. doi: 10.1080/14760584.2025.2550973. Epub 2025 Aug 29.PMID: 40836510

Pathogenic mechanisms and molecular features of a novel UL2 gene-deficient duck enteritis virus endemic to China.
Yin D, Gao Y, Xu M, Wang J, Song X, Li Z, Peng J, Kang M, Wei B, Yu C, Qian Y, Jung YS, Hu F, Lv J, Qin Z, Li Y.Virulence. 2025 Dec;16(1):2547325. doi: 10.1080/21505594.2025.2547325. Epub 2025 Aug 21.PMID: 40801158

Development and Preclinical Evaluation of Next-generation ΔsigH-based Live Candidate Vaccines.
Arora G, Munson CW, Ahmed M, Shivanna V, Devi A, Devireddy VS, Antony B, Hall-Ursone S, Gonzalez OD, Dick E Jr, Jagannath C, Alvarez X, Mehra S, Khader SA, Singh DK, Kaushal D.JCI Insight. 2025 Aug 28:e195947. doi: 10.1172/jci.insight.195947. Online ahead of print.PMID: 40875531

The emerging role of the gut microbiota in vaccination responses.
Decker V, Qureshi K, Roberts L, Powell N, Marchesi JR, Mullish BH, Alexander JL.Gut Microbes. 2025 Dec;17(1):2549585. doi: 10.1080/19490976.2025.2549585. Epub 2025 Aug 30.PMID: 40884514

Do Family Physicians' Recommendations for Influenza and Pneumococcal Vaccines Impact the Elderly Aged ≥60 Years? A Cross-Sectional Study in Six Chinese Cities.
Wang Y, Dai J, Yuan S, Chen Y, Zhang Z, Zhu L, Liu G, Zeng Q, Qiu Q, Luo C, Deng R, You L.Vaccines (Basel). 2025 Aug 21;13(8):886. doi: 10.3390/vaccines13080886.PMID: 40872970

Application prospects of tumor vaccines for pancreatic cancer: From TAAs to TSAs and combination strategies.
Lu Z, Zhu W, Liu X.Semin Oncol. 2025 Aug 20;52(5):152399. doi: 10.1016/j.seminoncol.2025.152399. Online ahead of print.PMID: 40839910

Spectroscopic Characterization and Differentiation of SARS-CoV-2 Virus-like Particles.
Dodla A, Giergiel M, Mclean A, Kochan K, Earnest L, Edeling MA, McAuley JL, Godfrey DI, Purcell DFJ, Yap AHY, Montoya JC, Roberts JA, Collett S, Shukla S, Saxena S, Torresi J, Wood BR.Anal Chem. 2025 Aug 19;97(32):17405-17414. doi: 10.1021/acs.analchem.5c01859. Epub 2025 Aug 6.PMID: 40767325

In Situ Vaccines in the Era of Cancer Immunotherapy: Conceptual Innovation and Clinical Translation.
Shi Y, Hou Y, Mabrouk MT, Yu C, Yang Y.Adv Sci (Weinh). 2025 Aug 19:e09836. doi: 10.1002/advs.202509836. Online ahead of print.PMID: 40827547

The potential impact of the next-generation COVID-19 mRNA-1283 **vaccine** in Canada.
Fust K, Kohli M, Cartier S, Joshi K, Van de Velde N, Beck E, Blake M.J Med Econ. 2025 Aug 19:1-14. doi: 10.1080/13696998.2025.2549630. Online ahead of print.PMID: 40827738

Molecular epidemiology of foot and mouth disease virus in Iran during 2019 and 2023.
Khoshnood S, Azimi SM, Ziafati Kafi Z, Najafi H, GhalyanchiLangeroudi A.Sci Rep. 2025 Aug 18;15(1):30178. doi: 10.1038/s41598-025-16115-0.PMID: 40825817

Multiplex bead assays enable integrated serological surveillance and reveal cross-pathogen vulnerabilities in Zambezia Province, Mozambique.
Carcelen AC, Monjane C, Bérubé S, Takahashi S, Sultane T, Chelene I, Cooley G, Goodhew EB, Patterson C, Tetteh K, Mutambe M, Higdon MM, Mwinnyaa G, Nhapure G, Duce P, Martin DL, Drakeley C, Moss WJ, Macicame I.Nat Commun. 2025 Aug 26;16(1):7946. doi: 10.1038/s41467-025-62305-9.PMID: 40858567

Service delivery costs of vaccination at health facilities in Guangzhou, China.
Zhang C, Liu Z, Huang Y, Zheng Z, Wang W, Zhang Z.Hum Vaccin Immunother. 2025 Dec;21(1):2545031. doi: 10.1080/21645515.2025.2545031. Epub 2025 Aug 18.PMID: 40820686

A randomised trial of simultaneous versus sequential pneumococcal vaccination in elderly.
Bahrs C, Andreas N, Lehmann T, Baumgart S, Jørgensen CS, Makarewicz O, Röll D, Moeser A, Hagel S, Watzl C, Bogdan C, Kamradt T, Pletz MW.Clin Microbiol Infect. 2025 Aug 23:S1198-743X(25)00410-0. doi: 10.1016/j.cmi.2025.08.014. Online ahead of print.PMID: 40854463

Correction: Safety and immunogenicity of fractional COVID-19 **vaccine** doses in Nigerian adults: A randomized non-inferiority trial.
Salako A, Musa A, Ige F, Abdullahi A, James A, Ekama S, Odubela O, Idigbe I, Ajibaye O, Altaf M, Adeneye K, Akinsolu FT, Olojo I, Okwuraiwe A, Egharevba H, Ekpenyong M, Elemuwa U, Ezenyi I, Bitrus F, Odubela O, Oba A, Idris G, Yusuf J, Akande I, Nwaiwu S, Omale L, Oyewunmi O, Agbabiaka A, Eyinade O, Ogunwale J, Garba A, Bello Y, Musa B, Ezejiofor O, Ejiro B, Iwalokun B, Rosenzweig L, Adigwe O, Adeyeye C, Shuaib F, Wicek W, Hamada Y, Ezechi O, Gupta R, Salako B.Sci Rep. 2025 Aug 20;15(1):30530. doi: 10.1038/s41598-025-16245-5.PMID: 40836008

In-silico screening of small compounds against Lassa fever haemorrhagic virus nucleoprotein.
Antai EE, Edet UO, Mbim EN, Bassey IU, Abdelkhalig SM, Nwaokorie FO, Moglad E, Ponmak J, Al-Shouli S, AlShouli S, Charlie DE, Abdalla M.Sci Rep. 2025 Aug 20;15(1):30558. doi: 10.1038/s41598-025-89989-9.PMID: 40835743

Factors influencing HPV vaccination willingness among male college students in Jinan according to the health belief model.
Xu Y, Wang W, Cheng C, Yang L, Xing C, Yang X, Chang C, Lu Q.Sci Rep. 2025 Aug 19;15(1):30369. doi: 10.1038/s41598-025-16299-5.PMID: 40830565

Nanoparticle **vaccine** based on the pre-fusion F glycoprotein of respiratory syncytial virus elicits robust protective immune responses.
Hu Z, Tian S, Zhou Y, Wang Y, Li Y, Zhang S, Wei P, Zhuang Z, Ren L, Liu J, Zang N, Yu R, Ding Y, Guo Y, Jing C, Chen H, Zhang C, Yao Y, Deng C, Wei R, Zhou P, Zou Y, Zhao D, Liu S, Fu M, Mo X, Peng G, Liu E, Zhao J, Li Y, Jin J.J Virol. 2025 Aug 26:e0090325. doi: 10.1128/jvi.00903-25. Online ahead of print.PMID: 40856491

BCG **Vaccine**-Induced Innate and Adaptive Pulmonary Immunity Correlating with Protective Efficacy Against Mycobacterium tuberculosis in the Lungs.
Khanna M, Ramsay AJ.Vaccines (Basel). 2025 Aug 19;13(8):876. doi: 10.3390/vaccines13080876.PMID: 40872961

Efficacy of a candidate **vaccine** against Leishmania infantum on naturally exposed dogs to sand flies.

Martorell S, Ligda P, Rai S, Alward L, Berish R, Weber A, Isaacson W, Millership J, King V, Pardali D, Theodorou K, Sotiraki S.Vaccine. 2025 Aug 23;63:127646. doi: 10.1016/j.vaccine.2025.127646. Online ahead of print.PMID: 40850294

The Role of Influencers and Echo Chambers in the Diffusion of **Vaccine** Misinformation: Opinion Mining in a Taiwanese Online Community.
Yin JD, Wu TC, Chen CY, Lin F, Wang X.JMIR Infodemiology. 2025 Aug 18;5:e57951. doi: 10.2196/57951.PMID: 40825242

Prevalence and molecular characterization of parvoviruses in dogs and domestic cats in Guangxi, China: new emergence of CPV-2c in cats.
Sun F, Huang X, Li B, Zhou H, Long J, Qin Y, Ouyang K, Wei Z, Huang W, Chen Y.Top Companion Anim Med. 2025 Aug 21;68:101008. doi: 10.1016/j.tcam.2025.101008. Online ahead of print.PMID: 40848913

Nanoshield Architecture Harnessing Neoantigen-Targeting Peptides Enables Durable Post-surgical Glioma Immunotherapy.
Yin Q, Li J, Zhang J, Leng J, Zhang K, Gao X, Wang F, Yue Q, Ma C, Xu H, Liu X, Zhang H, Liu K.Nano Lett. 2025 Aug 26. doi: 10.1021/acs.nanolett.5c03459. Online ahead of print.PMID: 40859665

Host Immune Response in Chronic Hepatitis Delta: Implications for Pathogenesis and Therapy.
Khanam A, Ameer A, Mathur P, Yurdaydin C, Kottilil S.Pathogens. 2025 Aug 21;14(8):828. doi: 10.3390/pathogens14080828.PMID: 40872338

High-Dose Influenza **Vaccine** Effectiveness against Hospitalization in Older Adults.
Johansen ND, Modin D, Loiacono MM, Harris RC, Dufournet M, Larsen CS, Larsen L, Wiese L, Dalager-Pedersen M, Claggett BL, Janstrup KH, Bartholdy KV, Bernholm KF, Borchsenius JIH, Davidovski FS, Davodian LW, Dons M, Duus LS, Espersen C, Fussing FH, Jensen AMR, Landler NE, Langhoff ACF, Lassen MCH, Nielsen AB, Ottosen CI, Sengeløv M, Skaarup KG, Solomon SD, Landray MJ, Gislason GH, Køber L, Ralfkiaer L, Nealon J, Sivapalan P, Martel CJ, Jensen JUS, Biering-Sørensen T.N Engl J Med. 2025 Aug 30. doi: 10.1056/NEJMoa2509907. Online ahead of print.PMID: 40888720

Engineered Nanobody Chimeras Recruits Anti-HBV Antibodies for Target Cancer Immunotherapy.
Zhang Z, Li Y, Wang Z, Hong H, Wu Z.J Med Chem. 2025 Aug 28;68(16):17189-17201. doi: 10.1021/acs.jmedchem.5c00666. Epub 2025 Aug 5.PMID: 40763296

Evaluating cost-effectiveness of 9-valent HPV vaccination for men who have sex with men by HIV status in Hong Kong.
You D, Quan J, Bishai D, Lam WWT, Grépin KA, Chan L, Wu DD, Wong DKK, Wong WCW, Zhou J.Vaccine. 2025 Aug 22;63:127625. doi: 10.1016/j.vaccine.2025.127625. Online ahead of print.PMID: 40848676

N-glycosylation of the PEDV spike protein modulates viral replication and pathogenicity.
Zhu H, Feng Z, Sun M, Zhang S, Yang Z, Bai J, Jiang P, Liu G, Liu X, Wang X.Vet Res. 2025 Aug 29;56(1):172. doi: 10.1186/s13567-025-01606-9.PMID: 40883772

Corrigendum to "In silico prediction and experimental evaluation of LIP3228 of pathogenic Leptospira as a potential subunit **vaccine** target against leptospirosis" (Biochem. Biophys. Res. Commun. 2025 Jan, 745, 151229. https://doi.org/10.1016/j.bbrc.2024.151229).
Nakornpakdee Y, Techawiwattanaboon T, Prasai S, Komanee P, Sangkanjanavanich N, Boonkea S, Patarakul K.Biochem Biophys Res Commun. 2025 Aug 30;776:152268. doi: 10.1016/j.bbrc.2025.152268. Epub 2025 Jul 5.PMID: 40619336

Rationally designed self-assembled peptide nanofibers provoke robust humoral immunity against nervous necrosis virus.
Zhang C, Zhou Y-C, Song W-Y, Liu X-X, Peng H-H, Sun Y.J Virol. 2025 Aug 19;99(8):e0031925. doi: 10.1128/jvi.00319-25. Epub 2025 Jul 15.PMID: 40662756

"They were saying that it's the end of the world": Experiences of COVID-19 and beliefs about the COVID-19 **vaccine** among refugees in Rhode Island, US.
Connolly S, Liebermann E, Greaney ML, Cohen SA, Lindsey H, Prue O, Keller JC.Hum Vaccin Immunother. 2025 Dec;21(1):2550097. doi: 10.1080/21645515.2025.2550097. Epub 2025 Aug 26.PMID: 40859692

Promotion over pixels: a mixed-methods analysis of **vaccine** communication strategies in Plateau State, Nigeria.
Kakwi JD, Yakasai KM, Kakwi JD, Raimi MO.BMJ Open. 2025 Aug 24;15(8):e094029. doi: 10.1136/bmjopen-2024-094029.PMID: 40850925

A randomized pilot study of HPV16 L2E7E6 fusion protein vaccination site post-treatment for HPV16+ cervical cancer.
Gaillard S, Alvarez J, Zhang T, Wang H, Tsai HL, Cope L, Deery A, Palande V, Lee CF, Fader AN, Huh WK, Arend RC, Liang MI, Straughn JM Jr, Vang R, Ostrander D, Horner K, Zhang L, Singh D, Smith KN, Wu TC, Leath CA 3rd, Roden RBS.Gynecol Oncol. 2025 Aug 20;201:86-96. doi: 10.1016/j.ygyno.2025.08.006. Online ahead of print.PMID: 40839957

Vaccine-induced antibodies to a C-terminal Plasmodium falciparum circumsporozoite protein epitope are associated with protection.
Friedman-Klabanoff DJ, Jensen TL, Gelber CE, Pinapati RS, Tan JC, Deye GA, Regules JA, Bergmann-Leitner ES, Laurens MB, Travassos MA, Goll JB, Takala-Harrison S, Berry AA.J Infect Dis. 2025 Aug 19:jiaf391. doi: 10.1093/infdis/jiaf391. Online ahead of print.PMID: 40826493

AI-driven epitope prediction: a system review, comparative analysis, and practical guide for **vaccine** development.
Villanueva-Flores F, Sanchez-Villamil JI, Garcia-Atutxa I.NPJ Vaccines. 2025 Aug 30;10(1):207. doi: 10.1038/s41541-025-01258-y.PMID: 40885731

Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2025-26 Influenza Season.
Grohskopf LA, Blanton LH, Ferdinands JM, Reed C, Dugan VG, Daskalakis DC.MMWR Morb Mortal Wkly Rep. 2025 Aug 28;74(32):500-507. doi: 10.15585/mmwr.mm7432a2.PMID: 40879559

Design and preclinical assessment of mRNA-1345 prefusion F glycoprotein-encoding mRNA **vaccine** for respiratory syncytial virus.
Shaw CA, Stewart-Jones GBE, Jorquera P, Narayanan E, Elbashir S, Kaplonek P, Ma L, Hunter N, Hanahoe E, Ketova T, Mihai C, Mani S, Ong E, Presnyak V, Rabideau AE, Reid DW, Woods A, Carfi

A.Vaccine. 2025 Aug 20;63:127589. doi: 10.1016/j.vaccine.2025.127589. Online ahead of print.PMID: 40840264

Building trust in community-academic partnerships: Strategies for enhancing **vaccine** confidence and demand - Lessons from Prevention Research Centers.
Jeffers A, Kuiper NM, Ramakrishnan A, Swarna H, Goodman K, Gandhi P, Mendez Morello MI.Vaccine. 2025 Aug 23;60 Suppl 1:127624. doi: 10.1016/j.vaccine.2025.127624. Online ahead of print.PMID: 40850074

Pathogenicity disparities between two avian reovirus strains of the same genetic cluster.
Kovács E, Varga-Kugler R, Homonnay Z, Tatár-Kis T, Mató T, Marton S, Bányai K, Kiss I.Avian Pathol. 2025 Aug 27:1-23. doi: 10.1080/03079457.2025.2551119. Online ahead of print.PMID: 40862651

Antimicrobiota **vaccine** induces lysine-mediated modulation of tick immunity affecting Borrelia colonization.
Mateos-Hernandez L, Abuin-Denis L, Wu-Chuang A, Maitre A, Roháčková H, Rego ROM, Piloto-Sardiñas E, Valdes J, Porcelli S, Heckmann A, Moutailler S, Lucas-Torres C, Moos M, Opekar S, Kratou M, Obregon D, Cabezas-Cruz A.FEMS Microbiol Ecol. 2025 Aug 23;101(9):fiaf082. doi: 10.1093/femsec/fiaf082.PMID: 40810454

Pre-clinical characterization of virus-like particles as a platform for nanovaccines against heroin and oxycodone.
Tronconi D, Marecki C, Seaman RW Jr, Hannon B, Kim CM, Hamid FA, Pravetoni M.Vaccine. 2025 Aug 23;62:127488. doi: 10.1016/j.vaccine.2025.127488. Online ahead of print.PMID: 40850041

A Programmable Nanovaccine Platform Based on M13 Bacteriophage for Personalized Cancer **Vaccine** and Therapy.
Huang S, He Y, Madow A, Peng H, Griffin M, Qi J, Huang M, Amoroso H, Abrashoff R, Heldman N, Belcher AM.Adv Mater. 2025 Aug 27:e10229. doi: 10.1002/adma.202510229. Online ahead of print.PMID: 40873053

Genetics of natural recombinant infectious bronchitis viruses isolated in Kagoshima Prefecture of Japan.
Tanikawa T, Mase M, Hiramatsu K, Watanabe S, Iseki H.Arch Virol. 2025 Aug 27;170(9):203. doi: 10.1007/s00705-025-06389-0.PMID: 40864262

An epitope **vaccine** derived by analyzing clinical trial samples safeguards hosts with prior exposure to S. aureus against reinfection.
Zhang X, Ge S, Wang Y, Wang M, Xu Y, Chen Y, Song Z, Zhao L, Zhang J, Qi J, Sun Y, Gu J, Zhao Z, Jiang X, Gong M, Zha Y, Yang Y, Jing H, Yang F, Zeng N, Xia X, Zhang Y, Luo P, Zhang W, Cheng P, Zeng H, Zou Q.Sci Transl Med. 2025 Aug 20;17(812):eadr7464. doi: 10.1126/scitranslmed.adr7464. Epub 2025 Aug 20.PMID: 40834103

A mix of views: Perspectives on pregnant women's participation in maternal **vaccine** trials.
Nalubega P, Namugumya R, Kyohere M, Seeley J, Le Doare K, Ssali A.Vaccine. 2025 Aug 31;63:127627. doi: 10.1016/j.vaccine.2025.127627. Online ahead of print.PMID: 40889445

Nasopharyngeal carriage and risk factors of major meningitis pathogens among asymptomatic healthcare workers in paediatric units in Benin, with serogroup distribution of Neisseria meningitidis.
Bello CI, Degbey CC, Denon YE, Hinvi SAR, Baba-Moussa L.BMC Infect Dis. 2025 Aug 22;25(1):1056. doi: 10.1186/s12879-025-11492-3.PMID: 40847276

A novel mRNA-based multi-epitope **vaccine** for rabies virus computationally designed via reverse vaccinology and immunoinformatics.
Tombari W, Khamessi O, Othman H, Kallala O, Mahjoub R, Ghedira K, Trabelsi A.Sci Rep. 2025 Aug 19;15(1):30355. doi: 10.1038/s41598-025-16143-w.PMID: 40830404

A Mini Review on Monkey-Pox: Outbreak, Challenges, and Management Strategies.
Thorat DS, Ushir YV, Singh S, Nagime PV.Infect Disord Drug Targets. 2025 Aug 21. doi: 10.2174/0118715265378067250717103733. Online ahead of print.PMID: 40873169

What is the relationship between viral prospecting in animals and medical countermeasure development?
Aatresh AV, Lipsitch M.mBio. 2025 Aug 25:e0203325. doi: 10.1128/mbio.02033-25. Online ahead of print.PMID: 40852983

Validation of a parent HPV **vaccine** misperceptions scale and its association with children's HPV vaccination status.
McDaniels-Davidson C, Parada H Jr, Martinez ME, Martinez LS, Nodora JN, Stack-Babich M, Keleman O, Miller EE, Felner JK, Strong D.Vaccine. 2025 Aug 24;63:127616. doi: 10.1016/j.vaccine.2025.127616. Online ahead of print.PMID: 40854274

Turning challenges into opportunities: Lessons from Ethiopia's COVID-19 response for strengthening health systems and health security.
Mossie MY, Shannon J, Desta AB, Brhanesilassie E, Dufera A, Nawaz S.PLOS Glob Public Health. 2025 Aug 20;5(8):e0005052. doi: 10.1371/journal.pgph.0005052. eCollection 2025.PMID: 40833969

Association of parental education with adolescents' COVID-19 **vaccine** uptake: A nationwide register-based study in Finland.
Variskallio S, Moustgaard H, Remes H, Martikainen P.Vaccine. 2025 Aug 18;63:127615. doi: 10.1016/j.vaccine.2025.127615. Online ahead of print.PMID: 40829287

Enhancing DC cancer **vaccine** by allogeneic MHC class II expression and Treg depletion.
Seishima N, Becker W, Olkhanud PB, Maeng HM, Lopez-Lago MA, Williams WV, Berzofsky JA.JCI Insight. 2025 Jul 15;10(16):e189024. doi: 10.1172/jci.insight.189024. eCollection 2025 Aug 22.PMID: 40857404

Immunological orchestration and dysregulation in COVID-19 pneumonia: from viral pathogenesis to precision therapeutics in the post-pandemic era.
Qin Y, Li C, Yuan X, Li Z.Folia Microbiol (Praha). 2025 Aug 18. doi: 10.1007/s12223-025-01315-y. Online ahead of print.PMID: 40826253

The complex architecture of COVID-19: clinical determinants and deepening of inequities as three epidemic waves progress.
da Costa GS, Pellanda LC, Silva LHF, Dos Santos RDRM, Tovo-Rodrigues L, Genro BP, Fiegenbaum M, Genro JP.Clinics (Sao Paulo). 2025 Aug 21;80:100751. doi: 10.1016/j.clinsp.2025.100751. Online ahead of print.PMID: 40845477

Effectiveness of a Single Dose of Pneumococcal Conjugate **Vaccine** Against Invasive Pneumococcal Disease in Children: A Systematic Literature Review.
Dunne EM, Hong L, Althouse BM, Hayford K, Jodar L, Gessner BD, Theilacker C.Infect Dis Ther. 2025 Aug 19. doi: 10.1007/s40121-025-01211-5. Online ahead of print.PMID: 40828221

COVID-19 Incidence and Factors Influencing Infection Risk Among People Living With HIV in Turkiye: Is Current Issue the **Vaccine** Hesitancy-Opposition?
Inan A, Barkay O, Karapınar A, Yılmaz-Karadag F, Aktas S, Bolukcu S.Can J Infect Dis Med Microbiol. 2025 Aug 18;2025:6767853. doi: 10.1155/cjid/6767853. eCollection 2025.PMID: 40860331

Advances in recombinant protein vaccines against Leishmania infantum: A Sistematic Review of vaccinal constructs and delivery strategies.
Martins AZ, de Oliveira ALG, Bueno LL, Oliveira FMS, Fujiwara RT.Acta Trop. 2025 Aug 19:107796. doi: 10.1016/j.actatropica.2025.107796. Online ahead of print.PMID: 40840696

Correction to "Closed-Loop" O(2)-Economizer Induced In Situ Therapeutic **Vaccine** against Hypoxic Tumors.
Zhao Y, Zhang M, Lv B, Xue G, Jiang H, Chen G, Ma Y, Sun Y, Cao J.ACS Nano. 2025 Aug 22. doi: 10.1021/acsnano.5c12988. Online ahead of print.PMID: 40845364

TeenVac.org: A Mobile Web App to Improve Human Papillomavirus **Vaccine** Uptake for Adolescent Boys.
Woodall WG, Buller D, Zimet G, Kong AS, Reither J, Chilton L, Martinez L, Brooks M, Chirico N, Ginossar T.J Adolesc Health. 2025 Aug 18:S1054-139X(25)00266-6. doi: 10.1016/j.jadohealth.2025.06.015. Online ahead of print.PMID: 40824226

Validation of the Danish translation of the vaccination attitudes examination (VAX) scale.
Buhl C, Jacobsen R, Traulsen JM, Andersen A, Almarsdóttir AB.Vaccine. 2025 Aug 18;62:127620. doi: 10.1016/j.vaccine.2025.127620. Online ahead of print.PMID: 40829384

Investigating genetic, antigenic, and structural diversity in the Neisseria gonorrhoeae outer membrane protein, PorB: implications for **vaccine** design.
Harrison OB, Bash M, Ramirez-Bencomo F, Thistlethwaite A, Jones R, Stejskal L, Sanders E, Feavers IM, Jerse A, Derrick JP, Tang CM, Maiden MCJ.mBio. 2025 Aug 25:e0130925. doi: 10.1128/mbio.01309-25. Online ahead of print.PMID: 40853111

Organoids: physiologically relevant *ex vivo* models for viral disease research.
Wang Y, Peng D, Li M, Yao M, Li T, Li S, Qiu H-J, Li L-F.J Virol. 2025 Aug 29:e0113225. doi: 10.1128/jvi.01132-25. Online ahead of print.PMID: 40879383

Proof-of-concept trial in mature bulls prophylactically and therapeutically vaccinated with an experimental whole-cell killed Tritrichomonas foetus **vaccine**.
Santos JHM, Cavallaro AS, McCosker KD, McGowan MR, Siddle HV, Nguyen LT, Raza A, Boe-Hansen GB, Tabor AE.Parasitology. 2025 Aug 22:1-33. doi: 10.1017/S0031182025100772. Online ahead of print.PMID: 40843490

Cloning, expression and purification of AsSGU protein and its immunogenic response analysis as target candidate for transmission blocking **vaccine** against malaria.
Singh H, Kirar M, Janjoter S, Dahiya N, Yadav M, Sehrawat N.Int Immunopharmacol. 2025 Aug 31;165:115430. doi: 10.1016/j.intimp.2025.115430. Online ahead of print.PMID: 40889466

Next-generation multi-epitope subunit **vaccine** design: A computational approach utilizing two stable proteins to combat Human Metapneumovirus (HMPV).

Mahmud Supto MS, Hasan Shanto MR, Tanoy NM, Anam Fahim MF, Hasan M, Mia MM, Ahmed S.Comput Biol Med. 2025 Aug 18;196(Pt C):110935. doi: 10.1016/j.compbiomed.2025.110935. Online ahead of print.PMID: 40829349

Factors Influencing COVID-19 Viral Clearance: Implications for Vaccination and Antiviral Therapy.
Zeng J, Xu H, Luo S, Zhou X, Li X, Zeng Y, Wang Y, Jiang H, Lin C, Zheng C, Ruan J, Yu W, Yao J, Zhao J.Infect Drug Resist. 2025 Aug 21;18:4227-4240. doi: 10.2147/IDR.S515224. eCollection 2025.PMID: 40861788

Low levels of **vaccine** coverage and immunity against hepatitis B virus in children with hematological malignancies in Brazil.
Krüger VM, da Silva AL, Goldani LZ.Braz J Infect Dis. 2025 Aug 28;29(5):104575. doi: 10.1016/j.bjid.2025.104575. Online ahead of print.PMID: 40882467

A cross-sectional study of the predictors of COVID-19 **vaccine** hesitancy in Pakistan.
Ahmad S, Safdar MR, Ahmed MNQ.Hum Vaccin Immunother. 2025 Dec;21(1):2549164. doi: 10.1080/21645515.2025.2549164. Epub 2025 Aug 27.PMID: 40859741

Immunogenicity and safety of a rabies-based highly pathogenic influenza A virus H5 **vaccine** in cattle.
Paran N, Wirblich C, Olal C, Tarquinio A, Lohmeyer KH, Kurup D, Schultz-Cherry S, Shittu I, Gray GC, Bente DA, Olafson PU, Schnell MJ.NPJ Vaccines. 2025 Aug 19;10(1):197. doi: 10.1038/s41541-025-01238-2.PMID: 40830096

[Influenza prevention among hospital employees in Poland - a narrative review].
Rykowska D, Kuchar E.Med Pr. 2025 Aug 19:207243. doi: 10.13075/mp.5893.01606. Online ahead of print.PMID: 40843937

Ultrasound-enhanced Pt-coordinated polymer immunopotentiators and heterogenic fusion membrane-based multifunctional tumor **vaccine** nanoplatforms for melanoma treatment.
Guo R, Du F, Xiang X, Feng Z, Huang J, Nie C, Ma L, Qiu L.Signal Transduct Target Ther. 2025 Aug 25;10(1):278. doi: 10.1038/s41392-025-02355-z.PMID: 40854883

Postvaccine early-onset (PoVEO) forms of Graves' disease after anti-SARS-CoV-2 vaccination are characterized by favourable long-term disease outcomes.
di Filippo L, Acanfora M, Vassallo A, Valsecchi F, Castellino L, Rosen CJ, Giustina A.Endocrine. 2025 Aug 26. doi: 10.1007/s12020-025-04389-3. Online ahead of print.PMID: 40856956

Anti-inflammatory agent 35 reduces ASFV replication by suppressing the nuclear translocation of p65.
Dai G, Zhou Y, Song D, Cai Y, Yan L, Li D, Zheng H.Virology. 2025 Aug 20;611:110664. doi: 10.1016/j.virol.2025.110664. Online ahead of print.PMID: 40848492

BNT162b2 COVID-19 vaccination uptake, safety, effectiveness, and waning in children and young people aged 5-11 years in Scotland.
Rudan I, Kerr S, Sullivan C, Jeffrey K, Grange Z, Fenton L, Kurdi A, Shi T, Cullen L, Simpson CR, Katikireddi SV, Ritchie LD, Robertson C, Sheikh A.J Glob Health. 2025 Aug 29;15:04250. doi: 10.7189/jogh.15.04250.PMID: 40879019

Comprehensive assessment of the impact of universal rotavirus vaccination program on the burden of diarrheal disease in children after 10 years of implementation in Argentina.

Degiuseppe JI.Vaccine. 2025 Aug 29;63:127681. doi: 10.1016/j.vaccine.2025.127681. Online ahead of print.PMID: 40884908

Passivation-Engineered Zinc Peroxide Nanoparticles as Th1-Biased Adjuvant for Antitumor Immunity.
Luo J, Wang Y, Dai Z, Shi Y, Wu W, Qu J, Zhong Y, Xian J, Yu C, Yang Y.Small. 2025 Aug 26:e05250. doi: 10.1002/smll.202505250. Online ahead of print.PMID: 40856233

Pneumococcal Vaccination Rates Among Patients Hospitalized for Pneumococcal Infection at a Community Teaching Hospital.
Mishra S, Harimohan H, Ayabe K, Johnson R, Fang M.Cureus. 2025 Aug 21;17(8):e90703. doi: 10.7759/cureus.90703. eCollection 2025 Aug.PMID: 40862030

Influenza **vaccine** strain selection with an AI-based evolutionary and antigenicity model.
Shi W, Wohlwend J, Wu M, Barzilay R.Nat Med. 2025 Aug 28. doi: 10.1038/s41591-025-03917-y. Online ahead of print.PMID: 40877477

Is Perceived COVID-19 **Vaccine** Efficacy Associated With Risk Compensation in Preventative Behavior in Indonesia?
Kusumo DY, Schulz T.Asia Pac J Public Health. 2025 Aug 24:10105395251368426. doi: 10.1177/10105395251368426. Online ahead of print.PMID: 40851260

Nanoparticle Delivery of Alu RNA Adjuvants Enhances **Vaccine** Immunogenicity.
Kwiatkowski AJ, Schulman JA, Pagendarm HM, Pastora LE, Tossberg JT, Zhang R, Chada NC, Woodruff ME, Sheehy TL, Arora K, Karijolich J, Aune TM, Wilson JT.ACS Appl Mater Interfaces. 2025 Aug 28. doi: 10.1021/acsami.5c16047. Online ahead of print.PMID: 40878005

Handling multiple time-varying exposures in survival analysis using real-world pediatric data from the pedianet database.
Gonzato E, Annicchiarico L, Cantarutti A, Di Chiara C, Rigamonti V, Valentini D.Sci Rep. 2025 Aug 22;15(1):30827. doi: 10.1038/s41598-025-14849-5.PMID: 40841570

Optimizing school-based delivery of HPV and other routine vaccines for adolescents with disability in specialist schools in Victoria, Australia: a co-design study.
Tuckerman J, Mohamed Y, Justice F, Andersson T, Wyatt K, Broun K, Bastable A, Kaufman J, Danchin M.J Public Health (Oxf). 2025 Aug 29;47(3):469-477. doi: 10.1093/pubmed/fdaf028.PMID: 40052534

The mRNA **vaccine** encoding Gc protein confers complete protection against severe fever with thrombocytopaenia syndrome virus.
Zhang X, Zhang X, Lu J, Yang P, Lu M, Tan S, Guo W, Hu X, Lin J, Shan C.Vaccine. 2025 Aug 21;63:127631. doi: 10.1016/j.vaccine.2025.127631. Online ahead of print.PMID: 40845791

Anti-SARS-CoV-2 Antibodies in Urine of Individuals Vaccinated with Janssen AD26.COV2.S COVID-19 **Vaccine**.
Melo MFN, Lira RCD, Câmara RSB, Pereira IAG, Ramos FF, Costa CSF, Amorim LF, Teixeira QD, da Fonseca FG, Nobre V, Ferreira FGF, Pinto J, Coelho EAF, Ludolf F, Caporali JFM.Pathogens. 2025 Aug 21;14(8):827. doi: 10.3390/pathogens14080827.PMID: 40872337

Understanding the relations of social dominance orientation, right-wing authoritarianism, and vaccination outcomes: applying a multidimensional conceptualization of **vaccine** hesitancy.

Howard MC.J Public Health (Oxf). 2025 Aug 29;47(3):619-628. doi: 10.1093/pubmed/fdaf051.PMID: 40331575

Serological survey to determine measles and rubella immunity gaps across age and geographic locations in The Gambia: a study protocol.
Wariri O, Muhammad AK, Sowe A, Strandmark J, Utazi CE, Metcalf CJE, Kampmann B.Glob Health Action. 2025 Dec;18(1):2540135. doi: 10.1080/16549716.2025.2540135. Epub 2025 Aug 20.PMID: 40833299

Commentary: Improving the vaccination experience for children and adults.
Rand CM, Szilagyi PG.Hum Vaccin Immunother. 2025 Dec;21(1):2546743. doi: 10.1080/21645515.2025.2546743. Epub 2025 Aug 25.PMID: 40853329

Influence of the pre-membrane and envelope proteins on structure, pathogenicity, and tropism of tick-borne encephalitis virus.
Rosendal E, Bisikalo K, Willekens SMA, Lindgren M, Holoubek J, Svoboda P, Lappalainen A, Könighofer E, Mirgorodskaya E, Nordén R, Morini F, Rosenbaum W, Růžek D, Ahlgren U, Anastasina M, Merits A, Butcher SJ, Nilsson E, Överby AK.J Virol. 2025 Aug 19:e0087025. doi: 10.1128/jvi.00870-25. Online ahead of print.PMID: 40827915

Quaternized Chitosan-Coated Nano-MOFs as Antigen Nanocarriers with Enhanced Stability and Immunogenicity.
Gu H, Zhang J, Xu S, Yang Y, Li Y, Xie Y, Hao Z, Li N, Li Y, Zhu W, Li Y, Wang K, Li Q.ACS Appl Bio Mater. 2025 Aug 18;8(8):6865-6880. doi: 10.1021/acsabm.5c00618. Epub 2025 Jul 22.PMID: 40695724

Molecular epidemiology and emerging genotypes of canine distemper virus in Istanbul, Türkiye.
Liu X, Ozkan IE, Naeem R, Umar S, Kayar A, Tali HE, Yılmaz A, Richt JA, Turan N, Yilmaz H.BMC Vet Res. 2025 Aug 26;21(1):522. doi: 10.1186/s12917-025-04963-x.PMID: 40855483

Prospective study of safety, immunogenicity, and efficacy of inactivated COVID-19 **vaccine** in tuberous sclerosis complex children on sirolimus.
Lin S, Zhao X, Li L, Su Q, Long W, Tian X, Ye J, Yuan B, Hu Y, Liao J, Zhang H.Hum Vaccin Immunother. 2025 Dec;21(1):2535120. doi: 10.1080/21645515.2025.2535120. Epub 2025 Aug 19.PMID: 40830965

Perspectives of patients with cancer on influenza and pneumococcal vaccinations in an oncology setting: Is there a role for pharmacists?
Johnstone K, Cooper J, Mylrea M, Smithson J, Glass B.J Oncol Pharm Pract. 2025 Aug 21:10781552251369721. doi: 10.1177/10781552251369721. Online ahead of print.PMID: 40842275

Characterization of a novel invasive virulence of chymotrypsin-like elastase family member 2A from Trichinella spiralis.
Guo X, Zhang XZ, Zhang Y, Zhang R, Long SR, Dan Liu R, Cui J, Wang ZQ.Acta Trop. 2025 Aug 23;270:107803. doi: 10.1016/j.actatropica.2025.107803. Online ahead of print.PMID: 40854405

Evaluation of possible human papillomavirus (HPV) type replacement after **vaccine** introduction, overall and by race/ethnicity, United States.
Brewer SK, Lewis RM, Querec TD, Unger ER, Markowitz LE.Vaccine. 2025 Aug 26;62:127576. doi: 10.1016/j.vaccine.2025.127576. Online ahead of print.PMID: 40865244

Impact of HPV vaccination on the incidence and clearance of HPV infections in sexually active young women.
Kassam P, Laurie C, El-Zein M, Tota JE, Tellier PP, Coutlée F, Burchell AN, Franco EL.Vaccine. 2025 Aug 23;63:127632. doi: 10.1016/j.vaccine.2025.127632. Online ahead of print.PMID: 40850293

Effects of Scalable, Wordless, Short, Animated Storytelling Videos on Flu **Vaccine** Hesitancy in China: Nationwide, Single-Blind, Parallel-Group, Randomized Controlled Trial.
Chen W, Jiao L, Chen Q, Zheng Z, Geldsetzer P, Greuel M, Gates J, Zhao J, Bärnighausen T, Adam M, Chen S, Wang C.J Med Internet Res. 2025 Aug 27;27:e66758. doi: 10.2196/66758.PMID: 40864975

COVID-19 and regional inequalities in childhood vaccination uptake in England: a spline regression.
Sacre A, Sowden S, Bambra C, Bennett N, Todd A.BMC Public Health. 2025 Aug 25;25(1):2913. doi: 10.1186/s12889-025-24207-9.PMID: 40855537

Schistosoma japonicum leishmanolysin SjLLPi1 facilitates the invasion of cercariae into the host skin.
Chen F, Zhu B, Fang Y, Li Z, Lei Z, Xue Z, Shen T, Zhou S, Chen X, Xu L, Li Y, Zhu J, Hu W, Su C.PLoS Pathog. 2025 Aug 26;21(8):e1013446. doi: 10.1371/journal.ppat.1013446. Online ahead of print.PMID: 40857348

An extension of the Benefit Risk Assessment of VaccinEs toolkit to evaluate Comirnaty and Spikevax vaccination in the European Union.
Loedy N, Dorta HG, Abrams S, Crèvecoeur J, Morales DR, Cohet C, Willem L, Molenberghs G, Hens N, Kurz X, Quinten C, Verbeeck J.Eur J Public Health. 2025 Aug 19:ckaf135. doi: 10.1093/eurpub/ckaf135. Online ahead of print.PMID: 40829167

Parents' acceptance of human papilloma virus vaccination for their daughters in adet town, North Gojjam zone, Northwest Ethiopia: A mixed method study.
Kassa B, Mohammed A, Wassie GT.PLoS One. 2025 Aug 26;20(8):e0330911. doi: 10.1371/journal.pone.0330911. eCollection 2025.PMID: 40857284

High-Dose vs Standard-Dose Influenza **Vaccine** and Cardiovascular Outcomes in Older Adults: A Prespecified Secondary Analysis of the DANFLU-2 Randomized Clinical Trial.
Johansen ND, Modin D, Loiacono MM, Harris RC, Dufournet M, Larsen CS, Larsen L, Wiese L, Dalager-Pedersen M, Claggett BL, Janstrup KH, Bartholdy KV, Bernholm KF, Borchsenius JIH, Davidovski FS, Davodian LW, Dons M, Duus LS, Espersen C, Fussing FH, Jensen AMR, Landler NE, Langhoff ACF, Lassen MCH, Nielsen AB, Ottosen CI, Sengeløv M, Skaarup KG, Pareek M, Solomon SD, Landray MJ, Gislason GH, Køber L, Sivapalan P, Martel CJ, Jensen JUS, Biering-Sørensen T.JAMA Cardiol. 2025 Aug 30:e253460. doi: 10.1001/jamacardio.2025.3460. Online ahead of print.PMID: 40884442

Clinical, epidemiological, and laboratory analysis of hospitalized and fatal COVID-19 cases in the first fully vaccinated municipality in Northeast Brazil.
Costa LB, Nobre AP, Santos MESD, Farias LABG, Almeida MM, Bekman ALS, Souza SS, Barreto FKA, Máximo ACBM, Silva DB, Freire de Freitas RWJ, Cavalcanti LPG.Rev Inst Med Trop Sao Paulo. 2025 Aug 18;67:e50. doi: 10.1590/S1678-9946202567050. eCollection 2025.PMID: 40834143

Implementation Status and Usability of Digital Health Interventions Among Health Care Workers and End Users at the Primary Health Care Level in Chandigarh, North India: Cross-Sectional Study.
Jat M, Gupta M, Prinja S.JMIR Form Res. 2025 Aug 25;9:e69824. doi: 10.2196/69824.PMID: 40854229

Mucosal vaccination with long-form TSLP induces migratory cDC1-mediated adaptive immunity against SARS-CoV-2 infection.
Hu J, Zheng H, Ran W, Wang X, Liao C, Zhou J, Ye L.J Virol. 2025 Aug 19:e0123125. doi: 10.1128/jvi.01231-25. Online ahead of print.PMID: 40827912

Contextualizing future maternal RSV vaccination acceptance and trust among pregnant and lactating women in Kenya: A latent class analysis.
Sauer MA, Fesshaye B, Miller ES, Schue JL, Singh P, Jalang'o R, Nyiro J, Karanja-Chege C, Njogu R, Were F, Karron RA, Limaye RJ.PLOS Glob Public Health. 2025 Aug 28;5(8):e0004505. doi: 10.1371/journal.pgph.0004505. eCollection 2025.PMID: 40875757

The early impact of COVID-19 vaccines on major events in cardiac, pulmonary, and thromboembolic disease: a population-based study.
Choi MG, Kim MH, Chun EM.Korean J Intern Med. 2025 Aug 26. doi: 10.3904/kjim.2025.056. Online ahead of print.PMID: 40859806

Cladophora wrightiana Var. Minor Extract Acts as an Adjuvant to Promote Natural Killer Cell Activation by Nasal Influenza **Vaccine**.
Ho TL, Ahn SY, Ko EJ.Food Sci Nutr. 2025 Aug 19;13(8):e70807. doi: 10.1002/fsn3.70807. eCollection 2025 Aug.PMID: 40842664

Stabilization of norovirus GII.3 virus-like particles by rational disulfide engineering.
Warren C, Galli JD, Bystol K, O'Donnell G, Swartz AR, Dewar EA, Fulton CM, Shen P, Gonzalez-Fernandez E, DeWitt LA, Jeong U, Pan OC, Miller S, Fridman A, David C, Chen Z, Wei J.NPJ Vaccines. 2025 Aug 19;10(1):196. doi: 10.1038/s41541-025-01254-2.PMID: 40830611

An archaeal protein nanoparticle platform for cancer cell-specific targeting and therapeutics.
Byun JH, Kim YR, Kim YS, Choi MJ, Ryu CJ, DasSarma P, DasSarma S, Kim JM.Int J Biol Macromol. 2025 Aug 18;322(Pt 4):146967. doi: 10.1016/j.ijbiomac.2025.146967. Online ahead of print.PMID: 40834944

Factors Associated with Respiratory Syncytial Virus-Neutralizing Antibody Titers in Adults.
Shoji K, Yamada M, Hisano M, Okubo Y, Obikane E, Yamaguchi K.J Infect Chemother. 2025 Aug 26:102801. doi: 10.1016/j.jiac.2025.102801. Online ahead of print.PMID: 40876754

Exploring community health workers' perspectives on recommending influenza vaccination to older adults: a phenomenological study.
Shang S, Dai Z, Zhang E, Fang Q.J Public Health (Oxf). 2025 Aug 29;47(3):602-609. doi: 10.1093/pubmed/fdaf075.PMID: 40611476

Nanoparticle based oral delivery of vaccines: A promising solution for immunization challenges in developing nations; A comprehensive review.
Tafere C, Siraj EA, Yayehrad AT, Workye M.Int J Pharm. 2025 Aug 20;681:125848. doi: 10.1016/j.ijpharm.2025.125848. Epub 2025 Jun 14.PMID: 40523548

Factors determining the overlap between recipients of the first and second dose of measles **vaccine** in nineteen surveys.
Papadopoulos T, Jit M, Ferrari MJ, Vynnycky E.Sci Rep. 2025 Aug 21;15(1):30737. doi: 10.1038/s41598-025-10678-8.PMID: 40841401

CpG-mediated TLR9 signaling pathway enhances the efficacy of the OprF/PcrV DNA **vaccine** with cGAS-STING-activating properties.
Tian L, He H, Liu H, Zhang Y, Yu X.Life Sci. 2025 Aug 29:123930. doi: 10.1016/j.lfs.2025.123930. Online ahead of print.PMID: 40886938

Cost-effectiveness of including herpes zoster vaccines into the national immunization program in the Republic of Korea.
Cheong C, Choi WS, An JE, Cho J, Yoon YK, Yu SY.Vaccine. 2025 Aug 28;63:127648. doi: 10.1016/j.vaccine.2025.127648. Online ahead of print.PMID: 40882264

Characterization of *Shigella* virulence factor intracellular spread A (IcsA, or VirG) functional epitopes against *S. flexneri* 2a and *S. sonnei* invasion and adherence.
Madhwal A, Vakamalla SSR, Li S, Zhang W.Appl Environ Microbiol. 2025 Aug 22:e0117525. doi: 10.1128/aem.01175-25. Online ahead of print.PMID: 40844264

Engineering silica-stabilized Pickering emulsions as versatile protein carriers.
Guan X, Ming Y, Zhou Y, Chio CC, Jiang H, Li L, Tse YS, Xia Y, Ngai T.J Colloid Interface Sci. 2025 Aug 20;702(Pt 1):138790. doi: 10.1016/j.jcis.2025.138790. Online ahead of print.PMID: 40882546

Novel rabies **vaccine** candidates development based on pseudotyped lentiviral vectors with rabies virus glycoprotein.
Shuai L, Xu M, Pei N, Zhu C, Belghait M, Hu Z, Li J, Li H, Mao Y, Du H.PLoS Negl Trop Dis. 2025 Aug 26;19(8):e0013404. doi: 10.1371/journal.pntd.0013404. eCollection 2025 Aug.PMID: 40857335

Uptake of COVID-19 **vaccine** among female healthcare workers in Syria: results from a 2022 cross-sectional survey.
Nikoloski Z, Aliyev E, Bain R, Menchini L, Hegazi S, Zalkha M, Mouawad S, Kapil N, Gillespie A.Confl Health. 2025 Aug 18;19(1):63. doi: 10.1186/s13031-025-00700-1.PMID: 40826109

Trehalose-loaded LNPs enhance mRNA stability and bridge in vitro in vivo efficacy gap.
Liu XH, Song HP, Tao LL, Zhai Z, Huang JX, Cheng YX.NPJ Vaccines. 2025 Aug 20;10(1):201. doi: 10.1038/s41541-025-01253-3.PMID: 40835843

Examination of HPV knowledge levels of young adults between 18-30 years of age and the associated factors.
Yücel Y, Doğan EK, Kahraman A, Aytekin MŞ, Alparslan Ö.Afr J Reprod Health. 2025 Aug 26;29(8):112-122. doi: 10.29063/ajrh2025/v29i8.11.PMID: 40856611

IL-2 and IFN-γ Secretion of Activated Jurkat T Cells *via* a Microdroplet-SERS based Single-Cell Immunoassay (Drop-SCIA).
Wang X, Wang J, Liang C, Xu S.Anal Chem. 2025 Aug 26;97(33):18064-18074. doi: 10.1021/acs.analchem.5c02142. Epub 2025 Aug 13.PMID: 40804042

Analysis of HBV infection characteristics and OBI prevalence in pregnant women: a focus on HBcAb + alone or in combination with HBeAb + subgroups in Northwest China.
Xie Y, Kang R, Cheng X, Li D, Wang Q, Li J, Guo X, Gao W, He X, Jiang L, Meng G.BMC Infect Dis. 2025 Aug 18;25(1):1034. doi: 10.1186/s12879-025-11463-8.PMID: 40826398

Early transcriptional divergence in mRNA vaccines reveals molecular correlates of humoral efficacy.

Wang Q, Song Z, Zhang J, Song L, Liu D, Wu X, Gao F, Liu M, Li L, Wang Y, He Q, Zhang X, Mao Q, Liang Z.Biochem Biophys Res Commun. 2025 Aug 30;776:152199. doi: 10.1016/j.bbrc.2025.152199. Epub 2025 Jun 14.PMID: 40543227

Herpes zoster vaccination and **vaccine** preferences among persons aged 50-64 years in Australia: Findings from a discrete choice experiment.
Shantakumar S, Litt J, Booy R, Vandervoort L, Grillo V, Bandy E, Parikh R.Hum Vaccin Immunother. 2025 Dec;21(1):2550102. doi: 10.1080/21645515.2025.2550102. Epub 2025 Aug 28.PMID: 40874719

Efficacy, Immunogenicity, Safety, and Tolerability of AADvac1 in Alzheimer Disease: A Systematic Review and Meta-Analysis of Placebo-Controlled Trials.
Pereira da Silva AM, Falcão Carneiro Filho L, Virgilio Ribeiro F, Rodrigues Menezes I, Leite M, Honorato de Farias E, Nascimento MDV, Silva Corin A, Gonçalves Quiroga D, Franco ES, de Sousa Maia MB.Alzheimer Dis Assoc Disord. 2025 Aug 18. doi: 10.1097/WAD.0000000000000686. Online ahead of print.PMID: 40820539

Mapping the global risk of chikungunya virus endemicity and autochthonous transmission following importation.
Yang YF, Qiu YB, Xu Q, Gao RC, Tang T, Tian Y, Wang YH, Lin SH, Shi YD, Chen LT, Zhang Y, Ma J, Lv CL, Wang GL, Pan HF, Liu W, Fang LQ.Travel Med Infect Dis. 2025 Aug 19;67:102892. doi: 10.1016/j.tmaid.2025.102892. Online ahead of print.PMID: 40835163

Changing Attitudes and Motivations Around Coronavirus Disease 2019 Vaccination Within an Agricultural Community in Southwest Guatemala.
Rojop N, Weikel B, Lamb MM, Barrientos DM, Gomez M, Olson D.Am J Trop Med Hyg. 2025 Aug 26:tpmd250149. doi: 10.4269/ajtmh.25-0149. Online ahead of print.PMID: 40858123

B-vac a robust software package for bacterial **vaccine** design.
Ali A, Hamid MHB, Nasir S, Ishaq Z, Anwer F.Sci Rep. 2025 Aug 28;15(1):31745. doi: 10.1038/s41598-025-01201-0.PMID: 40877337

New-Onset Palmar Psoriasis Following mRNA COVID-19 Vaccination: A Case Report.
Alzamami HFA, AlSulaiman OA, Alkaltham GKI, Alotaibi HK.Int Med Case Rep J. 2025 Aug 23;18:1085-1091. doi: 10.2147/IMCRJ.S535657. eCollection 2025.PMID: 40881047

Evaluation of an authorized nurse immunizer led opportunistic patient influenza and COVID-19 vaccination program under the RE-AIM framework.
Davies S, Taylor K, Moore D.J Public Health (Oxf). 2025 Aug 29;47(3):e391-e399. doi: 10.1093/pubmed/fdaf049.PMID: 40349203

Effects of herpes zoster infection, antivirals and vaccination on risk of developing dementia: A systematic review and meta-analysis.
Marra F, Gomes K, Liu E, Vadlamudi NK, Richardson K, Cragg JJ.Hum Vaccin Immunother. 2025 Dec;21(1):2546741. doi: 10.1080/21645515.2025.2546741. Epub 2025 Aug 19.PMID: 40828095

[Development and immunogenicity evaluation in mice of a novel mRNA **vaccine** expressing herpes simplex virus type 2 envelope glycoprotein gD].
Bing J, Jin L, Deng Y, Sun S, Han X, Cheng X, Qi Z, Wang T, Han R, Zhai D, Tan W.Sheng Wu Gong Cheng Xue Bao. 2025 Aug 25;41(8):3241-3251. doi: 10.13345/j.cjb.250158.PMID: 40873325

Characterization and enzymatic function of thioredoxin glutathione reductase in Orientobilharzia turkestanicum isolated from Xizang.
Tang W, Yue Y, Shi B, Zhao X, Hong Y.BMC Vet Res. 2025 Aug 18;21(1):517. doi: 10.1186/s12917-025-04964-w.PMID: 40820135

Intellectual Property Rights and Global Access to Health Technologies During Pandemics: Reflecting on **Vaccine** Nationalism, COVID-19 & the WHO Pandemic Agreement Negotiations - The Need for Collective Action and Institutional Change.
McMahon AM.J Law Med Ethics. 2025 Aug 29:1-17. doi: 10.1017/jme.2025.10149. Online ahead of print.PMID: 40878692

A post-marketing safety surveillance study on vaccines in Chongqing, China from 2006 to 2021: Using a nationwide spontaneous reporting database with multiple data mining methods.
Xu B, Wang Q, Xu J, Li J, Bai N.Hum Vaccin Immunother. 2025 Dec;21(1):2538353. doi: 10.1080/21645515.2025.2538353. Epub 2025 Aug 27.PMID: 40865054

Regulatory limits of aluminium content of vaccines have not been set based on toxicological studies.
Angrand L, Gherardi RK, Crépeaux G.Environ Toxicol Pharmacol. 2025 Aug 26;119:104812. doi: 10.1016/j.etap.2025.104812. Online ahead of print.PMID: 40876523

Cross-neutralization effect of the third dose of inactivated COVID-19 **vaccine** against the SARS-CoV-2 variants.
Li Y, He J, Liu W, Qi R, Li J, Zhu F.Expert Rev Vaccines. 2025 Aug 25. doi: 10.1080/14760584.2025.2550984. Online ahead of print.PMID: 40853047

Modelling of strategies for the introduction and routine use of multivalent meningococcal conjugate vaccines (MMCVs) in the African meningitis belt.
Karachaliou Prasinou A, Trotter C.PLoS One. 2025 Aug 29;20(8):e0330627. doi: 10.1371/journal.pone.0330627. eCollection 2025.PMID: 40880354

SFTSV utilizes AXL/GAS6 for entry via PI3K-PLC-dependent macropinocytosis activated by AXL-kinase.
Jin Z, Taguwa S, Hirano J, Uemura K, Ono C, Saito A, Okabayashi T, Maeda Y, Kinoshita T, Matsuura Y.J Virol. 2025 Aug 25:e0022125. doi: 10.1128/jvi.00221-25. Online ahead of print.PMID: 40853130

Accelerating HPV-related cancer elimination - a meeting report.
Burdier FR, Bosch FX, Waheed DE, Teblick L, Poljak M, Baay M, de Sanjosé S, Bardou M, Baussano I, Man I, Franco EL, Vorsters A.BMC Proc. 2025 Aug 29;19(Suppl 19):22. doi: 10.1186/s12919-025-00337-1.PMID: 40877872

Recombinant live attenuated measles virus-based vaccines inducing comprehensive protection against Ebola and Marburg viruses.
Zhou J, Zhang X, Yao Y, Xie Y, Li F, Wang W, Yan F, Peng C, Zhang B, Wu Y, Cao Z, Peng Y, Gao G, Zhang H, Gong P, Chiu S.Mol Ther. 2025 Aug 19:S1525-0016(25)00652-5. doi: 10.1016/j.ymthe.2025.08.022. Online ahead of print.PMID: 40836428

Genomic analysis reveals two dominant strains of *Ornithobacterium rhinotracheale* in Austria and Hungary with distinct multidrug resistance profiles.
Palmieri N, Hess C, Pollák B, Magyar T, Pinter K, Doman M, Bilic I, Hess M.Appl Environ Microbiol. 2025 Aug 20;91(8):e0056925. doi: 10.1128/aem.00569-25. Epub 2025 Jul 21.PMID: 40689607

Effects of telehealth during pregnancy on childhood **vaccine** attitudes and timeliness: A randomized controlled trial.
Aksucu G, Çağlar S.Vaccine. 2025 Aug 28;63:127678. doi: 10.1016/j.vaccine.2025.127678. Online ahead of print.PMID: 40882266

Clonal expansion and diversification of germinal center and memory B cell responses to booster immunization in primates.
Deimel LP, Nishimura Y, Silva Santos GS, Baharani VA, Hernandez B, Oliveira TY, MacLean AJ, Canis M, Shawraz S, Gazumyan A, Hartweger H, Bieniasz PD, Hatziioannou T, Martin MA, Nussenzweig MC.Cell Rep. 2025 Aug 26;44(8):116142. doi: 10.1016/j.celrep.2025.116142. Epub 2025 Aug 12.PMID: 40802507

Leaky or polarised immunity: Non-Markovian modelling highlights the impact of immune memory assumptions.
Reyné B, Kamiya T, Djidjou-Demasse R, Alizon S, Sofonea MT.PLoS Comput Biol. 2025 Aug 19;21(8):e1013399. doi: 10.1371/journal.pcbi.1013399. Online ahead of print.PMID: 40828879

High binding potency overcomes the requirement of Fc effector functions for broadly reactive anti-alphavirus antibodies.
Callahan V, Sutton MS, Gardner CL, Prado-Smith J, Kenchegowda D, Dunagan MM, Gosavi M, Embong A, Green C, Kamphaugh H, Chen TY, Long D, Vogel JL, Kosik I, Yewdell JW, Kristie TM, Clancy CS, Burke CW, Roederer M, Fox JM.Sci Transl Med. 2025 Aug 20;17(812):eadt9853. doi: 10.1126/scitranslmed.adt9853. Epub 2025 Aug 20.PMID: 40834099

Process evaluation of the flucare cluster randomised controlled trial: assessing the implementation of a behaviour change intervention to increase influenza vaccination uptake among care home staff in England.
Katangwe-Chigamba T, Alsaif F, Anyiam-Osigwe A, Bion V, Clark A, Garrett H, Griffiths AW, Guillard C, Hammond A, Holland R, Jones L, Patel A, Pitcher J, Risebro H, Scott S, Seeley C, Sims E, Stirling S, Wagner A, Wright D, Birt L.BMC Health Serv Res. 2025 Aug 21;25(1):1118. doi: 10.1186/s12913-025-13298-0.PMID: 40835927

Deep generative models design mRNA sequences with enhanced translational capacity and stability.
Zhang H, Liu H, Xu Y, Huang H, Liu Y, Wang J, Qin Y, Wang H, Ma L, Xun Z, Hou X, Lu TK, Cao J.Science. 2025 Aug 28:eadr8470. doi: 10.1126/science.adr8470. Online ahead of print.PMID: 40875799

Immunofocusing on the conserved fusion peptide of HIV envelope glycoprotein in rhesus macaques.
Pratap PP, Cottrell CA, Quinn J, Carnathan DG, Bader DLV, Tran AS, Enemuo CA, Ngo JT, Richey ST, Gao H, Shen X, Greene KM, Hurtado J, Michaels KK, Ben-Akiva E, Lemnios A, Melo MB, Allen JD, Ozorowski G, Crispin M, Briney B, Montefiori D, Silvestri G, Irvine DJ, Crotty S, Ward AB.NPJ Vaccines. 2025 Aug 20;10(1):200. doi: 10.1038/s41541-025-01252-4.PMID: 40835839

A longitudinal study examining determinants of essential health services during the COVID-19 pandemic in regional referral hospitals across Uganda.
Komasawa M, Tsuji T, Ssekitoleko R, Saito K, Aung MN, Yuasa M.Sci Rep. 2025 Aug 28;15(1):31706. doi: 10.1038/s41598-025-15934-5.PMID: 40877450

Protecting Native Families from COVID-19: Implementation and Lessons Learned from a Community-Based Approach to Collecting Evidence to Support Uptake of Health Behaviors During the COVID-19 Pandemic.

Oguntade HA, Grubin F, Foster H, Tessay R, Neault N, Mitchell K, Masten K, Sundbo A, Rosenstock S, Sutcliffe CG, Hammitt LL, Barlow A, Cwik M.J Racial Ethn Health Disparities. 2025 Aug 22. doi: 10.1007/s40615-025-02598-0. Online ahead of print.PMID: 40844569

Intranasal Delivery of HPV Therapeutic Vaccines for Enhanced Mucosal Immunization and Anti-Tumor Immunity.
Xu Y, Yan X, Zhang F, Li Q, Wei T, Xiao Z, Chai Y, Wang C, Liu Z.ACS Nano. 2025 Aug 26;19(33):30046-30059. doi: 10.1021/acsnano.5c05354. Epub 2025 Aug 12.PMID: 40794451

Respiratory Syncytial Virus Immunization Coverage Among Infants Through Receipt of Nirsevimab Monoclonal Antibody or Maternal Vaccination - United States, October 2023-March 2024.
Boundy EO, Fast H, Jatlaoui TC, Razzaghi H, Harris L, Nguyen K, Mells J, Peacock G, Black CL.MMWR Morb Mortal Wkly Rep. 2025 Aug 21;74(31):484-489. doi: 10.15585/mmwr.mm7431a3.PMID: 40839535

Safety monitoring of health outcomes following influenza vaccination during the 2023-2024 season among U.S. Commercially-insured individuals aged 6 months through 64 years: Self-controlled case series analyses.
Lloyd PC, Acharya G, Zhao H, Chen B, Beachler DC, Secora A, Djibo DA, Amend KL, Ambarsoomzadeh D, Clarke TC, Ng X, Parlett L, Thelus R, Wang X, McMahill-Walraven CN, Lyu R, Wilkinson M, Parambi R, Song J, Seeger JD, Yang G, Stone A, Ding N, Tarazi WW, Hu M, Chillarige Y, Anderson SA, Forshee RA.Vaccine. 2025 Aug 21;63:127614. doi: 10.1016/j.vaccine.2025.127614. Online ahead of print.PMID: 40845790

Post-marketing safety monitoring of RSV vaccines: A real-world study based on the **Vaccine** Adverse Event Reporting System (VAERS).
Bao Z, Gao W, Yu X, Chai L, Liu Y.Hum Vaccin Immunother. 2025 Dec;21(1):2550857. doi: 10.1080/21645515.2025.2550857. Epub 2025 Aug 27.PMID: 40862314

A modification to heptad repeat 1 of gp41 improves yield and/or quality of soluble pre-fusion HIV-1 envelope glycoprotein trimers.
Chaturbhuj DN, Sliepen K, Cupo A, Steinberg B, Kazimierczyk S, Munawar T, Kramer K, Yasmeen A, Andrade TG, Lee W-H, van der Maas L, Gibson G, Feliciano O, Del Moral Sanchez I, Schermer E, Bronson R, Benner A, Prabhakaran M, Mason R, Klasse PJ, Ward AB, Ozorowski G, Sanders RW, Moore JP.J Virol. 2025 Aug 27:e0091325. doi: 10.1128/jvi.00913-25. Online ahead of print.PMID: 40862550

Longitudinal patterns of penile human papillomavirus detection among Ugandan men: A prospective sampling study.
Feng X, Patel EU, Kigozi G, Gravitt PE, Galiwango RM, Petersen MR, Nalugoda F, Redd AD, Reynolds SJ, Quinn TC, Grabowski MK, Tobian AAR.Int J Cancer. 2025 Aug 25. doi: 10.1002/ijc.70107. Online ahead of print.PMID: 40879263

Evaluation of adherence to anti-rabies vaccination schedule and its predictive factors at Addis Alem hospital, Bahir Dar, Ethiopia.
Siraj EA, Behulu T, Shumye S, Gebral W, Gizachew B, Tebabal AT, Yayehrad AT, Kebede SY, Motbaynor G, Addisu ZD.Sci Rep. 2025 Aug 28;15(1):31784. doi: 10.1038/s41598-025-13320-9.PMID: 40877326

[Quantification of viral particles in adenovirus vector-based vaccines by nano-flow cytometry].
Shi Z, Zhang Y, Tian Q, Wang Z, Shao H.Sheng Wu Gong Cheng Xue Bao. 2025 Aug 25;41(8):3155-3164. doi: 10.13345/j.cjb.250160.PMID: 40873318

Structural elucidation of a unique binding mode by an intact alphavirus human IgG molecule to a quaternary epitope.
Bandyopadhyay A, Williamson LE, Sirohi D, Bailey K, Gilliland T Jr, Klose T, Buda G, Trivette A, Sun C, Julander JG, Klimstra WB, Crowe JE Jr, Kuhn RJ.Nat Commun. 2025 Aug 19;16(1):7716. doi: 10.1038/s41467-025-60505-x.PMID: 40830099

Molecular mechanisms for direct sensing of virus-like antigens by B cells.
Cheng W, Zikherman J.Int Immunol. 2025 Aug 30:dxaf052. doi: 10.1093/intimm/dxaf052. Online ahead of print.PMID: 40884252

Uropathogenic Escherichia coli niche occupancy determines the effects of mucosal **vaccine** against FimH.
Santiago-Borges JM, Rosen AL, Hernandez-Leyva A, Tomera CP, Lint MA, Paharik AE, Vanyo V, Pinkner JS, Dodson KW, Chen SL, Hsieh CS, Hultgren SJ, Kau AL.Cell Rep. 2025 Aug 26;44(8):116077. doi: 10.1016/j.celrep.2025.116077. Epub 2025 Aug 2.PMID: 40751913

Broad neutralizing antibody response of a monomeric spike-based SARS-CoV-2 bivalent **vaccine** against diverse variants.
Wang S, Sun H, Wang Y, Wang Z, Yuan L, Guo H, Gao J, Lan M, Wu Y, Shang H, Chen X, Chen Z, Hu J, Tang Z, Wen G, Ying D, Liu C, Jiang Y, Su J, Lin M, Wu T, Li S, Zhang T, Zhang J, Guan Y, Xia N, Yuan Q, Zheng Q, Zhang Y, Zheng Z.Proc Natl Acad Sci U S A. 2025 Sep 2;122(35):e2503254122. doi: 10.1073/pnas.2503254122. Epub 2025 Aug 25.PMID: 40854137

A Phase II Random, Double-Blind, Placebo-Controlled Study of the Safety and Immunogenicity of a Recombinant G Protein-Based Respiratory Syncytial Virus **Vaccine** in Healthy Older Adults.
Zhang L, Zhao G, Cheng X, Wang S, Wang J, Huai X, Xia Y, Xiao Y, Ren S, Zhang S, Wang Q, Wang B.Vaccines (Basel). 2025 Aug 21;13(8):885. doi: 10.3390/vaccines13080885.PMID: 40872968

Vaccine disinformation motivated gunman's attack on US CDC headquarters.
Furlow B.Lancet Respir Med. 2025 Aug 21:S2213-2600(25)00323-6. doi: 10.1016/S2213-2600(25)00323-6. Online ahead of print.PMID: 40850330

Flu Caused Highest Number of Pediatric Deaths Since 2009-2010.
Roush K.Am J Nurs. 2025 Sep 1;125(9):14. doi: 10.1097/AJN.0000000000000150a. Epub 2025 Aug 21.PMID: 40828822

In vivo antiviral activity of two newly developed compounds reduces the harmful effects of ZIKV in chicken embryos.
Rosa de Oliveira M, Wermann KM, Muterle Varela AP, Soster PRDL, Danilevicz CK, Fiuza MFM, Vianna FSL, Wallner O, Kalderén C, Helleday T, Pettke A, Rosa Fraga L.Biochem Biophys Res Commun. 2025 Aug 20;781:152527. doi: 10.1016/j.bbrc.2025.152527. Online ahead of print.PMID: 40850183

Genetic diversity and natural selection of cell-traversal protein for ookinetes and sporozoites (CelTOS) in Plasmodium falciparum isolates from Vietnam.
Võ TC, Lê HG, Kang JM, Minh Trinh NT, Cho M, Goo YK, Quang HH, Na BK.Gene. 2025 Aug 25:149731. doi: 10.1016/j.gene.2025.149731. Online ahead of print.PMID: 40865741

The Costs of Digital Health Interventions to Improve Immunization Data in Low- and Middle-Income Countries: Multicountry Mixed Methods Study.

Federici C, Verykiou M, Cavazza M, Olomi W, Irakiza P, Kayumba K, Rodriguez E, Castillo Mendoza LE, Malvolti S, Hugo C, Ntinginya NE, Camara S, Sabi I, Sano N, Sibomana H, Condo J, Torbica A, Jommi C, Mantel C, Mangiaterra V.J Med Internet Res. 2025 Aug 18;27:e62746. doi: 10.2196/62746.PMID: 40825241

Application of a Rationally Designed Mucosal Nanovaccine Platform in Bacterial Disease Prophylactics Using Fish as a Model Organism.
Zhang C, Zhang PP, Wei CY, Song WY, Peng HH, Liu XX, Zhou YC, Sun Y.ACS Appl Mater Interfaces. 2025 Aug 19. doi: 10.1021/acsami.5c11815. Online ahead of print.PMID: 40830814

Adverse events of special interest after vaccination with COVID-19 vaccines: a cohort event monitoring study in Iran.
Aliyari R, Emamian MH, Mahdavi S, Enayatrad M, Sahab-Negah S, Nili S, Fereidouni M, Mangolian Shahrbabaki P, Ansari-Moghadam A, Shahraki-Sanavi F, Fateh M, Khajeha H, Emamian Z, Behmanesh E, Sharifi H.Eur J Med Res. 2025 Aug 18;30(1):764. doi: 10.1186/s40001-025-03015-2.PMID: 40826472

Evaluation of Chlamydia pecorum major outer membrane protein **vaccine** a management tool in wild koala (Phascolarctos cinereus) populations.
Simpson SJ, Higgins DP, Timms P, Kidd A, Crowther MS, Mella VSA, Phillips S, Krockenberger MB.Sci Rep. 2025 Aug 20;15(1):30601. doi: 10.1038/s41598-025-13296-6.PMID: 40835871

Innate and T-cellular immune responses to sequential vaccination with chimeric hemagglutinin split influenza virus vaccines in mice.
Vasilev K, Puente-Massaguer E, Hoxie I, Bushfield K, Krammer F.Vaccine. 2025 Aug 27;63:127626. doi: 10.1016/j.vaccine.2025.127626. Online ahead of print.PMID: 40876140

Structural basis of a human antibody targeting SARS-CoV-2 nucleocapsid protein dimerization domain and interfering with RNA-binding.
Xue S, He S, Huang Z, Yang M, Hu G, Chen X, Chen Q, Zhou W, Lin S, Chen S.Commun Biol. 2025 Aug 19;8(1):1248. doi: 10.1038/s42003-025-08648-x.PMID: 40830575

Validating and leveraging non-SARS-CoV-2 respiratory infection as a negative control outcome in a phase 3 COVID-19 **vaccine** trial with extended observational follow-up.
Ashby E, Janes H, Follmann D, Gilbert PB, Zhou H, Wang X, Girard B, Priddy F, Kublin JG, Corey L, Neuzil KM, Baden LR, El Sahly HM, Zhang B, Cove Study Group OBO.Am J Epidemiol. 2025 Aug 21:kwaf176. doi: 10.1093/aje/kwaf176. Online ahead of print.PMID: 40838594

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) **vaccine** in children aged 6-17 years: Final results of a phase 2, single-blind, randomised controlled trial (COV006).
Li G, Marchevsky NG, Macaulay G, Aley P, Baughan H, Plested E, Bibi S, Cappuccini F, Faust SN, Heath PT, Muller J, Robinson H, Roderick M, Snape M, Smith D, Song R, Liu X, Lambe T, Pollard AJ; COV006 trial team.Vaccine. 2025 Aug 25;62:127597. doi: 10.1016/j.vaccine.2025.127597. Online ahead of print.PMID: 40857840

Engineered Salmonella Enteritidis vector targeting innate immune molecules provides protection against Salmonella Enteritidis and Salmonella Typhimurium.
Li W, Li YA, Zhang Y, Shi H.Poult Sci. 2025 Aug 24;104(11):105724. doi: 10.1016/j.psj.2025.105724. Online ahead of print.PMID: 40876118

Accelerated cGMP production of near-native HIV-1 Env trimers following electroporation transfection and immunogenicity analysis.
Bale S, Gustchina E, Guenaga J, Ayala V, Lee WH, Ozorowski G, Whitney S, Wilson R, Baboo S, Diedrich JK, Doyle ED, Hudacik L, Ben-Akiva E, Rodrigues KA, Irvine DJ, Yates JR 3rd, Paulson JC, Ward AB, Fouts T, Wyatt RT.NPJ Vaccines. 2025 Aug 20;10(1):198. doi: 10.1038/s41541-025-01218-6.PMID: 40835829

[Effects of blocking apoptosis and lactic acid metabolism pathways on robustness and foreign protein expression of CHO cells].
Lu H, Zhang T, Lyu R, Hou B, Fan T, Yang H, Na J.Sheng Wu Gong Cheng Xue Bao. 2025 Aug 25;41(8):3098-3109. doi: 10.13345/j.cjb.250106.PMID: 40873313

Mpox infection: A state-of-the-art overview of epidemiological, molecular, and clinical aspects following the 2024 public health emergency.
Zamani S, Noroozi E, Hasanzadeh A, Zamani E, Trinidad JC, Firooz A.J Infect Public Health. 2025 Aug 28;18(10):102940. doi: 10.1016/j.jiph.2025.102940. Online ahead of print.PMID: 40885131

Should vaccination status be a consideration during secondary triage?
Jarratt Barnham I.J Med Ethics. 2025 Aug 20;51(9):642-646. doi: 10.1136/jme-2023-109386.PMID: 38050108

Implementation of smartphone application for reporting adverse events following immunization by the treating doctors in tertiary care teaching hospitals in Chennai, India: Pilot and feasibility study.
Krishnamurthy VK, Ilangovan K, Viswanathan V, Suresh S, Chandrasekar R, Chandramohan R, Padmanabhan B, Manjunathaswamy A, Padmanabhan R, Subramaniam S, Dhanasekaran J, Ponnusamy A, Balaji N, Polpakkara D, Selvavinayagam TS, Dhalaria PM, Kumar P.Vaccine. 2025 Aug 21;63:127644. doi: 10.1016/j.vaccine.2025.127644. Online ahead of print.PMID: 40845796

Immunogenicity and Safety of a 2 + 1 DTPa Priming Schedule in Australian Infants and the Impact of Maternally Derived Antibodies on Pertussis Antibody Responses up to 4 Years of Age.
McAlister SM, Dierig A, van den Biggelaar AHJ, Thornton R, Cooper MN, McIntyre P, Richmond PC, Wood N.J Pediatric Infect Dis Soc. 2025 Aug 27;14(8):piaf067. doi: 10.1093/jpids/piaf067.PMID: 40795273

Improved protection against H9N2 avian influenza virus challenge in chickens by the presence of LTB adjuvant on the 3M2e-NP nanoparticle **vaccine** delivered by sifA deficient Salmonella.
Wang M, Zhang T, Guo Q, Sun Y, Yang T, Gao Y, Zhang Y, Zhang Y, Ge C, Jia F, Tian Y, Wang W, He Y, Zhang G, Gong J, Wang Z, Jiang Y.Int Immunopharmacol. 2025 Aug 28;161:115075. doi: 10.1016/j.intimp.2025.115075. Epub 2025 Jun 12.PMID: 40505226

Reduced recurrence of prostate cancer with novel autologous cancer **vaccine** (FK- PC101) post-prostatectomy: long-term results from a single-center phase 1/2 study.
Freitas DMO, Stein AC, Berger M, Kreutz FT.Future Sci OA. 2025 Dec;11(1):2550917. doi: 10.1080/20565623.2025.2550917. Epub 2025 Aug 29.PMID: 40878915

Modelling transmission of Middle East respiratory syndrome coronavirus in camel populations and the potential impact of animal vaccination.
Dighe A, Jombart T, Ferguson N.Nat Commun. 2025 Aug 18;16(1):7679. doi: 10.1038/s41467-025-62365-x.PMID: 40825940

Rational design of respiratory syncytial virus dimeric F-subunit vaccines in protein and mRNA forms.
Li J, Ma X, Xu Z, Guo W, Peng R, Zhang Y, Meng Y, Zhao J, Wang Q, Li S, Chen J, Guo Y, Lu X, Wang Q, Guo Y, Jia MA, Li Y, Zhang Y, Li S, Du P, Wang Q, Gao GF, Qi J.EBioMedicine. 2025 Aug 30;119:105902. doi: 10.1016/j.ebiom.2025.105902. Online ahead of print.PMID: 40886405

Parallel evolution of the elite neutralizer phenotype in divergent HIV-1 clades.
Mesa KA, Li SW, Hutchinson JM, O'Rourke S, Alexander DL, Yu B, Shen X, Wrin T, Petropoulos CJ, Berman PW, Pogson GH.J Virol. 2025 Aug 21:e0043325. doi: 10.1128/jvi.00433-25. Online ahead of print.PMID: 40838752

Burden of Shigella among children with diarrhea in the Americas: A systematic review and meta-analysis.
Lubeck-Schricker M, Rivas-Nieto AC, Rosauer J, Mpinganjira S, Malhotra A, Bastias M, Rogawski McQuade E, Kosek M, Lanata CF, Paredes Olortegui M, Ochoa TJ, Platts-Mills JA, Vannice K, Pavlinac PB.PLoS Negl Trop Dis. 2025 Aug 18;19(8):e0013393. doi: 10.1371/journal.pntd.0013393. Online ahead of print.PMID: 40825034

Genetic polymorphism of circumsporozoite protein of Plasmodium falciparum isolates in children in Brazzaville, Republic of Congo.
Baina MT, Djontu JC, Ntabi JDM, Lissom A, Eouasse AGK, Elenga VA, Mapanguy CCM, Mouanga AM, Ntoumi F.Malar J. 2025 Aug 29;24(1):279. doi: 10.1186/s12936-025-05502-7.PMID: 40883793

Cellular and humoral response after mRNA SARS-CoV-2 vaccination in kidney transplant recipients living with HIV: A cross-sectional study.
Cacho J, Nomah DK, Egri N, Cofán F, Marcos MÁ, Mosquera MM, Sanchez-Palomino S, Bruguera A, Esforzado N, Bodro M, Rovira C, Hurtado C, Vilella A, Diekmann F, Moreno A, Miro JM, Cucchiari D; COVIHVAC investigators.HIV Med. 2025 Aug 25. doi: 10.1111/hiv.70087. Online ahead of print.PMID: 40853031

Patient-reported outcomes and home-based self-swabs for influenza-like illness events - lessons learned from the 2023/2024 DANFLU-2 Homeswab PRO substudy.
Davidovski FS, Skaarup KG, Johansen ND, Modin D, Shaikh N, Bartelt-Hofer J, Loiacono MM, Harris RC, Larsen CS, Larsen L, Wiese L, Dalager-Pedersen M, Jessen R, Steenhard N, Claggett BL, Solomon SD, Køber L, Sivapalan P, Jensen JUS, Martel CJ, Biering-Sørensen T.J Patient Rep Outcomes. 2025 Aug 22;9(1):108. doi: 10.1186/s41687-025-00936-8.PMID: 40844659

HLA **Vaccine** Effect in Double Cord Blood Transplant: Chinese Cohort.
Wong CH, Chan WYK, Lee PPW, Cheuk DKL, Leung W.Blood Adv. 2025 Aug 19:bloodadvances.2025017346. doi: 10.1182/bloodadvances.2025017346. Online ahead of print.PMID: 40829113

Interplay between maternal Tdap and infant pneumococcal vaccination in shaping infant pneumococcal **vaccine** serotype carriage.
Van den Bosch E, Vermeulen H, Ekinci E, Paranthoen L, Van Heirstraeten L, Malhotra-Kumar S, Desmet S, Theeten H, Maertens K.J Infect Dis. 2025 Aug 30:jiaf458. doi: 10.1093/infdis/jiaf458. Online ahead of print.PMID: 40884828

Effectiveness of bivalent respiratory syncytial virus prefusion F protein-based **vaccine** in individuals with or without atherosclerotic cardiovascular disease: the DAN-RSV trial.
Pareek M, Lassen MCH, Johansen ND, Christensen SH, Aliabadi N, Skaarup KG, Modin D, Claggett BL, Larsen CS, Larsen L, Wiese L, Dalager-Pedersen M, Lindholm MG, Jensen AMR, Dons M, Bernholm KF,

Davidovski FS, Duus LS, Ottosen CI, Nielsen AB, Borchsenius JH, Espersen C, Köse G, Fussing FH, Køber L, Solomon SD, Jensen JUS, Martel CJ, Gessner BD, Schwarz C, Gonzalez E, Skovdal M, Zhang P, Begier E, Biering-Sørensen T.Eur Heart J. 2025 Aug 30:ehaf679. doi: 10.1093/eurheartj/ehaf679. Online ahead of print.PMID: 40884439

Epistasis in the receptor-binding domain of contemporary H3N2 viruses that reverted to bind sialylated di-LacNAc repeats.
Liang R, Peccati F, Ponse NLD, Uslu E, de Rooij AJH, Han AX, Boons GJ, Unione L, de Vries RP.Cell Rep. 2025 Aug 26;44(8):116007. doi: 10.1016/j.celrep.2025.116007. Epub 2025 Jul 17.PMID: 40679911

The resident gut microbiome modulates the effect of synbiotics on the immunogenicity after SARS-COV-2 vaccination in elderly and diabetes patients.
Zhang L, Wang S, Wong MCS, Mok CKP, Ching JYL, Mak JWY, Chen C, Huo B, Yan S, Cheung CP, Chiu EOL, Fung EYT, Cheong PK, Chan FKL, Ng SC.NPJ Biofilms Microbiomes. 2025 Aug 25;11(1):171. doi: 10.1038/s41522-025-00804-9.PMID: 40851072

Innate immunity and training to subvert original antigenic sin by the humoral immune response.
Nait Mohamed FA, Lingwood D.Elife. 2025 Aug 28;14:e106654. doi: 10.7554/eLife.106654.PMID: 40874943

Contextualizing HPV vaccination intention among Haitian immigrant and migrant women through exploring cultural worldviews and affective risk perception: a qualitative study.
Guillaume D, Alcaide ML, Sternberg CA, Hay J, Augustin A, Wenzel J, Doriscan LJ, Limaye R, Brown J, Pierre-Joseph N, Rolland C, Alexander KA.Ethn Health. 2025 Aug 19:1-18. doi: 10.1080/13557858.2025.2544114. Online ahead of print.PMID: 40827459

The impact of pneumococcal vaccination and nasopharyngeal colonization on the performance of a serotype-specific urine antigen detection (SSUAD) assay.
Cheon K, Buchwald UK, Hammitt LL, LeBlanc JJ, Tso C, Riley DP, VanDeRiet D, Weatherholtz R, Musey L, Shekar T, Cooper S, Patel R, Chamcha R, Cronk J, Rajam G, Fu W, Nolan KM.Vaccine. 2025 Aug 30;62:127453. doi: 10.1016/j.vaccine.2025.127453. Online ahead of print.PMID: 40886427

The effectiveness of repeated vaccination for COVID-19 symptom resolution during the KP.3-dominant epidemic period in Japan: A retrospective multicenter study.
Bando T, Ikematsu H, Kawai N, Shibao K, Mizuguchi M, Amemiya T, Tsuchiya S, Oribe Y, Lee WJ, Maeda T, Kawashima T, Matsuura S, Doniwa KI, Asamoto H, Sugawara M.J Infect Chemother. 2025 Aug 18;31(10):102798. doi: 10.1016/j.jiac.2025.102798. Online ahead of print.PMID: 40835168

Population structure of Escherichia coli isolated from the human bloodstream, human and animal feces, and the environment in northern Tanzania.
Madut DB, Rubach MP, Scheutz F, Call DR, Gogry FA, Carugati M, Kalengo N, Marandu A, Maze MJ, Morrissey AB, Lwezaula BF, Mmbaga BT, Kilonzo KG, Maro VP, Crump JA.J Infect Dis. 2025 Aug 19:jiaf437. doi: 10.1093/infdis/jiaf437. Online ahead of print.PMID: 40825555

Using the COM-B model to explore factors influencing influenza vaccination among the elderly: Insights from primary healthcare workers in China.
Liu C, Wang Y, Yang X, Tao T, Jin H.Hum Vaccin Immunother. 2025 Dec;21(1):2550859. doi: 10.1080/21645515.2025.2550859. Epub 2025 Aug 26.PMID: 40856361

Development of HiBiT-tagged mumps virus-like particles assembled from authentic viral structural proteins for neutralizing testing.
Wakata A, Bae C, Hatayama Y, Okura T, Otsuki N, Takahashi K, Nagashima M, Sadamasu K, Kato F, Mizukoshi F, Ryo A.Biochem Biophys Res Commun. 2025 Aug 30;776:152236. doi: 10.1016/j.bbrc.2025.152236. Epub 2025 Jun 19.PMID: 40544761

The 40Fp8 **vaccine** strain is safe and protects pregnant ewes from a virulent RVFV challenge.
Borrego B, Alonso C, Moreno S, Calvo-Pinilla E, Lorenzo G, Sánchez-Cordón PJ, Brun A.NPJ Vaccines. 2025 Aug 29;10(1):206. doi: 10.1038/s41541-025-01250-6.PMID: 40883324

Association of the BoLA-DRB3*12:01 allele with resistance to bovine leukosis virus infection in Crioula Lageana cattle.
Fonteque GV, da Silva Casa M, Ribeiro GSN, da Silva Z, Vogel CIG, Fonteque JH, da Costa UM, Giovambattista G, Takeshima SN, Miletti LC.J Appl Genet. 2025 Aug 27. doi: 10.1007/s13353-025-01003-0. Online ahead of print.PMID: 40858974

Effectiveness of a mRNA **Vaccine** Booster Dose Against COVID-19 Among Oregon Healthcare Personnel, January 2021 - June 2023.
Schreiber M, Ocampo VLS, Zhang A, Dusko A, Hall E.Am J Infect Control. 2025 Aug 28:S0196-6553(25)00560-7. doi: 10.1016/j.ajic.2025.08.022. Online ahead of print.PMID: 40885260

Ultrasound-Activatable Lipid Nanoplatform for Region-Confined Innate Immune Stimulation and mRNA Vaccination Therapy of Cancer.
Chen F, Ren S, Huang L, Wu Q, Li M, Li S, Gao J, Lai Y, Cai Z, Liu X, Tao W, Lammers T, Xu Z, Yu H.J Am Chem Soc. 2025 Aug 25. doi: 10.1021/jacs.5c06028. Online ahead of print.PMID: 40854182

Longitudinal dynamics of immune responses after mRNA and inactivated COVID-19 vaccination, boosters, and breakthrough infections in Malaysia.
Fu JYL, Syed Omar SF, Rajasuriar R, Kukreja A, Basri S, Kamarulzaman A, Tan CS, Said A, Su'ut L, Lim SK, Jalalonmuhali M, Bador MK, Sam IC, Chan YF; ASSeSS Consortia.Vaccine. 2025 Aug 27;63:127657. doi: 10.1016/j.vaccine.2025.127657. Online ahead of print.PMID: 40876143

Neutralizing activity against Omicron subvariants BA.1, BA.2, and BA.4/5 following the third SARS-CoV-2 vaccination in cancer patients undergoing chemotherapy.
Yun J, Kim B, Kim H, Lim SH, Choi SH, Kim JY, Kim HJ, Park SK.Clinics (Sao Paulo). 2025 Aug 20;80:100757. doi: 10.1016/j.clinsp.2025.100757. Online ahead of print.PMID: 40840110

High-dose vs. standard-dose inactivated influenza **vaccine** and cardiovascular outcomes in persons with or without pre-existing atherosclerotic cardiovascular disease: the DANFLU-2 trial.
Pareek M, Johansen ND, Modin D, Loiacono MM, Harris RC, Dufournet M, Larsen CS, Larsen L, Wiese L, Dalager-Pedersen M, Claggett BL, Janstrup KH, Bartholdy KV, Bernholm KF, Borchsenius JIH, Davidovski FS, Davodian LW, Dons M, Duus LS, Espersen C, Fussing FH, Jensen AMR, Landler NE, Langhoff ACF, Lassen MCH, Nielsen AB, Ottosen CI, Sengeløv M, Skaarup KG, Solomon SD, Landray MJ, Gislason GH, Køber L, Sivapalan P, Martel CJ, Jensen JUS, Biering-Sørensen T.Eur Heart J. 2025 Aug 30:ehaf678. doi: 10.1093/eurheartj/ehaf678. Online ahead of print.PMID: 40884413

Orf virus-based vectors induce potent germinal center B cell, Tfh cell and $CD8^+$ T cell responses.
Kastner AL, Müller M, Marx AF, Dimitrova M, Wagner I, Merkler D, Amann R, Pinschewer DD.Mol Ther. 2025 Aug 27:S1525-0016(25)00667-7. doi: 10.1016/j.ymthe.2025.08.037. Online ahead of print.PMID: 40873034

Structurally conserved human anti-A35 antibodies protect mice and macaques from mpox virus infection.
Ju B, Liu C, Zhang J, Li Y, Yang H, Zhou B, Huang B, Ma J, Lu J, Cheng L, Cong Z, Zhu L, Shi T, Sun Y, Li N, Chen T, Wang M, Tang S, Ge X, Zhao J, Tan WJ, Yan R, Xue J, Zhang Z.Cell. 2025 Aug 21:S0092-8674(25)00919-5. doi: 10.1016/j.cell.2025.08.005. Online ahead of print.PMID: 40865530

Characterization of genetic mutations in hepatitis B virus isolated from HBsAg+/HBcAb+/HBsAb-/HBV DNA + Japanese blood donors.
Sedohara A, Takahashi K, Tsutsumi T, Arai K, Nakahara F, Ikeuchi K, Adachi E, Yotsuyanagi H.Sci Rep. 2025 Aug 25;15(1):31265. doi: 10.1038/s41598-025-17245-1.PMID: 40855119

Structurally conserved human anti-A35 antibodies protect mice and macaques from mpox virus infection.
Ju B, Liu C, Zhang J, Li Y, Yang H, Zhou B, Huang B, Ma J, Lu J, Cheng L, Cong Z, Zhu L, Shi T, Sun Y, Li N, Chen T, Wang M, Tang S, Ge X, Zhao J, Tan WJ, Yan R, Xue J, Zhang Z.Cell. 2025 Aug 21:S0092-8674(25)00919-5. doi: 10.1016/j.cell.2025.08.005. Online ahead of print.PMID: 40865530

Characterization of genetic mutations in hepatitis B virus isolated from HBsAg+/HBcAb+/HBsAb-/HBV DNA + Japanese blood donors.
Sedohara A, Takahashi K, Tsutsumi T, Arai K, Nakahara F, Ikeuchi K, Adachi E, Yotsuyanagi H.Sci Rep. 2025 Aug 25;15(1):31265. doi: 10.1038/s41598-025-17245-1.PMID: 40855119

Immunogenicity, biodistribution, and toxicology evaluation of Mycobacterium tuberculosis ag85a plasmid DNA in cynomolgus monkeys, mice and guinea pigs.
Zhang D, Yang Y, Zhang Z, Zhang J, Wu X, Liang Y.J Immunol Methods. 2025 Aug 28:113969. doi: 10.1016/j.jim.2025.113969. Online ahead of print.PMID: 40885465

Extended human lymph node explants for evaluation of adaptive immunity.
Fernando K, Quah HS, Suteja L, James A, Kuthubudeen FF, Wu KZ, Adine C, Bhuvaneswari H, Senthilkumar M, Selvarajan S, Iyer NG, Fong ELS.Trends Biotechnol. 2025 Aug 29:S0167-7799(25)00302-6. doi: 10.1016/j.tibtech.2025.07.020. Online ahead of print.PMID: 40885665

Understanding the immunity gap for serogroup B invasive meningococcal disease due to non-pharmaceutical interventions during the Covid-19 pandemic.
Louth J, Holland A, Chum C, Morgan L, Tonge S, Linley E, Lucidarme J, Clark SA, Borrow R.Vaccine. 2025 Aug 23;63:127647. doi: 10.1016/j.vaccine.2025.127647. Online ahead of print.PMID: 40850292

Contemporary Status and Frontiers of Cervical Cancer Screening in the United States.
Eli AV, Kasten BB, Mayer CM, Samant R, Hartman YE, Chaudhary I, Imran N, Dal Zotto VL, Kahn AG, Arend RC, Warram JM.Cancer Prev Res (Phila). 2025 Aug 29. doi: 10.1158/1940-6207.CAPR-25-0118. Online ahead of print.PMID: 40878773

Analysis of Google News Coverage During the 2025 U.S. Measles Outbreak.

Basch CH, Datuowei E, Mewani A, Jones V 2nd, Hillyer GC.Am J Infect Control. 2025 Aug 26:S0196-6553(25)00556-5. doi: 10.1016/j.ajic.2025.08.018. Online ahead of print.PMID: 40876544

Clonotype-enriched somatic hypermutations drive affinity maturation of a public human antibody targeting an occluded sarbecovirus epitope.
Rao VN, Sapse IA, Cohn H, Yoo DK, Tong P, Clark JJ, Bozarth B, Chen Y, Srivastava K, Singh G, Krammer F, Simon V, Wesemann DR, Bajic G, Coelho CH.Cell Rep. 2025 Aug 26;44(8):116122. doi: 10.1016/j.celrep.2025.116122. Epub 2025 Aug 12.PMID: 40803328

Novel Nanoadjuvant for Subunit Vaccines: Cyclic Seven-Membered Tertiary Amine-Based Polymer-Grafted Ethoxy-Acetalated Dextran Nanoparticles Encapsulating CpG Oligodeoxynucleotides.
Yang C, Wang Y, Han Y, Dong H, Tong W, Wu X.Mol Pharm. 2025 Aug 26. doi: 10.1021/acs.molpharmaceut.5c00122. Online ahead of print.PMID: 40859606

Different vaccines, different trust issues? Disentangling the effect of trust in various institutions using dominance analysis.
Ward JK, Youssef R, Peretti-Watel P.Vaccine. 2025 Aug 27;63:127668. doi: 10.1016/j.vaccine.2025.127668. Online ahead of print.PMID: 40876136

Recombinant vaccinia virus expressing MIC8, AMA1, or RON4 induce protection against Toxoplasma gondii ME49 strain infection.
Kang HJ, Quan FS.Acta Trop. 2025 Aug 29:107812. doi: 10.1016/j.actatropica.2025.107812. Online ahead of print.PMID: 40886931

Conjugation of TLR7/8 Adjuvants with Cholesteryl Pullulan for a Self-Assembled Nanogel **Vaccine**: Enhanced Immunostimulatory Activation with Reduced Systemic Inflammation.
Yazawa Y, Sawada SI, Sasaki Y, Akiyoshi K.ACS Appl Bio Mater. 2025 Aug 21. doi: 10.1021/acsabm.5c00866. Online ahead of print.PMID: 40839856

CDC: Kindergarten **Vaccine** Exemptions Rise.
Anderer S.JAMA. 2025 Aug 29. doi: 10.1001/jama.2025.11015. Online ahead of print.PMID: 40880098

HHS Ends mRNA **Vaccine** Development.
Anderer S.JAMA. 2025 Aug 29. doi: 10.1001/jama.2025.11013. Online ahead of print.PMID: 40880114

Good governance essential to expanding **vaccine** capacity and strengthening public trust.
Lee K, Kohler J.Lancet. 2025 Aug 29:S0140-6736(25)01681-2. doi: 10.1016/S0140-6736(25)01681-2. Online ahead of print.PMID: 40889510

Vaccine adjuvants as stand-alone immunoprophylaxis in strategies for 100-day rapid responses to future pandemics.
Kavian N, Kobiyama K, Ishii KJ, Coban C.Int Immunol. 2025 Aug 30:dxaf053. doi: 10.1093/intimm/dxaf053. Online ahead of print.PMID: 40884464

Pityriasis rubra pilaris following Shingrix **vaccine**: a report of two cases.
Han R, Wang CY, Simpson I, Lai FYX, Lee S.Clin Exp Dermatol. 2025 Aug 22;50(9):1871-1873. doi: 10.1093/ced/llaf188.PMID: 40286324

The Influence of Maternal S. aureus anti-Hla neutralizing antibody on infant skin and soft tissue (SSTI) development in the first year of life.
Kao CM, Wylie KM, Boyle MG, Schneider A, Uhlir R, Crick SL, Bubeck Wardenburg J, Fritz SA.J Pediatric Infect Dis Soc. 2025 Aug 28:piaf077. doi: 10.1093/jpids/piaf077. Online ahead of print.PMID: 40874553

Protein Nanocages as Building Blocks for Conjugated Supramolecular Materials Displaying Multitasking Properties.
Santillán-Uribe HC, Soto-Valerio IA, León-Contreras JC, Bustos-Jaimes I.Appl Biochem Biotechnol. 2025 Aug 30. doi: 10.1007/s12010-025-05364-4. Online ahead of print.PMID: 40884724

Targeted degradation of the HPV oncoprotein E6 reduces tumor burden in cervical cancer.
Smalley TB, Nicolaci AA, Tran KC, Lokhandwala J, Obertopp N, Matlack JK, Miner RE 3rd, Teng MN, Pilon-Thomas S, Binning JM.Mol Ther. 2025 Aug 26:S1525-0016(25)00663-X. doi: 10.1016/j.ymthe.2025.08.033. Online ahead of print.PMID: 40873032

The Role of IL-4+ Memory T Cells in SARS-CoV-2 Booster Vaccination.
Khalil J, Miyauchi K, Suzuki Y, Ki S, Harada Y, Sasaki T, Yamamoto Y, Hashimoto R, Yamamoto T, Matsuda M, Koseki H, Nakayama M, Fukasawa M, Wakita T, Ueno H, Noguchi K, Takayama K, Kubo M.Int Immunol. 2025 Aug 30:dxaf051. doi: 10.1093/intimm/dxaf051. Online ahead of print.PMID: 40884220

IgG Antibodies to Pneumococcal Serotypes 1 and 5 in Relation to PCV13 Vaccination Status in Children Aged Under 5 Years in Lao PDR: A Cross-Sectional Survey.
Toh ZQ, Tang KX, Vilivong K, Lai J, Bounkhoun T, Chanthaluanglath V, Chanthongthip A, Balloch A, Newton PN, Dubot-Pérès A, Dance DAB, Licciardi PV, Russell FM.Vaccines (Basel). 2025 Aug 18;13(8):873. doi: 10.3390/vaccines13080873.PMID: 40872958

Circulation of Measles Virus Genotype B3 in the Republic of the Congo Between 2023 and 2024: A Molecular Characterization Study.
Mavoungou YVT, Fritz M, Mayengue PI, Koukouikila FK, Louzolo IJ, Ngangoué LG, Lenguiya LH, Ahombo G, Butel C, Serrano L, Peeters M, Leroy EM, Niama FR.Health Sci Rep. 2025 Aug 26;8(9):e71201. doi: 10.1002/hsr2.71201. eCollection 2025 Sep.PMID: 40873887

Visualizing risk: Risk graphics' impact on patient understanding and choices in discrete choice experiments.
Marceta SM, de Bekker-Grob EW, Veldwijk J.Soc Sci Med. 2025 Aug 20;384:118504. doi: 10.1016/j.socscimed.2025.118504. Online ahead of print.PMID: 40886527

Envelope-dimer epitope 1 (EDE1) antibody (C10) treatment significantly reduces Zika virus replication in the male and female reproductive tracts.
Schramm NJ, Kovarova M, Manzoor S, Cockrell AS, Spagnuolo RA, Amblard F, Bassit L, Schinazi RF, Baric RS, Wahl A, Garcia JV.J Virol. 2025 Aug 18:e0114725. doi: 10.1128/jvi.01147-25. Online ahead of print.PMID: 40824033

HIV-1 controllers possess a unique CD8+ T cell activation phenotype and loss of control is associated with increased expression of exhaustion markers.
Jones AD, Capriotti Z, Santos E, Lin A, Van Duyne R, Smith S, Klase Z.PLoS One. 2025 Aug 28;20(8):e0328706. doi: 10.1371/journal.pone.0328706. eCollection 2025.PMID: 40875618

Identification and characterization of linear B cell epitopes of monoclonal antibodies against the S2 subunit of porcine deltacoronavirus.
Song R, Ma X, Zhao S, Yang J, Liu H, Hao C, Liu K, Hu Y, Guo D, Hu H, Ma S, Xiang Y, Lu H, Wei Z.Int J Biol Macromol. 2025 Aug 26;323(Pt 1):147116. doi: 10.1016/j.ijbiomac.2025.147116. Online ahead of print.PMID: 40876675

Offering Hepatitis B vaccination to vulnerable populations: How can we plug the gaps?
Barlow M, Flanagan S, Ghosh I, Carter J, Kemper A, Ko J, Bedford H, Noonan A, Sultan B, Gillyon-Powell M, Mandal S, Eisen S, Matthews PC.Vaccine. 2025 Aug 26;63:127639. doi: 10.1016/j.vaccine.2025.127639. Online ahead of print.PMID: 40865309

Participation in a Voluntary Blood Donation Program as an Opportunity to Assess and Enhance Tetanus Immunity in Adult Blood Donors with an Outdated or Unknown Vaccination Status.
Tkaczyszyn K, Szymczyk-Nużka M, Szenborn L.Vaccines (Basel). 2025 Aug 21;13(8):884. doi: 10.3390/vaccines13080884.PMID: 40872969

Immune factors produced by PBMCs upon stimulation with lactobacillus delbrueckii ssp. bulgaricus OLL1073R-1-derived exopolysaccharides inhibit HCoV-229E and SARS-CoV-2 replication.
Tang S, Takai-Todaka R, Ishii S, Kono H, Watanabe R, Ogawa M, Kano H, Katayama K, Sashihara T, Hojo K, Haga K.Sci Rep. 2025 Aug 27;15(1):31621. doi: 10.1038/s41598-025-17308-3.PMID: 40866523

Knowledge, attitudes and practices regarding cervical cancer screening among women in the Dindaeng community, Bangkok, Thailand: a cross-sectional community-based study.

Oranratanaphan S, Moonchai K, Pohthipornthawat N, Santibenchakul S, Phoolcharoen N.BMJ Open. 2025 Aug 31;15(8):e100896. doi: 10.1136/bmjopen-2025-100896.PMID: 40887120

Single amino acid substitution in Hendra virus attachment glycoprotein induces cross-neutralizing antibodies against Nipah virus.
Li Y, Huang X, Li R, Zai X, Yang Y, Zhang Y, Zhang Z, Zhang J, Xu J, Chen W.Signal Transduct Target Ther. 2025 Aug 29;10(1):276. doi: 10.1038/s41392-025-02370-0.PMID: 40877258

Breadth of antibody activity elicited by an influenza B hemagglutinin **vaccine** is influenced by pre-existing immune responses to influenza B viruses.
Carlock MA, Pierce SR, Ross TM.J Virol. 2025 Aug 19;99(8):e0070525. doi: 10.1128/jvi.00705-25. Epub 2025 Jul 15.PMID: 40662755

Single-dose Pasteurella multocida and Histophilus somni autogenous vaccines administered at induction significantly improved feedlot cattle performance and profitability in Australia.
Werid GM, Batterham T, O'Meara L, Petrovski K, Pitchford WS, Trott DJ.Aust Vet J. 2025 Aug 31. doi: 10.1111/avj.70012. Online ahead of print.PMID: 40887673

A Lyophilizable Nanoparticle **Vaccine** Specific for a Novel Linear Neutralizing Epitope in the alpha2-alpha3 Helices of Domain 3 of Lethal Factor from Bacillus anthracis.
Oscherwitz J, Cease K, Milich D, Braun T, Yu F, Whitacre D.Toxins (Basel). 2025 Aug 20;17(8):422. doi: 10.3390/toxins17080422.PMID: 40864098

Science vs. Politics: Who Will Win the **Vaccine** Debate Remains to Be Seen.
Roush K.Am J Nurs. 2025 Sep 1;125(9):12-13. doi: 10.1097/AJN.0000000000000150. Epub 2025 Aug 21.PMID: 40828821

High-Dose vs. Standard-Dose Influenza **Vaccine** in Heart Failure: A Prespecified Analysis of the DANFLU-2 Trial.
Skaarup KG, Johansen ND, Modin D, Loiacono MM, Harris RC, Dufournet M, Larsen CS, Larsen L, Wiese L, Dalager-Pedersen M, Claggett BL, Bartholdy KV, Bernholm KF, Borchsenius JI, Davidovski FS, Davodian LW, Dons M, Duus LS, Espersen C, Fussing FH, Jensen AMR, Landler NE, Langhoff ACF, Lassen MCH, Nielsen AB, Ottosen CI, Sengeløv M, Solomon SD, Landray MJ, Gislason GH, Køber L, Sivapalan P, Martel CJ, Jensen JUS, Mebazaa A, Biering-Sørensen T.Circ Heart Fail. 2025 Aug 30. doi: 10.1161/CIRCHEARTFAILURE.125.013678. Online ahead of print.PMID: 40884411

LYnet: Computational identification of tumor T cell antigens using convolutional and recurrent neural networks.
Lv Y, Liu T, Liu C, Ma Y, Liu Y, Liu Z, Li Y.Comput Biol Chem. 2025 Aug 19;120(Pt 1):108630. doi: 10.1016/j.compbiolchem.2025.108630. Online ahead of print.PMID: 40876398

The challenge of protracted measles outbreaks in Kismayo, Somalia: A mixed-method investigation of measles burden and vaccination coverage during a 2020-2021 outbreak.

Lau DK, Seebacher S, Abdi A, Ahmed S, Nur MB, Ciglenecki I, Guadarrama A, Gignoux E.PLOS Glob Public Health. 2025 Aug 29;5(8):e0005143. doi: 10.1371/journal.pgph.0005143. eCollection 2025.PMID: 40880399

Biogenic synthesis, purification and functional elucidation of pheomelanin from Streptomyces spinoverrucosus: a promising platform for next-generation typhoid **vaccine** development.
Periyasamy S, Saravanan K, Kathirvel P.Prep Biochem Biotechnol. 2025 Aug 20:1-15. doi: 10.1080/10826068.2025.2543289. Online ahead of print.PMID: 40834032

Leading US journal refuses RFK Jr's request to retract childhood **vaccine** study.
Tanne JH.BMJ. 2025 Aug 18;390:r1765. doi: 10.1136/bmj.r1765.PMID: 40825596

SARS-CoV-2 vaccination during pregnancy enhances offspring hippocampal neurogenesis and working memory via IFN-γ-responsive microglia.
Tang J, Qi F, Zou J, Liu H, Zuo Z, Wang L, Wang N, Li Z, Kumar A, Guo K, Hu D, Yao Z.Commun Biol. 2025 Aug 29;8(1):1307. doi: 10.1038/s42003-025-08691-8.PMID: 40883541

Analysis of the prevalence, spread, and mutation patterns of SARS-CoV-2 variants: data from COVID-19 testing expansion strategy study in salvador, Northeast Brazil.
Dantas ACS, Oliveira HBM, Pereira TTS, Lima AF, Santos LS, Matos JMF, Aranha T, Magno L, Soares F, Dourado I, Torres TS, Veloso VG, da Costa Ferreira Junior O, de Moraes L, Santos LA, Souto de Medeiros D, Barreto FK, Freitas LM, de Sá Guimarães AM, Campos GB, Marques LM.Sci Rep. 2025 Aug 29;15(1):31866. doi: 10.1038/s41598-025-17691-x.PMID: 40883405

Perception of healthcare administrators on the impediments of optimizing adverse events following immunization e-Reporting in Nigeria.
Erekosima GF, Isiaka SD, Oni F, Garba AR, Bassey O, Asaolu SO, Samuel OW, Ozioko G, Ayodeji OA, Agomuo EC, Okoye IO, Sampson S, Iyayi P, Daniel V.PLoS One. 2025 Aug 28;20(8):e0331093. doi: 10.1371/journal.pone.0331093. eCollection 2025.PMID: 40875746

Long-term immunogenicity and boostability of rabies pre-exposure prophylaxis (PrEP) in immunocompromised adults who received PrEP prior to the start of immunosuppressive therapy: an exploratory study.
Schnyder JL, Sinderen K, Schipper-Boer N, Terryn S, Nauwelaers I, Stijnis C, Grobusch MP, Goorhuis A.J Travel Med. 2025 Aug 28:taaf085. doi: 10.1093/jtm/taaf085. Online ahead of print.PMID: 40874561

Molecular modelling of diterpene compounds from *copaifera* oleoresin as potential bioactive compounds against SARS-CoV-2: calculations of density functional theory and *in silico* ADME-Tox properties.
Ribeiro R, Botelho FD, Cavalcante SFA, Dos Santos MC, Veiga-Junior VF.Nat Prod Res. 2025 Aug 20:1-12. doi: 10.1080/14786419.2025.2547312. Online ahead of print.PMID: 40834245

EU's Extraterritorial Obligations for Global Medicine Access Under the Convention on the Rights of Persons with Disability (CPRD).
Perehudoff K.J Law Med Ethics. 2025 Aug 29:1-9. doi: 10.1017/jme.2025.10144. Online ahead of print.PMID: 40878696

Evaluation of Leishmania homolog of activated C kinase (LACK) of Leishmania donovani in comparison to glycoprotein 63 as a **vaccine** candidate against visceral leishmaniasis.
Didwania N, Bhowmick S, Sabur A, Bhattacharya A, Ali N.Microbiol Spectr. 2025 Aug 19:e0339224. doi: 10.1128/spectrum.03392-24. Online ahead of print.PMID: 40827885

"Si Te la Pones, Yo También Me la Pongo": COVID Vaccines and Hispanic Communities at the Texas-Mexico Border Region.
Alvarez-Hernandez LR, Robledo C, Clark L, Vishwanatha JK, Torres-Hostos LR.Soc Work Public Health. 2025 Aug 30:1-20. doi: 10.1080/19371918.2025.2550353. Online ahead of print.PMID: 40884270

A new method for testing avian metapneumovirus **vaccine** efficacy: Evaluation of tracheal ciliary activity after a challenge.
Marzo E, Guirado E, Taberner E, Castanyer S, Teixidor I, Feu S.Vaccine. 2025 Aug 27;63:127641. doi: 10.1016/j.vaccine.2025.127641. Online ahead of print.PMID: 40876141

Conflicts of interest were at record low when RFK Jr dismissed "conflicted" **vaccine** panel.
O'Dowd A.BMJ. 2025 Aug 19;390:r1774. doi: 10.1136/bmj.r1774.PMID: 40829898

Structural insights into VRC01-class bnAb precursors with diverse light chains elicited in the IAVI G001 human **vaccine** trial.
Lin X, Cottrell CA, Kalyuzhniy O, Tingle R, Kubitz M, Lu D, Yuan M, Schief WR, Wilson IA.Proc Natl Acad Sci U S A. 2025 Aug 19;122(33):e2510163122. doi: 10.1073/pnas.2510163122. Epub 2025 Aug 11.PMID: 40789024

Addressing barriers to and strategies for herpes zoster vaccination in immunocompromised patients in Türkiye: an expert consensus.
Yeşiloğlu C, Altun B, Keskin O, Dizdar Ö, Kiraz S, Ünal S, Büyükaşık Y, Badur S.Expert Rev Vaccines. 2025 Aug 29. doi: 10.1080/14760584.2025.2550979. Online ahead of print.PMID: 40878546

Evaluation of methods for the measurement of antibody-dependent enhancement of dengue virus infection using different FcγRIIa expressing cell lines.
Chelluboina S, Kshirsagar D, Panzade G, Mishra AC, Arankalle V, Shrivastava S.PLoS One. 2025 Aug 29;20(8):e0331320. doi: 10.1371/journal.pone.0331320. eCollection 2025.PMID: 40880375

Altered amyloid plasma profile in patients with disabling headaches after SARS-CoV-2 infection and vaccination.

Aamodt AH, Ueland T, Boldingh M, Bezgal BE, Argren MB, Dunne CA, Otterdal K, Gregersen I, Bjerkeli V, Michelsen AE, Husøy A, Morsund ÅH, Devik K, Poole AC, Gjendemsjø KB, Schlüter K, Mathisen SM, Aalstad-Johansen M, Skattør TH, Sønnervik J, Boye TB, Popperud TH, Høgestøl EA, Harbo HF, Lund-Johansen F, Aukrust P, Tronvik E, Dahl TB, Halvorsen BE.BMJ Neurol Open. 2025 Aug 26;7(2):e001013. doi: 10.1136/bmjno-2024-001013. eCollection 2025.PMID: 40881041

Comparative immunogenicity study of quartet and bifurcated tetravalent dengue virus envelope domain III displayed virus-like particle **vaccine** candidates in BALB/c mice.
Muthuraman KR, Boonyakida J, Matsuda M, Suzuki R, Kato T, Park EY.Vaccine. 2025 Aug 27;63:127670. doi: 10.1016/j.vaccine.2025.127670. Online ahead of print.PMID: 40876139

Temporal dynamics of viral fitness and the adaptive immune response in HCV infection.
Walker MR, Leung P, Keoshkerian E, Pirozyan MR, Lloyd A, Luciani F, Bull RA.Elife. 2025 Aug 29;13:RP102232. doi: 10.7554/eLife.102232.PMID: 40878774

An active post-marketing surveillance study to evaluate the safety and immunogenicity of Zyvac TCV in healthy participants.
Mankar SV, Patel C, Chavan A, Modi R, Sarangi L, Tripathi VN, Dash DK, Narayan JP, Bandgar S, Kumar NR, Gill VK, Kakkar MK, Mitra M, Daultani P, Mittal R, Maithal K, Kansagra K, Parmar DV, Dutta T, Mahajan M, Desai S.Hum Vaccin Immunother. 2025 Dec;21(1):2550085. doi: 10.1080/21645515.2025.2550085. Epub 2025 Aug 26.PMID: 40855908

A novel synthetic bile acid derivative inhibits hepatitis B virus infection at entry step by interfering with the oligomerization of sodium taurocholate co-transporting polypeptide.
Rsi Suwardana GN, Abe T, Deng L, Matsui C, Okitsu T, Yamada T, Hatano M, Wiriyasermkul P, Nagamori S, Gad SA, Aly HH, Nishitsuji H, Shimotohno K, Shoji I.Antiviral Res. 2025 Aug 30:106267. doi: 10.1016/j.antiviral.2025.106267. Online ahead of print.PMID: 40889532

CDC director is forced out over **vaccine** policy, and four senior scientists resign.
Tanne JH.BMJ. 2025 Aug 29;390:r1831. doi: 10.1136/bmj.r1831.PMID: 40882999

Different vaccination debunking interventions: a randomized, controlled experiment estimating "backfiring" and positive effects.
Morgan JC, Kornides ML, Lee J, Fishman J.Vaccine. 2025 Aug 28;62:127463. doi: 10.1016/j.vaccine.2025.127463. Online ahead of print.PMID: 40882577

Shingles **vaccine** will be offered to more immunosuppressed adults in England.
Bowie K.BMJ. 2025 Aug 27;390:r1816. doi: 10.1136/bmj.r1816.PMID: 40866003

A novel glutathione peroxidase (EnGPX) from Eimeria necatrix contributes to oocyst wall biogenesis and confers protective immunity in chickens.
Wang F, Peng Y, Ye Z, Feng Y, Zhang Y, Xu J, Tao J, Liu D.Vet Parasitol. 2025 Aug 28;339:110588. doi: 10.1016/j.vetpar.2025.110588. Online ahead of print.PMID: 40885022

HPV vaccination in Aotearoa New Zealand: Impact of a school-based program on adolescent **vaccine** coverage.
Cosgrove S, Hider P, Anglemyer A, Walls T.Vaccine. 2025 Aug 27;63:127637. doi: 10.1016/j.vaccine.2025.127637. Online ahead of print.PMID: 40876142

MAIT and other innate-like T cells integrate adaptive immune responses to modulate interval-dependent reactogenicity to mRNA vaccines.
Amini A, Garner LC, Shaw RH, Kelly NW, Adele S, Skelly DT, Dejnirattisai W, Greenland M, Liu X, Heslington A, Hackstein CP, Murray SM, Vano CR, Stafford L, Johnson S, Sayaf K, Pudjohartono MF, Clutterbuck EA; PITCH Consortium‡; Com-COV Study Group‡; Bibi S, Conlon CP, James T, Jeffery K, Kronsteiner B, Mentzer AJ, O'Shea D, Ramasamy MN, Screaton GR, Snape MD, Hogan AE, Barnes E, Lambe T, Dunachie SJ, Provine NM, Klenerman P; PITCH Consortium; Com-COV Study Group.Sci Immunol. 2025 Aug 29;10(110):eadu3337. doi: 10.1126/sciimmunol.adu3337. Epub 2025 Aug 29.PMID: 40880519

Structural and functional characteristics of local immune memory formation in SARS-CoV-2-infected cynomolgus macaques.
Kim DY, Kim G, Oh T, Woo Y, Koo BS, Baek SH, Hwang EH, Min G, An YJ, Won J, Lee Y, Lim KS, Kim Y, Ryu CM, Nizet V, Hong JJ.Clin Immunol. 2025 Aug 27:110589. doi: 10.1016/j.clim.2025.110589. Online ahead of print.PMID: 40882689

The 2025 UK 4CMenB **vaccine** programme for GBMSM at high risk of gonorrhoea.
Ladhani SN, Fifer H.Sex Transm Infect. 2025 Aug 28;101(6):426. doi: 10.1136/sextrans-2025-056681.PMID: 40877016

Pepscan and bioinformatic strategies for identification of potential B-cell epitopes for a peptide-based **vaccine** for tick control.
Andrade-Silva V, Waldman J, Juliano MA, Tirloni L, da Silva Vaz I Jr.Mol Biochem Parasitol. 2025 Aug 28;263:111692. doi: 10.1016/j.molbiopara.2025.111692. Online ahead of print.PMID: 40885405

Lipid nanoparticles-mRNA based on the consensus sequences of avian coronavirus S1 and N genes protect animals against multiple viral infections.
Xiao H, Wu W, Yu S, Chen J, Lai L, Ren J, Yan X, Lin Q, Chen L, Ren T.J Nanobiotechnology. 2025 Aug 30;23(1):595. doi: 10.1186/s12951-025-03668-5.PMID: 40883775

Letter to editor: public response to Covid policies: diverse contextual influences correspondence: perceptions of COVID-19 **vaccine** side effects by political affiliation.
Yang YT, Hsu YE, Luo WT, Chu JS.J Public Health (Oxf). 2025 Aug 29;47(3):e496-e497. doi: 10.1093/pubmed/fdae276.PMID: 39387498

Corrigendum to 'Immune correlates analysis of the Imbokodo (HVTN 705/HPX2008) efficacy trial of a mosaic HIV-1 **vaccine** regimen evaluated in Southern African people assigned female sex at birth: a two-phase case-control study'. EBioMedicine 2024;108: 105320.
Kenny A, van Duijn J, Dintwe O, Heptinstall J, Burnham R, Sawant S, Zhang L, Mielke D, Khuzwayo S, Omar FL, Stanfield-Oakley S, Keyes T, Dunn B, Goodman D, Fong Y, Benkeser D, Zou R, Hural J, Hyrien O, Juraska M, Luedtke A, van der Laan L, Giorgi EE, Magaret C, Carpp LN, Pattacini L, van de Kerkhof T, Korber B, Willems W, Fisher LH, Schuitemaker H, Swann E, Kublin JG, Pau MG, Buchbinder S, Tomaka F, Nijs S, Lavreys L, Gelderblom HC, Corey L, Mngadi K, Gray GE, Borducchi E, Hendriks J, Seaton KE, Zolla-Pazner S, Barouch DH, Ferrari G, De Rosa SC, McElrath MJ, Andersen-Nissen E, Stieh DJ, Tomaras GD, Gilbert PB; Imbokodo Study and Correlates Group.EBioMedicine. 2025 Aug 23;119:105874. doi: 10.1016/j.ebiom.2025.105874. Online ahead of print.PMID: 40850015

Correction: Outcomes After Decompressive Surgery for Severe Cerebral Venous Sinus Thrombosis Associated or Not Associated with **Vaccine**-Induced Immune Thrombosis with Thrombocytopenia: A Multicenter Cohort Study.
Pelz JO, Kenda M, Alonso A, Etminan N, Wittstock M, Niesen WD, Lambeck J, Güresir E, Wach J, Lampmann T, Dziewas R, Wiedmann M, Schneider H, Bayas A, Christ M, Mengel A, Poli S, Brämer D, Lindner D, Pfrepper C, Roth C, Salih F, Günther A, Michalski D; IGNITE Study Group.Neurocrit Care. 2025 Aug 18. doi: 10.1007/s12028-025-02354-6. Online ahead of print.PMID: 40825920

Innovative use of self-controlled methods for the evaluation of waning effectiveness of the COVID-19 monovalent third dose: comparison with a test-negative design.
Korves C, Kulldorff M, Balajee AS, Smith J, Zwain GM, Graham DJ, Whitaker H, Izurieta HS.Vaccine. 2025 Aug 27;63:127658. doi: 10.1016/j.vaccine.2025.127658. Online ahead of print.PMID: 40876138

Analysis of *Treponema pallidum* subsp. *pallidum* predicted outer membrane proteins (OMPeomes) in 21 clinical samples: variant sequences are predominantly surface-exposed.
Pospíšilová P, Fedrová P, Vrbová E, Hennelly CM, Aghakhanian F, Hawley KL, Bettin EB, Davenport TC, Bruisten SM, Zondag HCA, Grange PA, Dupin N, Arora N, Noda AA, Seña AC, Caimano MJ, Salazar JC, Juliano JJ, Moody MA, Radolf JD, Parr JB, Šmajs D.mSphere. 2025 Aug 29:e0021325. doi: 10.1128/msphere.00213-25. Online ahead of print.PMID: 40879370

Iron Oxide Nanoparticles Activate Innate Immunity Through Toll-Like Receptors and Cooperate with CpG as a Potent Nano-Adjuvant.
Yang C, Meng J, Li W, Zhao Y, Li J, Wen Y, Liu S, Cheng X, Mi S, Huo H, Lu X, Gao M.Small. 2025 Aug 30:e08378. doi: 10.1002/smll.202508378. Online ahead of print.PMID: 40884113

Fulminant Myocarditis After mRNA COVID-19 **Vaccine** Evolving to Giant Cell Myocarditis.
Ouimet-Grennan E, Parent MC, Tremblay-Gravel M, Pelletier-Galarneau M, Boulet J.JACC Case Rep. 2025 Aug 27;30(25):105078. doi: 10.1016/j.jaccas.2025.105078.PMID: 40883063

Correction: Factors associated with COVID-19 **vaccine** uptake and hesitancy among healthcare workers in the Democratic Republic of the Congo.
Nzaji MK, Kamenga JD, Lungayo CL, Bene ACM, Meyou SF, Kapit AM, Fogarty AS, Sessoms D, MacDonald PDM, Standley CJ, Stolka KB.PLOS Glob Public Health. 2025 Aug 20;5(8):e0005096. doi: 10.1371/journal.pgph.0005096. eCollection 2025.PMID: 40833952

Protocol for the coculture of murine vaginal epithelial organoids and T cells to induce resident memory CD8 T cell differentiation.
Ramprashad JC, Lin Y, Beura LK.STAR Protoc. 2025 Aug 29;6(3):104054. doi: 10.1016/j.xpro.2025.104054. Online ahead of print.PMID: 40884788

Chickenpox **vaccine** to be offered to children in England.
Iacobucci G.BMJ. 2025 Aug 29;390:r1828. doi: 10.1136/bmj.r1828.PMID: 40883008

MDCK cell line expressing H9N2 avian influenza virus NS1 protein promotes replication of the NS1 gene truncation virus.
Liu Y, Yang Y, Quan K, Yin Y, Su X, Mao X, Yang H, Qin T, Peng D, Chen S.Vet Microbiol. 2025 Aug 25;309:110694. doi: 10.1016/j.vetmic.2025.110694. Online ahead of print.PMID: 40884961

Dosing interval is a major factor determining the quality of T cells induced by SARS-CoV-2 mRNA and adenoviral vector vaccines.
Murray SM, Amini A, Ferry H, Garner LC, Pudjohartono MF, Kronsteiner B, Bibi S, Pollard AJ, Barnes E, Lambe T, Dunachie S, Klenerman P, Provine NM.Sci Immunol. 2025 Aug 29;10(110):eadu4610. doi: 10.1126/sciimmunol.adu4610. Epub 2025 Aug 29.PMID: 40880518

Immunogenicity of DNA Vaccines against COVID-19 That Encode B- and T-Cell Immunogens after Combined Injection.
Borgoyakova MB, Rudometov AP, Starostina EV, Zadorozhny AM, Tigeeva EV, Yakovlev VA, Kisakov DN, Kisakova LA, Karpenko LI, Ilyichev AA.Bull Exp Biol Med. 2025 Aug 29. doi: 10.1007/s10517-025-06461-4. Online ahead of print.PMID: 40877652

Valuing combination vaccines: an incomplete picture and a pathway to a broader view.
Debellut F, Jit M, Portnoy A, Mvundura M, Giersing B, Hasso-Agopsowicz M, Hausdorff WP, Pecenka C.Vaccine. 2025 Aug 31;63:127675. doi: 10.1016/j.vaccine.2025.127675. Online ahead of print.PMID: 40889446

COVID-19 vaccinations in America: Don't forget long COVID and the post-acute sequelae.
Hotez PJ.Vaccine. 2025 Aug 27;63:127676. doi: 10.1016/j.vaccine.2025.127676. Online ahead of print.PMID: 40876137

Effectiveness of COVID-19 Vaccination to Prevent Healthcare Personnel Absences: A Single Site Experience.

Huang FS, Duan Q, Araya A, Sheets A, Schaffzin JK.Am J Infect Control. 2025 Aug 26:S0196-6553(25)00553-X. doi: 10.1016/j.ajic.2025.08.016. Online ahead of print.PMID: 40876543

A TLR7/8 agonist-chitosan conjugate as an adjuvant for carbohydrate-based anticancer **vaccine** development.
Yin XG, Tong GZ, Huang SQ, Chen LY, Yang AT, Teng WJ, Luo X, Zhu KW.Chem Commun (Camb). 2025 Aug 29. doi: 10.1039/d5cc03299g. Online ahead of print.PMID: 40879483

Effect of RSV **Vaccine** on Heart Failure Hospitalizations: A Prespecified Analysis of the DAN-RSV Trial.
Skaarup KG, Lassen MCH, Johansen ND, Christensen SH, Aliabadi N, Modin D, Claggett BL, Larsen CS, Larsen L, Wiese L, Dalager-Pedersen M, Lindholm MG, Jensen AMR, Dons M, Bernholm KF, Davidovski FS, Duus LS, Ottosen CI, Nielsen AB, Borchsenius JH, Espersen C, Köse G, Fussing FH, Køber L, Solomon SD, Jensen JUS, Martel CJ, Mebazaa A, Gessner BD, Schwarz C, Gonzalez E, Skovdal M, Zhang P, Begier E, Biering-Sørensen T.J Am Coll Cardiol. 2025 Aug 26:S0735-1097(25)07467-4. doi: 10.1016/j.jacc.2025.08.023. Online ahead of print.PMID: 40884521

Identification of neoantigen epitopes in cervical cancer by multi-omics analysis.
Yuan J, Xu N, Gong X, Ai J, Li K, Han Y.Eur J Med Res. 2025 Aug 18;30(1):763. doi: 10.1186/s40001-025-03036-x.PMID: 40826144

[Utilization of the influenza vaccination among individuals over 60 years: spatial variations and regional risk factors].
Akmatov MK, Kohring C, Holstiege J, Müller D.Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2025 Aug 18. doi: 10.1007/s00103-025-04103-8. Online ahead of print.PMID: 40825876

Human Papillomavirus Across the Reproductive Lifespan: An Integrative Review of Fertility, Pregnancy Outcomes, and Fertility-Sparing Management.
Terrinoni M, Golia D'Augè T, Mascellino G, Adinolfi F, Palisciano M, Rossetti D, Di Renzo GC, Giannini A.Medicina (Kaunas). 2025 Aug 21;61(8):1499. doi: 10.3390/medicina61081499.PMID: 40870544

Evaluating potential associations between prior maternal yellow fever vaccination and protection against infant adverse outcomes following Zika virus antenatal exposure.
Oliveira EF, Santos-Pinto CDB, Venancio FA, Quilião ME, Gabeira SCO, Carvalho AT, Leite SHDS, Lima SMB, Alves NDS, Moura LDC, Schwarcz WD, Azevedo AS, Demarchi LHF, Zardin MCSU, Lichs GGC, Taira DL, Souza Fernandes W, Alves NO, Arrua AEC, Nascimento AID, Mareto LK, Azevedo MV, Maciel CG, Medeiros MJ, Vasconcelos Z, Cunha RVD, Nielsen-Saines K.Int J Epidemiol. 2025 Aug 18;54(5):dyaf147. doi: 10.1093/ije/dyaf147.PMID: 40825594

Development of DNA and mRNA-LNP vaccines against an H5N1 clade 2.3.4.4b influenza virus.

Leonard RA, Spurrier MA, Skavicus S, Luo Z, Heaton BE, Spreng RL, Hong J, Yuan F, Heaton NS.J Virol. 2025 Aug 19;99(8):e0079525. doi: 10.1128/jvi.00795-25. Epub 2025 Jul 16.PMID: 40667976

Association Between Health-Related Quality of Life and Willingness of COVID-19 Vaccination: A Cross-sectional Study in China.
Wang J, Xi R, Su Z, Feng Y, Fan Y, Su W, Xia J, Pan Q, Shi L, Li Y, Li B, Wang P.Disaster Med Public Health Prep. 2025 Aug 22;19:e244. doi: 10.1017/dmp.2025.10133.PMID: 40842141

Primary care pediatricians' involvement in influenza vaccination campaign in Italy.
Indaco R, Leoni F, Panza C, Giorgi Rossi P.Ital J Pediatr. 2025 Aug 22;51(1):259. doi: 10.1186/s13052-025-02093-6.PMID: 40847306

Permissiveness of different TMEM154 genotype cell lines to different SRLV genotypes/subtypes.
Colitti B, Avanzato D, Moretti R, Moncayola I, Profiti M, Chessa S, Sacchi P, Rosati S, Reina R.J Virol. 2025 Aug 22:e0096125. doi: 10.1128/jvi.00961-25. Online ahead of print.PMID: 40844279

N-linked glycans on the stalk of influenza virus neuraminidase promote functional tetramer formation by compensating for local hydrophobicity.
Saeidi S, Wan H, Kang H, Gao J, Wu WW, Malik T, Daniels R.J Virol. 2025 Aug 18:e0087925. doi: 10.1128/jvi.00879-25. Online ahead of print.PMID: 40824089

Health and Economic Burden of Rabies in Northwest Ethiopia.
Azalu WW, Jemberu WT, Taye BW, Abebe WM, Mekonnen SA.Pharmacoecon Open. 2025 Aug 24. doi: 10.1007/s41669-025-00601-2. Online ahead of print.PMID: 40849876

Evaluation of One Health approach measures implemented in response to the human rabies outbreak in the Maxakali Indigenous Land, Brazil.
Tolentino Júnior DS, Santos Vasconcelos Marques M, Zatti Pereira JO, de Oliveira RC.One Health Outlook. 2025 Aug 22;7(1):41. doi: 10.1186/s42522-025-00167-3.PMID: 40847429

A refined low-dose murine model of *Mycobacterium ulcerans* infection to assess integrated immune networks in Buruli ulcer pathogenesis.
Muhi S, Foo IJH, Kedzierski L, Porter JL, McQuilten HA, Howden B, Kedzierska K, Buultjens AH, Chua BY, Stinear TP.mBio. 2025 Aug 18:e0193125. doi: 10.1128/mbio.01931-25. Online ahead of print.PMID: 40823822

Comparing Multiple Imputation Methods to Address Missing Patient Demographics in Immunization Information Systems: Retrospective Cohort Study.
Brown S, Kudia O, Kleine K, Kidd B, Wines R, Meckes N.JMIR Public Health Surveill. 2025 Aug 26;11:e73916. doi: 10.2196/73916.PMID: 40857554

Pneumococcal vaccination incentive campaign in chronic heart failure patients in France: a cluster-randomized trial.

Guillermou H, Mercier G, Litovsky B, Papinaud L, Roubille F.Eur J Prev Cardiol. 2025 Aug 29:zwaf529. doi: 10.1093/eurjpc/zwaf529. Online ahead of print.PMID: 40876857

Preparedness of the Local Population for the Uptake of Artificial Intelligence and Digital One Health for Home Healthcare of Emerging and Reemerging Infectious Diseases in Southwest and Littoral Regions of Cameroon.
Asonganyi EA, Tanue EA, Kwalar GI, Kibu OD, Ondua M, Sandeu MM, Ngono Ema PJ, Nkweteyim D, Nyamsi ML, Achankeng PL, Tchapga C, Ayuk J, Halle-Ekane GE, Kong JD, Nsagha DS.J Trop Med. 2025 Aug 19;2025:8896234. doi: 10.1155/jotm/8896234. eCollection 2025.PMID: 40873668

Breakthrough hepatitis B virus infection and its associated factors among vaccinated children in Northwest Ethiopia.
Geta M, Hailu A, Woldeamanuel Y.Sci Rep. 2025 Aug 28;15(1):31704. doi: 10.1038/s41598-025-02906-y.PMID: 40877358

Based on real-world data: Risk factors and prediction model for mental disorders induced by rabies vaccination.
Ding JY, Zhu JJ.World J Psychiatry. 2025 Aug 19;15(8):105929. doi: 10.5498/wjp.v15.i8.105929. eCollection 2025 Aug 19.PMID: 40837801

Effect of dietary supplementation with Saccharomyces cerevisiae fermentation product on clinical outcomes in dairy cows during challenge with Streptococcus uberis.
Kolar QK, Krogstad KC, Swartz TH, Mamedova LK, Mavangira V, Yoon I, Bradford BJ, Ruegg PL.J Dairy Sci. 2025 Aug 28:S0022-0302(25)00699-X. doi: 10.3168/jds.2025-26541. Online ahead of print.PMID: 40885303

Overall survival of recurrent/metastatic head & neck squamous cell carcinoma patients progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy: results of SAKK 11/16, a phase IIa trial.
Fernandez E, Vernet R, Urwyler M, Von Rohr O, Charrier E, Belkouch MC, Saingier V, Courtout F, DeVito C, Ancrenaz V, Dulguerov N, Karenovics W, Grogg J, Renaux J, Gobat K, Müller G, Brezina T, Rordorf T, Joerger M, Michielin O, Villard J, Mach N.Exp Hematol Oncol. 2025 Aug 31;14(1):113. doi: 10.1186/s40164-025-00703-x.PMID: 40887652

Emergence of extensively and pan-drug resistance in clinical bacterial isolates: A systematic scoping review from Ethiopian public health perspective.
Assefa M, Tigabie M, Amare A, Girmay G, Geteneh A, Ayalew G, Biset S, Almagharbeh WT.PLoS Negl Trop Dis. 2025 Aug 28;19(8):e0013363. doi: 10.1371/journal.pntd.0013363. eCollection 2025 Aug.PMID: 40875623

Decoding **vaccine** hesitancy: a health belief model-driven comparative study of vaccination awareness dynamics in COVID-19 vaccination intentions.

Li Z, Sun X.BMC Public Health. 2025 Aug 21;25(1):2865. doi: 10.1186/s12889-025-23843-5.PMID: 40841900

Immunological profile of pregnant women with preconception immunity with or without vertical transmission of human cytomegalovirus to the fetus: a retrospective observational study.
Zelini P, d'Angelo P, Fornara C, Zavaglio F, Furione M, Arossa A, Achille C, Tassis B, Ronchi A, Pugni L, Ornaghi S, Cavoretto PI, Candiani M, Fabbri E, Locatelli A, Consonni S, Rutolo S, Miotto E, Savasi V, Di Giminiani M, Prefumo F, Pellegrinelli L, Pietrasanta C, Spinillo A, Lilleri D, Baldanti F.Lancet Microbe. 2025 Aug 18:101162. doi: 10.1016/j.lanmic.2025.101162. Online ahead of print.PMID: 40840474

The role of collagen type VI alpha 6 chain as a potential tumor suppressor in breast cancer: an immune regulation perspective.
Li JD, Deng LL, Luo JY, Mo CH, Chi BT, Huang WY, He RQ, Qin DY, Song C, Zou W, Chen G.BMC Cancer. 2025 Aug 23;25(1):1363. doi: 10.1186/s12885-025-14680-1.PMID: 40846911

Body mass index and critical care outcomes in hospitalized COVID-19 patients-A national cohort study.
Bonilla Y, High D, Acosta Rullan J, Tabba J, Shalmiyev R, Noris T, Folds A, Martinez A, Heller D, Diaz R, Kathuria S, Sharma P, Danckers M.PLoS One. 2025 Aug 19;20(8):e0329779. doi: 10.1371/journal.pone.0329779. eCollection 2025.PMID: 40828810

A hybrid simulation model of HIV program interventions: from transmission behavior to macroeconomic impacts.
Crown W, Britton E, Razavi M, Luan Y, Veerunaidu S, Kates J, Gaumer G, Jordan M, Hurley CL, Nandakumar AK.Ther Adv Drug Saf. 2025 Aug 20;16:20420986251367510. doi: 10.1177/20420986251367510. eCollection 2025.PMID: 40851631

Patentes registradas en Patentscope

Estrategia de búqueda: (Vaccine) AND DP:([18.08.2025 TO 31.08.2025]) *as the publication date 67 records.*

1.WO/2025/176145NINE-VALENT HUMAN PAPILLOMAVIRUS VACCINE AND USE THEREOF

WO - 28.08.2025

Clasificación Internacional A61K 39/295Nº de solicitud PCT/CN2025/078034Solicitante BEIJING HEALTH GUARD BIOTECHNOLOGY INC.Inventor/a LIU, Yongjiang

Provided are a nine-valent human papillomavirus vaccine and use thereof. The nine-valent human papillomavirus vaccine comprises HPV6, HPV11, HPV16, HPV18, HPV31, HPV33, HPV45, HPV52, and HPV58 type truncated L1-VLP antigens. All antigen components in the provided nine-valent HPV vaccine are derived from L1, a major capsid protein of the HPV, and truncated. The yield of the L1 protein is improved by means of a truncated L1 protein expressed by an Escherichia coli system, thereby reducing the production

cost of the vaccine. Optimizing the particle size of each type of VLP antigens and the particle size of the aluminum hydroxide adjuvant, combined with control over the ratio of each type of VLP antigens to the adjuvant and the buffer system and the like, enables the obtained nine-valent HPV vaccine to induce a high-level immune response, especially to demonstrate a significant clinical effect.

2.20250269009VACCINE COMPOSITION FOR NOVEL CORONAVIRUS INFECTION

US - 28.08.2025

Clasificación Internacional A61K 39/215Nº de solicitud 18267355Solicitante RONGSEN BIOTECHNOLOGY (BEIJING) CO., LTDInventor/a Baidong HOU

The present application relates to a novel coronavirus pathogen-like antigen (PLA) vaccine, a preparation method therefor and an application thereof. The PLA vaccine consists of structurally-modified *Escherichia coli* virus-like particles (VLPs) and novel coronavirus antigens displayed thereon, and nucleic acid is encapsulated inside of the VLPs. The novel coronavirus PLA vaccine of the present invention formed by passing through modifications effectively prevents the aggregation or precipitation of particles, facilitating the production of the vaccine and ensuring the stability of vaccine efficacy; in addition, relative to conventional vaccines which require additionally adding an additional adjuvant, the PLA-SARS-CoV2 vaccine of the present invention is capable of inducing a significantly higher level of specific antibodies and neutralizing antibodies, having a significantly higher efficacy in challenge tests relative to conventional vaccines.

3.824117PRODUCTION OF POXVIRUSES FROM QUAIL CELL CULTURES

NZ - 29.08.2025

Clasificación Internacional C12N 7/00Nº de solicitud 824117Solicitante BAVARIAN NORDIC A/SInventor/a HAUSMANN, Jürgen

The present invention relates to methods of producing poxvirus viral vector-based vaccine products from avian cell lines. In some embodiments, the avian cells are suspension quail cell lines. Pharmaceutical compositions such as vaccines produced by the methods of the invention are also provided. In some embodiments, the poxvirus viral vector is Modified Vaccinia Virus Ankara ("MVA") or recombinant MVA. In some embodiments, the recombinant MVA encodes heterologous antigens and can be used to produce a vaccine against the antigens. In some embodiments, the recombinant MVA encodes antigens of Respiratory Syncytial Virus (RSV) and the avian cells are used to produce a vaccine against RSV comprising the recombinant MVA and/or the encoded antigens.

4.20250269006METHODS FOR PREDICTING EFFICACY OF A MODIFIED LIVE PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS (PRRSV) VACCINE

US - 28.08.2025

Clasificación Internacional A61K 39/12Nº de solicitud 18866887Solicitante ELANCO US INC.Inventor/a Mark Hammer

Methods are provided for eliciting heterologous immunogenicity against heterologous porcine reproductive and respiratory syndrome virus (PRRSV) strains to allow assessment of innate immunity and adaptive immunity. In other aspects are provided methods for determining the efficacy of a vaccine against PRRSV. In

still other aspects are provided methods for predicting the efficacy of a vaccine against PRRSV in pigs suspected of having an infection with PRRSV.

5.WO/2025/179050VACCINE COMPOSITIONS AND METHODS OF USE

WO - 28.08.2025

Clasificación Internacional A61K 40/42Nº de solicitud PCT/US2025/016645Solicitante BIONTECH US INC.Inventor/a FOLEY, Kendra

The present disclosure provides a therapy with vaccine compositions including multiepitopic polypeptides, recombinant nucleic acids encoding multiepitopic polypeptides and methods of use thereof. Also provided herein are T-cell receptors (TCRs) that can recognize one or more epitopes of the multiepitopic polypeptides. The therapy provided herein can comprise (i) a TCR, a recombinant nucleic acid encoding the TCR, or cells comprising the TCR or the recombinant nucleic acid encoding the TCR, and (ii) a vaccine composition described herein. The methods and compositions provided herein can be used for the treatment of cancer.

6.824298VACCINE COMPOSITION COMPRISING A SYSTEM FOR DELIVERING AN INACTIVATED WHOLE BACTERIUM VIA CATIONIC POLYSACCHARIDE NANOPARTICLES WITHOUT ANY ADJUVANT

NZ - 29.08.2025

Clasificación Internacional A61K 9/51Nº de solicitud 824298Solicitante VAXINANOInventor/a BETBEDER, Didier

The invention relates to the field of vaccine compositions. The invention more particularly relates to a prophylactic vaccine composition that is intended for mammals and birds and comprises a killed whole bacterium, said bacterium being covered with a cationic agent, in particular cationic nanoparticles.

7.202430707CYCLIN D1 BASED CANCER VACCINE

DK - 19.08.2025

Clasificación Internacional A61K 39/00Nº de solicitud PA 2024 30707Solicitante Anders Kaare NørgaardInventor/a Anders Kaare Nørgaard

The present disclosure provides a vaccine against cancers that express both high levels of Cyclin D1 and MHC-II. That includes hormone positive breast cancers and some prostate cancers and melanoma. Cyclin D1 is not presented well on MHC-I, and it expresses very little on non-cancerous tissues, so that it is possible, based on a genomic test of the individual, to design a polytope based on epitopes from Cyclin D1 that in most cases display on MHC-II and not on MHC-I, such that the cancer after vaccination with the polytope will reveal itself to the immune system and get eradicated while there are little side effects in that the vaccine will not make the immune system harm the healthy tissue. Since the invention utilizes the fact that the cancer expresses MHC-II, it may work with other antigens than Cyclin D1 as long as the cancer expresses MHC-II.

8.WO/2025/171792ANTI-TUMOR COMBINATION VACCINE

WO - 21.08.2025

Clasificación Internacional A61K 39/00Nº de solicitud PCT/CN2025/077276Solicitante SHAOXING YUERAN BIOMEDICAL TECHNOLOGY CO., LTD.Inventor/a XU, Honghui

Provided is use of a combination of three or more of the following microorganisms in the preparation of an anti-tumor combination vaccine: Bordetella pertussis, Salmonella typhi, Salmonella paratyphi A, Salmonella paratyphi B, Staphylococcus aureus, Listeria monocytogenes, Escherichia coli, Proteusbacillus vulgaris, Lactic acid bacteria, Bifidobacterium longum, Bordetella pertussis, Corynebacterium diphtheriae and Clostridium tetani, Clostridium acetobutylicum, Salmonella typhimurium, and Streptococcus pyogenes. The anti-tumor combination vaccine is broad-spectrum, safe and non-toxic, and thus has the prospect of clinical applications.

9.3826600ISFORET VACCINEKØLESKAB

DK - 25.08.2025

Clasificación Internacional A61J 1/16Nº de solicitud 19742747Solicitante B Medical Systems S.à.r.l.Inventor/a RIES, Gilles

An ice-lined vaccine refrigerator (10) comprises: a vaccine storage compartment (15); an electrically powered cooling circuit (16), the electrically powered cooling circuit being configured to generate an ice-lining and to cool the vaccine storage compartment; an AC power inlet (17) adapted for connection to an external supply of AC power; and a refrigerant compressor (21) forming part of the electrically powered cooling circuit and adapted to be powered by the external supply of AC power through the AC power inlet. Reliability is improved by using a DC powered compressor and an AC/DC convertor (24) to convert AC power received at the AC power inlet to DC power to power the compressor.

10.20250269005METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT

US - 28.08.2025

Clasificación Internacional A61K 39/12Nº de solicitud 18290146Solicitante TOPELIA AUST LIMITED (ACN 652 771 670)Inventor/a Thomas Julius BORODY

In alternative embodiments, provided are methods for treating, ameliorating, decreasing the chances of having any adverse effects from, decreasing the severity of adverse effects from, or preventing an infection, or boosting or enhancing natural immunity acquired by an infected individual, by administration of: an inactivated infectious causative agent of the infection, or an antibiotic and/or an anti-viral drugs and a vaccine directed to a causative agent of the infection and/or an attenuated and/or a live, viable or infectious causative agent of the infection. In alternative embodiments, the infection is bacterial or viral. In alternative embodiments, the viral infection is a coronavirus infection such a Covid-19 infection. In alternative embodiments, methods as provide herein prevent or decrease the prevalence or severity of "vaccine breakthrough infections" after vaccination, where external mutants of COVID-19 infect patients in spite of the fact that they have undergone immunization, for example, to prevent a mutant or variant COVID-19 infection. In alternative embodiments, an antiviral combination administered in coordination with a vaccine comprises PF-07321332 or PAXLOVID™ and/or ritonavir, or ivermectin, doxycycline and a zinc or a zinc salt. In alternative embodiments, methods as provided herein are used to prevent in vivo mutations of such mutant infectious agent to enhance the efficacy of an administered vaccination; in other words, methods as provided herein are used to prevent in vivo replication of an acquired viral mutant or variant infectious

agent, and thus also prevents ongoing mutations of the viral infectious agent because using the combination antiviral co-therapy where there is no replication of infectious agent and so there is no possible further mutation of the infectious agent.

11.4604997REKOMBINANTE PROTEINIMPFSTOFFE MIT ENANTIOSPEZIFISCHEM KATIONISCHEM LIPID R-DOTAP UND VERFAHREN ZUR VERWENDUNG DAVON

EP - 27.08.2025

Clasificación Internacional A61K 39/145Nº de solicitud 23880615Solicitante PDS BIOTECHNOLOGY CORPInventor/a CONN GREGORY

Provided herein are vaccine compositions including recombinant protein antigens derived from computationally optimized broadly reactive influenza antigen (COBRA) proteins and an immunomodulator, and methods of use thereof. The vaccine compositions include one or more COBRA proteins, and the immunomodulator is a cationic lipid. The cationic lipid includes R-DOTAP. The methods of use of the vaccine compositions includes methods of inducing a humoral immune response against influenza viruses, methods of inducing polyfunctional CD8+ and CD4+ effector T cells against influenza viruses, methods of inducing memory T cells against influenza viruses, methods of enhancing immunity against influenza viruses, and methods of inducing balanced Th1/Th2 immune response against influenza viruses in a subject.

12.20250262288CELLULAR ADJUVANTS FOR VIRAL INFECTION

US - 21.08.2025

Clasificación Internacional A61K 39/108Nº de solicitud 19203533Solicitante NantBio, Inc.Inventor/a Kayvan Niazi

Two-component vaccine formulations and methods are contemplated where the vaccine has an adjuvant component and a therapeutic component. The therapeutic component comprises preferably a recombinant therapeutic virus encoding a therapeutic antigen while the adjuvant component comprises a non-host cell or immune stimulating portion thereof. Notably, use of the adjuvant component will result in significant uptake of the therapeutic component into immune competent cells, even in the absence of receptors for entry of the therapeutic component. In addition, such adjuvant also stimulates expression of the therapeutic antigen.

13.0002845571VACCINE BASED ON AN ADENO-ASSOCIATED TYPE 9 VECTOR ENCODING SPIKE PROTEIN FOR THE PREVENTION OF SARS-COV-2 CORONAVIRUS INFECTION

RU - 21.08.2025

Clasificación Internacional C12N 15/50Nº de solicitud 2024131226SolicitanteInventor/a Фролова Мария Евгеньевна (RU)

FIELD: medicine. SUBSTANCE: invention relates to molecular biology, biotechnology, and medicine. A genetic construct is described for the expression in human or animal cells of a polynucleotide encoding a full-length spike protein of the SARS-CoV-2 virus containing mutations: partial deletion of the RRAR furine site with the removal of all arginines (R) included in the site, as well as mutations K986P, V987P and D614G. The construct is represented by the adeno-associated AAV9 virus, into which the specified polynucleotide is cloned. A recombinant adeno-associated viral vector AAV9 is described, which provides expression in human or animal cells of a polynucleotide encoding a full-length spike protein of the SARS-CoV-2 virus with a genetic

construct. The application of a genetic construct or recombinant adeno-associated viral vector AAV9 for the induction of an immune response against the SARS-CoV-2 virus is presented. EFFECT: the developed genetic construct and a vaccine based on it expand the arsenal of means for inducing specific immunity to the SARS-CoV-2 virus and can be used to effectively stimulate the humoral and cellular response in order to prevent coronavirus infection caused by SARS-CoV-2. 9 cl, 16 dwg, 6 tbl, 5 ex

14.4601686VERWENDUNG EINES DENGUE-IMPFSTOFFS BEI PERSONEN MIT SCHWANGEREN UND/ODER STILLEN

EP - 20.08.2025

Clasificación Internacional A61K 39/12Nº de solicitud 23805387Solicitante TAKEDA VACCINES INCInventor/a KLAS SHERI DENÉT

A dengue vaccine for use in a method of protecting against dengue disease in a pregnant and/or breastfeeding human subject.

15.4223311INDIVIDUALISEREDE VACCINER MOD CANCER

DK - 25.08.2025

Clasificación Internacional A61K 39/00Nº de solicitud 23169466Solicitante BioNTech SEInventor/a SAHIN, Ugur

The present invention relates to the provision of vaccines which are specific for a patient's tumor and are potentially useful for immunotherapy of the primary tumor as well as tumor metastases. In one aspect, the present invention relates to a method for providing an individualized cancer vaccine comprising the steps: (a) identifying cancer specific somatic mutations in a tumor specimen of a cancer patient to provide a cancer mutation signature of the patient; and (b) providing a vaccine featuring the cancer mutation signature obtained in step (a). In a further aspect, the present invention relates to vaccines which are obtainable by said method.

16.3609535HBV-VACCINE

DK - 18.08.2025

Clasificación Internacional A61K 39/29Nº de solicitud 18719248Solicitante Oxford University Innovation Ltd.Inventor/a BARNES, Eleanor

The invention relates to a multi-HBV immunogen viral vector vaccine comprising: a viral vector comprising an immunogen expression cassette, wherein the expression of a protein encoded by the expression cassette is arranged to be driven by a promoter, wherein the immunogen expression cassette encodes: a) HBV Core; b) a modified HBV polymerase (P_{mut}), wherein the modification is a mutation to wild-type HBV polymerase to substantially remove polymerase function; c) HBV surface antigen (HbsAg); and d) an intergenic sequence that is arranged to cause expression of at least the HBV surface antigen (HbsAg) as a separate protein from the HBV core and the modified HBV polymerase (P_{mut}), wherein the intergenic sequence is downstream (3') of the sequences encoding the HBV core and the modified HBV polymerase (P_{mut}) and upstream (5') of the sequence encoding the HBV surface antigen (HbsAg); and related compositions, vaccination methods and methods of treatment or prophylaxis of HBV infection.

17.WO/2025/174962NOVEL SAFE POTENT SINGLE VECTOR PLATFORM VACCINES AGAINST MELIOIDOSIS AND GLANDERS

WO - 21.08.2025

Clasificación Internacional A61K 39/104Nº de solicitud PCT/US2025/015720Solicitante THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventor/a HORWITZ, Marcus A.

Embodiments of the invention include single vector platform vaccine compositions for preventing the disease Melioidosis caused by *Burkholderia pseudomallei* in humans and animals. Embodiments of the invention include single vector platform vaccine compositions for preventing the disease glanders caused by *Burkholderia mallei* in humans and animals. Embodiments of the invention include methods of immunizing a susceptible host against *Burkholderia pseudomallei* and/or *Burkholderia mallei* using the disclosed compositions.

18.20250263448VETERINARY VACCINES AND METHODS FOR THE TREATMENT OF PASTEURELLA MULTOCIDA INFECTIONS IN FOOD PRODUCTION ANIMALS

US - 21.08.2025

Clasificación Internacional C07K 14/285Nº de solicitud 18858473Solicitante ENGINEERED ANTIGENS INC.Inventor/a Trevor MORAES

Disclosed are novel veterinary vaccine compositions comprising a *P. multocida* PmSLP protein or an immunogenically equivalent portion thereof. The vaccine compositions may be used to ameliorate, treat or prevent pathogenic infections of food production animals, such as bovine and porcine animals, caused by *Pasteurella multocida*. Related methods and uses are also disclosed.

19.20250262292VETERINARY VACCINES AND METHODS FOR THE TREATMENT OF PASTEURELLA MULTOCIDA INFECTIONS IN FOOD PRODUCTION ANIMALS

US - 21.08.2025

Clasificación Internacional A61K 39/102Nº de solicitud 18858510Solicitante ENGINEERED ANTIGENS INC.Inventor/a Trevor MORAES

Disclosed are novel veterinary vaccine compositions comprising a *P. multocida* PmSLP protein or an immunogenically equivalent portion thereof. The vaccine compositions may be used to ameliorate, treat or prevent pathogenic infections of food production animals, such as bovine and porcine animals, caused by *Pasteurella multocida*. Related methods and uses are also disclosed.

20.WO/2025/172363VACCINE AGAINST BOVINE VIRAL DIARROHEA VIRUS AND BOVINE RESPIRATORY DISEASE

WO - 21.08.2025

Clasificación Internacional A61K 39/12Nº de solicitud PCT/EP2025/053726Solicitante HIPRA SCIENTIFIC, S.L.U.Inventor/a GIBERT LLEIXA, Marta

The present invention relates to an immunogenic or vaccine composition for use in the treatment and/or prevention of Bovine Viral Diarrohea Virus type 1 (BVDV-1) and/or Bovine Viral Diarrohea Virus type 2 (BVDV-2) infection in cattle and associated Bovine Respiratory Disease.

21.20250270296POTENT NEUTRALIZING ANTIBODIES FOR PREVENTION AND TREATMENT OF COVID-19

US - 28.08.2025

Clasificación Internacional C07K 16/10Nº de solicitud 18028687Solicitante Academia SinicaInventor/a Han-Chung WU

Potent neutralizing antibodies for prevention and treatment of covid-19. Human chimeric antibodies (RBD-chAbs) specifically against SARS-COV-2 Spike(S) receptor-binding domain (RBD) are disclosed. Antibody cocktails or vaccine compositions comprising the RBD-chAbs are also disclosed. The RBD-chAbs, the antibody cocktails, and the vaccine compositions are effective for protection and/or treatment of COVID-19 and are potent against COVID-19 variants including United Kingdom variant B.1.1.7 (Alpha), South African variant B.1.351 (Beta), Brazil variant PI (Gamma), California variant B.1.429 (Epsilon), New York variant B.1.526 (Iota), Indian variants B.1.617.1 (Kappa) and B.1.617.2 (Delta).

22.20250269010NOVEL NUCLEIC ACID MOLECULE

US - 28.08.2025

Clasificación Internacional A61K 39/215Nº de solicitud 18276086Solicitante ST PHARM CO., LTD.Inventor/a Kyungjin KIM

The present invention relates to a nucleic acid molecule for preventing or treating viral infection or cancer, comprising a nucleic acid encoding a signal peptide and a nucleic acid encoding an antigen. Furthermore, it relates to a vaccine composition for preventing or treating viral infection or cancer, comprising the nucleic acid molecule.

The nucleic acid molecule according to the present invention has excellent intracellular protein expression rate and protein secretion ability to the outside of the cell. In addition, when administered in vivo, it allows the subject to acquire humoral immunity, such as inducing antigen-specific neutralizing antibodies, and cellular immunity, such as increasing the amount of immune cells directly involved in killing the virus. Thus, it can be useful as a vaccine for the prevention and treatment of viral infection or cancer.

23.4604994DENGUE-IMPFSTOFFFORMULIERUNG

EP - 27.08.2025

Clasificación Internacional A61K 39/12Nº de solicitud 23804875Solicitante TAKEDA VACCINES INCInventor/a KOMMAREDDY SUSHMA

The present invention relates to a dengue vaccine formulation comprising a tetravalent dengue virus composition comprising a live attenuated dengue virus serotype 1, a live attenuated dengue virus serotype 2, a live attenuated dengue virus serotype 3, and a live attenuated dengue virus serotype 4, at least one non-reducing disaccharide, at least one poloxamer, urea, at least one amino acid having a positively charged side chain at neutral pH, tromethamine, and human serum albumin.

24.4606887KULTURVERFAHREN FÜR FISCHZELLEN UND DAFÜR VERWENDETES ZELLKULTURMEDIUM SOWIE ORALER IMPFSTOFF FÜR FISCHE

EP - 27.08.2025

Clasificación Internacional C12N 5/071Nº de solicitud 23879808Solicitante BIOSIENSE CO LTDInventor/a OKUTANI ASUKA

The present disclosure provides a cell culture medium for use in culturing of fish cells, a method for culturing fish cells, and an oral vaccine for fish. In the present disclosure, the cell culture medium for use in culturing of fish cells preferably comprises serum obtained from adult fish.

25.4604990NEUARTIGE T-ZELLEN-AKTIVIERENDE IMMUNTHERAPEUTIKUM ZUR BEHANDLUNG VON MUCIN-1-PROTEIN-EXPRIMIERENDEM MENSCHLICHEM KREBS

EP - 27.08.2025

Clasificación Internacional A61K 39/00Nº de solicitud 23880573Solicitante PDS BIOTECHNOLOGY CORPInventor/a BEDU-ADDO FRANK

Provided herein are multiepitope peptides including at least one mucin 1 (MUC1) peptide, the multiepitope peptides have MHC affinity for at least one of HLA serotype and are recognized by a CD4+ T cell receptor and/or by a CD8+ T cell receptor. Also provided herein are compositions comprising the multiepitope peptides and a cationic lipid, including vaccine compositions. In various aspects, the cationic lipid is R-DOTAP. The invention also provides methods of use of the multiepitope peptides and of the compositions and vaccine compositions. The methods of use include methods of treating cancer and method of inducing a MUC-specific polyfunctional cytolytic T cell response in a subject.

26.4604995KOMBINATIONSIMPFSTOFFE GEGEN CORONAVIRUS-INFEKTION, INFLUENZA-INFEKTION UND/ODER RSV-INFEKTION

EP - 27.08.2025

Clasificación Internacional A61K 39/12Nº de solicitud 23806135Solicitante BIONTECH SEInventor/a SAHIN UGUR

This disclosure relates to the field of RNA to prevent or treat multiple infectious agents. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection, influenza infection, and/or RSV infection and inducing effective coronavirus, influenza virus, and/or RSV antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject (i) a bivalent RNA vaccine encoding peptides or proteins comprising epitopes of SARS-CoV-2 spike proteins (S proteins) and (ii) a tetravalent RNA vaccine encoding peptides or proteins comprising epitopes of hemagglutinin (HA), for inducing an immune response against coronavirus S proteins, in particular S proteins of SARS-CoV-2, and influenza proteins, in particular HA proteins of type A and type B influenza viruses, in the subject.

27.4601681SAPONIN-DMLT-ADJUVANTIEN UND ZUGEHÖRIGE VERWENDUNGEN

EP - 20.08.2025

Clasificación Internacional A61K 39/00Nº de solicitud 23878219Solicitante Q VANT BIOSCIENCES INCInventor/a NORTON ELIZABETH

A composition, preferably an immune adjuvant system, for vaccines containing a saponin component and a dmLT component. The combination of the saponin component and the dmLT component shows a synergistic effect in the treatment of various conditions, illnesses and diseases. The methods of use for prophylactic use or therapeutic treatment are disclosed. Exemplary adjuvant compositions include a double-mutant heat-labile

toxin adjuvant derived from an *Escherichia coli* enterotoxin and a saponin, optionally with an additional vaccine component (e.g., an antigen), particularly when used in a vaccine.

28.WO/2025/175807METHOD FOR PREPARING STREPTOCOCCUS PNEUMONIAE CAPSULAR POLYSACCHARIDE

WO - 28.08.2025

Clasificación Internacional C08B 37/00Nº de solicitud PCT/CN2024/126421Solicitante BEIJING MINHAI BIOTECHNOLOGY CO., LTD.Inventor/a LI, Yuelong

The present invention relates to the technical field of biologics, and in particular to a method for preparing a Streptococcus pneumoniae capsular polysaccharide. The present invention provides a method for preparing a Streptococcus pneumoniae capsular polysaccharide. The method comprises: using β-propiolactone to treat a Streptococcus pneumoniae fermentation culture, separating and collecting a supernatant, purifying the supernatant, and collecting a capsular polysaccharide. In the present invention, β-propiolactone is used to treat the Streptococcus pneumoniae fermentation culture, thereby reducing residual impurities such as proteins, and achieving relatively high polysaccharide yield; in addition, the β-propiolactone is susceptible to hydrolysis, and the hydrolysate is non-toxic and harmless and has higher safety. The Streptococcus pneumoniae capsular polysaccharide prepared by the method of the present invention have quality control indexes meeting requirements, and can be used for preparing a Streptococcus pneumoniae capsular polysaccharide vaccine and a polysaccharide conjugate vaccine.

29.WO/2025/172775MACHINE LEARNING APPROACH TO PREDICT VIRUS OR CANCER MUTATIONS FOR VACCINE PRODUCTION OR DRUG DESIGN

WO - 21.08.2025

Clasificación Internacional G16B 20/50Nº de solicitud PCT/IB2025/050405Solicitante NEC LABORATORIES EUROPE GMBHInventor/a SIARHEYEU, Raman

A computer-implemented, machine learning method for predicting a top-k most likely mutated molecular sequences includes encoding a molecular sequence at a first time into a first vector in a latent space. A second vector is generated, by a time-varying mutation models, in the latent space using as input the first vector. The second vector indicates a time-varying influence of the molecular sequence on a mutated version of the molecular sequence at a subsequent time. The second vector is decoded to generate a prediction of the top-k most likely mutated molecular sequences for the molecular sequence at the subsequent time. The method has applications including, but not limited to, use cases in computational biology and medical AI and healthcare for optimizing vaccine design or supporting decision making in diagnosis and treatment of patients.

30.20250269007NUCLEIC ACID MOLECULES AND USES THEREOF

US - 28.08.2025

Clasificación Internacional A61K 39/125Nº de solicitud 19204075Solicitante CureVac SEInventor/a Susanne RAUCH

The present invention is directed to an artificial nucleic acid and to polypeptides suitable for use in treatment or prophylaxis of an infection with Norovirus or a disorder related to such an infection. In particular, the present

invention concerns a Norovirus vaccine. The present invention is directed to an artificial nucleic acid, polypeptides, compositions and vaccines comprising the artificial nucleic acid or the polypeptides. The invention further concerns a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial nucleic acid, polypeptides, compositions and vaccines. Further, the invention is directed to a kit, particularly to a kit of parts, comprising the artificial nucleic acid, polypeptides, compositions and vaccines.

31.20250263442RECOMBINANT CEDAR VIRUS CHIMERAS

US - 21.08.2025

Clasificación Internacional C07K 14/005Nº de solicitud 18557247Solicitante THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.Inventor/a Christopher C. Broder

Described herein are replication-competent recombinant Cedar virus chimeras are described that are engineered to express antigenic surface or soluble proteins/polypeptides of a non-CedV henipavirus, such as of a pathogenic henipavirus, such as Nipah virus or Hendra virus. Vaccine compositions containing the recombinant Cedar virus chimeras are also described, as are therapeutic methods and uses for protecting against pathogenic henipavirus infection.

32.20250269008VACCINATION OF IMMUNOCOMPROMISED SUBJECTS

US - 28.08.2025

Clasificación Internacional A61K 39/145Nº de solicitud 19182727Solicitante Seqirus UK LimitedInventor/a Giuseppe DEL GIUDICE

Disclosed herein are methods for enhancing immune responses to a vaccine in immunocompromised individuals, including those receiving a slatin therapy. Related products are also provided.

33.4604998MATERIALIEN UND VERFAHREN ZUR BEHANDLUNG VON EPSTEIN-BARR-VIRUS (EBV) UND EBV-INDUZIERTEN ERKRANKUNGEN

EP - 27.08.2025

Clasificación Internacional A61K 39/245Nº de solicitud 23794305Solicitante UNIV WIEN MEDInventor/a VIETZEN HANNES

The present invention relates to means and methods to prevent and/or treat Epstein-Barr virus (EBV) and EBV-induced diseases, such as EBV infection, infectious mononucleosis (IM), malignant or non-malignant post-transplant lymphoproliferative disorder (PTLD) and other EBV-associated diseases. In particular, the invention provides a SQAPLPCVL peptide that can be used in a treatment or a method of treatment to induce an EBV-specific immune response in a subject. The SQAPLPCVL can be used in a treatment or method of treatment as a vaccine against EBV and EBV-induced diseases. It is preferred herein that Epstein-Barr virus (EBV) and/or EBV-induced diseases are prevented.

34.WO/2025/178495METHOD OF PREPARING A MICRONEEDLE ARRAY

WO - 28.08.2025

Clasificación Internacional A61M 37/00Nº de solicitud PCT/NL2025/050088Solicitante CERAVX B.V.Inventor/a DE OLIVEIRA, Daniel Campling

The invention relates to a method of preparing a microneedle array, comprising the steps of dissolving a water-soluble copolymer, comprising maleic anhydride and isobutylene monomers, in an aqueous solvent to obtain an aqueous solution, adding a ceramic material to said aqueous solution to obtain an aqueous ceramic slurry for gel casting, adding at least a portion of said aqueous ceramic slurry to a mould to obtain a layer of aqueous ceramic slurry in said mould, degassing said layer of aqueous ceramic slurry to obtain a degassed layer of aqueous ceramic slurry in said mould, gelling said degassed layer of aqueous ceramic slurry to remove said aqueous solvent from said aqueous ceramic slurry and removing said mould to obtain a gelled tape, drying said gelled tape to obtain a green tape, sintering said green tape to obtain said microneedle array. Further, the invention provides for a green tape, comprising a base plate and a set of microneedles integrated with said base plate, a microneedle array, comprising a base plate and a set of microneedles integrated with said base plate, a system for enabling transport of a substance through a material barrier, and a use of a microneedle array for intradermal drug or vaccine delivery, diagnostics, cosmeceuticals,, sensing of biomarkers found in the skin and monitoring of physiological conditions of the body.

35.20250269003NANO-ENHANCED VACCINE

US - 28.08.2025

Clasificación Internacional A61K 39/00Nº de solicitud 18859144Solicitante University of Virginia Patent FoundationInventor/a Mark Kester

Provided are composition that include stable TLR4 agonist (e.g., KDO2) containing nanoliposomes. In some embodiments, the TLR4 agonist (e.g., KDO2) containing nanoliposome include a lipid component comprising, consisting essentially of, or consisting of DSPC, DOPE, PEG(2000)-PE, one or more TLR4 agonists (e.g., KDO2), Cholesterol, Rhodamine or DiD, and optionally DOTAP and/or DHP. In some embodiments, the TLR4 agonist (e.g., KDO2) containing nanoliposomes are cationic, anionic, or neutral liposomes. In some embodiments, the TLR4 agonist (e.g., KDO2) containing nanoliposome encapsulate one or more immunogenic peptides, which can be peptides associated with malignant melanoma, which optionally can be subsequences of tyrosinase, gplOO, MAGE-1,2,3,6, Melan-A/MART-1, and/or MAGE-3. Also provided are methods for treating and/or preventing malignant melanoma and for inducing anti-melanoma immune responses in subjects using the presently disclosed compositions.

36.WO/2025/172435HBV ANTIGEN FORMULATION FOR TREATING HEPATITIS B

WO - 21.08.2025

Clasificación Internacional A61K 39/12Nº de solicitud PCT/EP2025/053853Solicitante HELMHOLTZ ZENTRUM MÜNCHEN - DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH)Inventor/a PROTZER, Ulrike

The invention relates to methods of vaccination, comprising administering to a human subject a first dose of an HBcAg particle, an HBsAg, and c-di-AMP; a second dose of the HBcAg particle, the HBsAg, and c-di-AMP; and a dose of a vaccine vector. The invention also relates pharmaceutical compositions, combinations of HBcAg particles, HBsAg and c-di-AMP, and kits for use in said methods.

37.20250262291MICROPARTICLES FROM STREPTOCOCCUS PNEUMONIAE AS VACCINE ANTIGENS

US - 21.08.2025

Clasificación Internacional A61K 39/09Nº de solicitud 19200040Solicitante ZalVac ABInventor/a Birgitta Henriques Normark

An isolated *Streptococcus pneumoniae* membrane vesicle microparticle (MP), wherein said MP comprises: the protein Ply at the level of ≥0.070 µg/mg total protein in the MP; and/or the protein LytA at the level of ≥0.070 µg/mg total protein in the MP; and/or the protein PspC at the level of ≥0.130 µg/mg total protein in the MP; and/or the protein RrgB at the level of ≥0.020 µg/mg total protein in the MP. Compositions comprising such MPs. Uses thereof in particular in immunization, as well as methods of manufacture thereof.

38.20250273291SELECTION OF DIVERSE CANDIDATE PEPTIDES FOR PEPTIDE THERAPEUTICS

US - 28.08.2025

Clasificación Internacional G16B 15/30Nº de solicitud 19207999Solicitante Genentech, Inc.Inventor/a William John THRIFT

A method for developing a therapeutic such as, for example, a peptide vaccine. A machine learning model is trained using a metric learning algorithm, training peptide sequence data, and training allele presentation data corresponding to the training peptide sequence data. Peptide sequence data identifying peptide sequences that correspond to peptides is received. A peptide sequence vector is generated, via a machine learning model, for each peptide sequence using the peptide sequence data to form a plurality of peptide sequence vectors. An output is generated using the plurality of peptide sequence vectors. The output provides an indication of similarity between peptide sequences of the plurality of peptide sequences. A group of candidate peptides is selected from the plurality of peptides for development of the therapeutic based on the output such that the group of candidate peptides includes at least two dissimilar candidate peptides.

39.4604926NEUARTIGER NICHT-HLA-BESCHRÄNKTER T-ZELL-IMPFSTOFF FÜR KREBS MIT EXPRESSION VON TCR-GAMMA-ALTERNATIVEM LESERASTERPROTEIN (TARP)-PROTEIN

EP - 27.08.2025

Clasificación Internacional A61K 9/127Nº de solicitud 23880501Solicitante PDS BIOTECHNOLOGY CORPInventor/a BEDU-ADDO FRANK

Novel compositions of TCR Gamma Alternate Reading Frame Protein (TARP) peptides combined with cationic lipids such as the DOTAP and specifically R-DOTAP, induce high levels of TARP-specific polyfunctional cytolytic T-cells. Compositions and methods of use are provided. The compositions comprise N-terminal and C-terminal overlapping peptide sequence pairs duplicating the critical central antigenic region of TARP and encompassing the entire protein selected and designed to be effectively processed by antigen-presenting cells to prime cytotoxic T cells specific for TARP-derived T cell peptide antigens when delivered in combination with immunostimulatory nanoparticles composed of R-DOTAP cationic lipids.

40.WO/2025/176928NANOESTRUCTURAS VÍRICAS SINTÉTICAS Y SUS USOS

WO - 28.08.2025

Clasificación Internacional A61K 9/50Nº de solicitud PCT/ES2025/070090Solicitante FUNDACIÓN INSTITUTO DE INVESTIGACIÓN MARQUÉS DE VALDECILLAInventor/a GARCÍA HEVIA, Lorena

Nanoestructuras víricas sintéticas y sus usos La presente invención se refiere a una nanoestructura que comprende un núcleo magnético recubierto por uno o más componentes celulares, donde dicho núcleo magnético comprende nanopartículas magnéticas, al método de obtener dicha nanoestructura, y al empleo

de dicha nanoestructura como medicamento, como vacuna, o para el análisis in vitro de compuestos capaces de inhibir virus, para la validación in vitro de anticuerpos o como sistema in vitro de biopsia intracelular.

41.824463NUCLEOCAPSID ANTIGEN IMMUNOTHERAPY FOR COVID-19 FUSION PROTEINS AND METHODS OF USE

NZ - 29.08.2025

Clasificación Internacional A61K 39/215Nº de solicitud 824463Solicitante VAKSTON, INC.Inventor/a LANCASTER, Thomas M.

The present disclosure provides recombinantly manufactured fusion proteins comprising a SARS-CoV-2 nucleocapsid protein (N-protein) fragment or an analog thereof linked to a human Fc fragment for use in relation to the 2019 Novel Coronavirus (COVID-19). Embodiments include the administration of the fusion proteins to patients that have recovered from COVID- 19 as a booster vaccination, to antibody naive patients to produce antibodies to the SARS-CoV-2 virus to enable the patients to become convalescent plasma donors, to patients who have been infected by the SARS-CoV-2 virus and have contracted COVID-19 in order to limit the scope of the infection and ameliorate the disease, and as a prophylactic COVID-19 vaccine. Exemplary' Fc fusion proteins and pharmaceutical formulations of exemplary' Fc fusion proteins are provided, in addition to methods of use and preparation.

42.WO/2025/179103PENTAVALENT AND OCTAVALENT INFLUENZA VIRUS IMMUNOGENS, COMPOSITIONS AND METHODS OF USE THEREOF

WO - 28.08.2025

Clasificación Internacional A61K 39/145Nº de solicitud PCT/US2025/016726Solicitante UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.Inventor/a ROSS, Ted M.

Provided are an immunogenic multivalent (e.g., pentavalent or octavalent) composition, vaccine, and formulations thereof, composed of five or eight, isolated, non-naturally occurring, immunogenic antigens derived from influenza viruses that are capable of eliciting a broadly reactive immune response, e.g., a broadly reactive neutralizing antibody response directed against influenza virus antigens, following introduction into a subject. Also provided are immunogens and virus-like particles (VLPs) comprising the multivalent composition. Methods of generating an immune response in a human or non-human subject by administering the multivalent composition are provided. In particular, the multivalent immunogen comprises isolated, broadly reactive hemagglutinin (HA) protein antigens of influenza virus strains, such as H1, H3, and IBV, and/or viral neuraminidase (NA) N1 and N2 protein antigens, which may be recombinant and/or recombinantly produced.

43.WO/2025/179238CORONAVIRUS VACCINE

WO - 28.08.2025

Clasificación Internacional A61P 31/14Nº de solicitud PCT/US2025/016933Solicitante BIONTECH SEInventor/a SWANSON, Kena Anne

This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective

coronavirus antigen-specific immune responses such as antibody and/or T cell responses against various SARS-CoV-2 variants of concern.

44.WO/2025/172592ALPHA SYNUCLEIN THERAPEUTIC VACCINE

WO - 21.08.2025

Clasificación Internacional A61K 39/00Nº de solicitud PCT/EP2025/054124Solicitante AC IMMUNE SAInventor/a STAFFLER, Günther

The present invention relates to immunogenic compositions that can be employed for the prevention, alleviation or treatment of a condition associated with diseases, disorders and abnormalities associated with alpha synuclein (alpha synuclein, α-synuclein, A-synuclein, aSynuclein, A-syn, α-syn, aSyn, a-syn) aggregates including, but not limited to, Lewy bodies and/or Lewy neurites, such as Parkinson's disease, Multiple System Atrophy, Lewy Body dementia (LBD; dementia with Lewy bodies (DLB) ("pure" Lewy body dementia), Parkinson's disease dementia (PDD)), or Diffuse Lewy Body Disease.

45.20250273288ANTIGEN PREDICTIONS FOR INFECTIOUS DISEASE-DERIVED EPITOPES

US - 28.08.2025

Clasificación Internacional G16B 15/30Nº de solicitud 18908082Solicitante Gritstone Bio, Inc.Inventor/a Joshua Klein

Disclosed herein is a system and methods for determining the alleles, antigens, and infectious disease-based vaccine composition as determined on the basis of a patient's expressed HLA alleles. Additionally described herein are unique infectious disease-derived vaccines.

46.823892VACCINE FOR STREPTOCOCCUS EQUI SUBSP. ZOOEPIDEMICUS

NZ - 29.08.2025

Clasificación Internacional A61K 39/09Nº de solicitud 823892Solicitante University of SaskatchewanInventor/a COSTA, Matheus

Provided herein is a composition comprising a live strain of S. zooepidemicus and a pharmaceutically acceptable carrier, wherein the live strain of S. zooepidemicus contains a mutated M protein trans-acting positive regulator (MGA) gene that results in impaired DNA binding. Also provided are methods and uses to eliciting an immune response against an infection by S. zooepidemicus in a subject, comprising administering to the subject an effective amount of the composition described herein. Also provided is a method of generating strains of S. zooepidemicus with reduced virulence.

47.20250263704NUCLEIC ACID-POLYPEPTIDE NANO-PHARMACEUTICAL COMPOSTION FOR TREATING AND PREVENTING HUMAN PAPILLOMA VIRUS INFECTION

US - 21.08.2025

Clasificación Internacional C12N 15/113Nº de solicitud 18561596Solicitante SIRNAOMICS, INC.Inventor/a Alan Lu

Disclosed is a nucleic acid-polypeptide nano-pharmaceutical composition for treating and preventing human papilloma virus infection. A small interfering nucleic acid siRNA molecule used for inhibiting and treating various diseases caused by a HPV infection can block the virus replication life cycle by means of targeted inhibition of the expression of the HP16/18 key gene, reduce a viral infection and finally remove viruses. A pharmaceutical composition based on the siRNA molecule comprises a siRNA molecule and another molecule, including a siRNA molecule for inhibiting PD-1/PD-L1, a small molecule compound against a HPV infection, a therapeutic mRNA/neoantigen vaccine, and the like. The siRNA molecule and other anti-HPV drugs are coupled by means of a specific chemical bond to form a new coupled molecule, and the composition further includes a pharmaceutically acceptable polypeptide polymer nano-introduction carrier. In some embodiments, the carrier is a histidine-lysine polypeptide polymer nanocarrier.

48.20250263740NON-REPLICATING BOVINE INFECTIOUS LYMPHOMA VIRUS (BLV) AND CELLS FOR PRODUCING SAME

US - 21.08.2025

Clasificación Internacional C12N 15/86Nº de solicitud 18857565Solicitante THE UNIVERSITY OF TOKYOInventor/a Yoko AIDA

An object of the present invention is to provide a novel non-replicating bovine leukemia virus (BLV) and a producing cell thereof. According to the present invention, there is provided a bovine leukemia virus (BLV) in which at least a part of the function of a pol gene is deficient. Also, according to the present invention, there is provided a non-replicating BLV-producing cell comprising a gene of a BLV in which at least a part of the function of a pol gene is deficient. The present invention is advantageous in that it can provide a BLV vaccine which is highly immunogenic, and is highly safe without replicating in an infected subject.

49.20250262294VACCINE

US - 21.08.2025

Clasificación Internacional A61K 39/145Nº de solicitud 18032367Solicitante THE PIRBRIGHT INSTITUTEInventor/a Munir Iqbal

The present invention relates to a genetically engineered protein comprising: at least one binding domain which is capable of binding to a cell surface protein on an avian antigen presenting cell; and a) at least one antigenic polypeptide orb) at least one binding domain which is capable of binding to at least one antigenic polypeptide. The present invention also relates to avian vaccines comprising at least one binding domain which is capable of binding to a cell surface protein on an avian antigen presenting cell; and a) at least one antigenic polypeptide or b) at least one binding domain which is capable of binding to at least one antigenic polypeptide and to the use of such vaccines to treat and/or prevent disease in avian subjects.

50.WO/2025/179112IMMUNOGENIC COMPOSITIONS FOR THE PREVENTION OF HERPES ZOSTER

WO - 28.08.2025

Clasificación Internacional A61K 39/25Nº de solicitud PCT/US2025/016744Solicitante CUREVO, INC.Inventor/a DE LA ROSA, Guy, R.

The present disclosure provides immunogenic and vaccine compositions comprising a Varicella Zoster Virus (VZV) glycoprotein E (gE) antigen comprising SEQ ID NO: 2 and an SLA adjuvant for use in the prevention of herpes zoster.

51.20250268997A SUBUNIT CRYPTOCOCCUS VACCINE

US - 28.08.2025

Clasificación Internacional A61K 39/00Nº de solicitud 18705007Solicitante University of MassachusettsInventor/a Stuart Levitz

Provided herein are subunit vaccines against *Cryptococcus.*

52.20250270656METHODS AND SYSTEMS FOR DEVELOPING PERSONALIZED VACCINE BY IDENTIFICATION AND PRIORITIZATION OF MUTATION-DERIVED NEOANTIGENS

US - 28.08.2025

Clasificación Internacional C12Q 1/6886Nº de solicitud 19205975Solicitante Personal Genome Diagnostics Inc.Inventor/a Victor Velculescu

Cancer immunology provides promising new avenues for cancer treatment but validation of potential neoantigens to target is costly and expensive. Analysis of MHC binding affinity, antigen processing, similarity to known antigens, predicted expression levels (as mRNA or proteins), self-similarity, and mutant allele frequency, provides screening method to identify and prioritize candidate neoantigens using sequencing data. Methods of the invention thereby save time and money by identifying the priority candidate neoantigens for further experimental validation.

53.4605412VERFAHREN ZUR HERSTELLUNG REKOMBINANTER TRANSFERRINBINDENDER PROTEINE UND IMPFSTOFFZUSAMMENSETZUNGEN DAMIT

EP - 27.08.2025

Clasificación Internacional C07K 14/22Nº de solicitud 23805182Solicitante SERUM INST OF INDIA PVT LTDInventor/a KARALE ABHIJEET JAGANNATH

The present disclosure relates to manufacturing transferrin binding proteins. Specifically, the present disclosure relates to a simple, scalable, commercially viable fermentation and purification process for obtaining recombinant transferrin binding protein (rTbp-B) along with high recovery, low impurity/ aggregate content, and at the same time retains the integrity of the protein. The method uses a single chromatographic step and does not require tagging of proteins as compared to multiple chromatographic steps used previously and still manages to provide r-Tbp-B with at least 95 % purity.

54.824465PREFUSION-STABILIZED HMPV F PROTEINS

NZ - 29.08.2025

Clasificación Internacional A61K 39/155Nº de solicitud 824465Solicitante BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventor/a MCLELLAN, Jason

Provided herein are engineered hMPV F proteins. In some aspects, the engineered F proteins exhibit enhanced conformational stability and/or antigenicity. Methods are also provided for use of the engineered F proteins as diagnostics, in screening platforms, and/or in vaccine compositions.

55.20250262287ARTHROSPIRA PLATENSIS ORAL VACCINE DELIVERY PLATFORM

US - 21.08.2025

Clasificación Internacional A61K 39/015Nº de solicitud 19202734Solicitante Lumen Bioscience, Inc.Inventor/a James ROBERTS

The present disclosure provides oral antigenic compositions comprising a recombinant Spirulina comprising at least one exogenous antigenic epitope. Oral antigenic compositions of the present disclosure can be used as vaccines. Oral antigenic compositions of the present disclosure can be used to induce a protective immune response to infectious microorganism, tumor antigens, or self-antigens.

56.20250270298MULTIVALENT ANTI-CAMPYLOBACTER ANTIBODIES AND VACCINE

US - 28.08.2025

Clasificación Internacional C07K 16/12Nº de solicitud 18692967Solicitante BiomEdit, LLCInventor/a Arvind Kumar

One or more antibodies, particularly nanobodies or VHH single domain antibodies, directed against one or more *Campylobacter* bacteria targets with roles in *Campylobacter* colonization, particularly *Campylobacter jejuni*, in animals, particularly in poultry are provided. The nanobodies are useful in reducing or blocking *Campylobacter* colonization or infection. The invention provides methods for reducing or blocking *Campylobacter* colonization or infection, for improving food safety, and for reducing bacterial gastroenteritis in animals, including humans.

57.4604992IMPFSTOFF

EP - 27.08.2025

Clasificación Internacional A61K 39/09Nº de solicitud 23793721Solicitante GLAXOSMITHKLINE BIOLOGICALS SAInventor/a GOMES MORIEL DANILO

The present invention relates to compositions comprising at least one Group A Streptococcus antigen, an aluminium salt and (a) a TLR7 agonist, or (b) a benzonapthyridine compound. The present invention further relates to methods of making an immunogenic composition comprising at least one antigen, an aluminium salt and (a) a TLR7 agonist, and/or (b) a benzonapthyridine compound. The present invention also relates to vaccines comprising the compositions, and methods of using and uses of the compositions.

58.0002845642VACCINE FORMULATIONS AGAINST CORONAVIRUS

RU - 25.08.2025

Clasificación Internacional C07K 16/10Nº de solicitud 2022122879SolicitanteInventor/a СМИТ, Гейл (US)

FIELD: biotechnology. SUBSTANCE: described is, different from naturally occurring spike (S) glycoprotein of coronavirus 2 associated with acute respiratory syndrome of transient development (SARS-CoV-2), where different from the naturally occurring S-glycoprotein SARS-CoV-2 contains: (i) an inactivated furin cleavage site; and (ii) proline at amino acid positions 973 and 974; where the amino acids are numbered in accordance with SEQ ID NO: 2. Described is nucleic acid which codes glycoprotein. Presented is a host cell containing vectors with nucleic acid for glycoprotein expression. Disclosed is an immunogenic composition containing: (a) glycoprotein; (b) an adjuvant; and (c) a pharmaceutically acceptable buffer; immunogenic composition containing: (a) a nanoparticle comprising glycoprotein and a core comprising a non-ionic detergent; (b) an adjuvant; and (c) a pharmaceutically acceptable buffer. Disclosed is a method for stimulating the immune response against SARS-CoV-2 in a human, comprising administering a glycoprotein or an immunogenic

composition to the human. EFFECT: invention widens the range of agents for stimulating the immune response against SARS-CoV-2 in humans. 36 cl, 46 dwg, 5 tbl, 8 ex

59.WO/2025/172883PROCESS FOR THE PURIFICATION OF OMVS FROM GRAM-NEGATIVE BACTERIA, AND RELATIVE USES

WO - 21.08.2025

Clasificación Internacional C07K 14/22Nº de solicitud PCT/IB2025/051536Solicitante DI CIOCCIO, VitoInventor/a DI CIOCCIO, Vito

The present invention relates to a process for the purification of vesicles released from the outer membrane (OMVs) of Gram-negative bacteria, the OMVs thus obtained and their relative uses as antigen carriers in vaccine formulations and as a system for conveying the administration of molecules for therapeutic applications.

60.4601683GEGEN GRUPPE-B-STREPTOCOCCUS (GBS) GERICHTETER MAP-IMPFSTOFF

EP - 20.08.2025

Clasificación Internacional A61K 39/02Nº de solicitud 23878304Solicitante CHILDRENS MEDICAL CT CORPInventor/a THOMPSON CLAUDETTE

Technologies for the prevention and/or treatment of GBS infections. The technology relates to compositions, including vaccines compositions and methods comprising an immunogenic complex that is a GBS multiple antigen presenting system (MAPS-GBS), where two or more biotinylated GBS polysaccharide antigens are joined together by non-covalent associations with one or more bifunctional fusion proteins comprising, in any order, (i) a sialic acid binding protein (SBD), a GBS polypeptide antigen and (iii) a biotin-binding moiety (BBD), thereby facilitating the linking of multiple GBS polysaccharide antigens together in the complex to form a MAPS-GBS immunogenic complex. The polysaccharide antigens that are linked can be on the same polysaccharide macromolecule or on distinct polysaccharide macromolecules.

61.4606817HERSTELLUNG UND ANWENDUNG VON FLAGELLINIMMUNPOTENZIERENDEN DERIVATEN MIT TLR5-AKTIVITÄT UNTER VERWENDUNG EUKARYOTISCHER ZELLEXPRESSIONSSYSTEME

EP - 27.08.2025

Clasificación Internacional C07K 14/28Nº de solicitud 23879958Solicitante UNIV NAT CHONNAM IND FOUNDInventor/a RHEE JOON HAENG

The present invention relates to the manufacture and application of flagellin immunopotentiating derivatives with TLR5 activity using an eukaryotic cell expression system. The flagellin derivative according to the present invention has a high immunostimulatory effect and can be used in various vaccine and immunotherapy compositions.

62.823890RSV F VACCINE FORMULATIONS

NZ - 29.08.2025

Clasificación Internacional A61K 39/155Nº de solicitud 823890Solicitante Novavax, Inc.Inventor/a TIAN, Jing-Hui

Disclosed herein are RSV F glycoproteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

63.202502690002CTA VACCINE CASSETTES

US - 28.08.2025

Clasificación Internacional A61K 39/00Nº de solicitud 19044124Solicitante Gritstone Bio, Inc.Inventor/a Karin Jooss

Disclosed herein are compositions that include antigen-encoding nucleic acid sequences having multiple iterations of CTA epitope-encoding sequences or Cancer Testis Antigen (CTA)-encoding nucleic acid sequences and KRAS-encoding nucleic acid sequences. Also disclosed are nucleotides, cells, and methods associated with the compositions including their use as vaccines.

64.202502690004ENTEROCOCCUS FAECALIS VACCINE AND USES THEREOF

US - 28.08.2025

Clasificación Internacional A61K 39/09Nº de solicitud 18857949Solicitante Vaxcyte, Inc.Inventor/a Jeffery C. Fairman

The present disclosure provides immunogenic compositions comprising at least one recombinant polypeptide antigen derived from an *Enterococcus* bacterium (e.g., *E. faecalis, E. faecium, E. durans*). The disclosure further provides methods, and uses of the immunogenic compositions, for protecting or treating a subject from infection by an *Enterococcus* bacterium. Such infections may cause, or worsen, conditions such as root canal failure, endocarditis, bacteremia, urinary tract infections, prostatitis, intraabdominal infection, cellulitis, dysbiotic gastrointestinal tract, prosthetic joint infection, or wound infections.

65.824300NUCLEIC ACID MOLECULES

NZ - 29.08.2025

Clasificación Internacional A61K 39/12Nº de solicitud 824300Solicitante ASTRAZENECA ABInventor/a LOO, Yueh-Ming

The present disclosure relates to a nucleic acid molecule comprising 5'-UTR and/or 3'-UTR sequences that yield high translation levels. Aspects of the disclosure further relate to nucleic acid molecules suitable for use as a vaccine in the treatment and prevention of infectious diseases, including those caused by a coronavirus, compositions comprising said nucleic acid molecules and methods of treating or preventing infectious diseases.

66.202502644467NOVEL HCV NUCLEIC ACIDS AND ENCODED GLYCOPROTEIN ANTIGENS AND METHODS

US - 21.08.2025

Clasificación Internacional G01N 33/569Nº de solicitud 19053963Solicitante Purdue Research FoundationInventor/a Devika Sirohi

The present disclosure provides for novel nucleic acid constructs and methods for expressing HCV E2 protein on a cell surface as an active antigen. The present disclosure provides for a method for evaluation of protein expression. Vaccine formulations, constructs and expression vectors are all within the scope of this disclosure.

67.20250269035INHALABLE LIPID NANOPARTICLE, LIPID-CHARGED MOLECULE CONJUGATE, AND LIPID-ZWITTERIONIC MOLECULE CONJUGATE

US - 28.08.2025

Clasificación Internacional A61K 47/54Nº de solicitud 19205101Solicitante INSTITUTE OF CHEMISTRY, CHINESE ACADEMY OF SCIENCESInventor/a Xueguang LU

Disclosed herein are a lipid-charged molecule conjugate, an inhalable lipid nanoparticle, a preparation method therefor, and use thereof. The lipid-charged molecule conjugate of the present invention comprises a lipid unit and a charged unit. The charged unit is selected from a negative charge unit and/or a positive charge unit. The lipid nanoparticle of the present invention comprises an ionizable lipid, an auxiliary phospholipid, cholesterol, a pegylated lipid, and the lipid-charged molecule conjugate. After the lipid nanoparticle of the present invention is administered by means of atomization inhalation, the anti-atomization stability of the lipid nanoparticle and the nucleic acid delivery efficiency are improved. When the lipid nanoparticle was used to encapsulate mRNA vaccine, inhaled mRNA-LNP can activate humoral, cellular, and mucosal immune responses.

Patentes registradas en United States Patent and Trademark Office (USPTO)

Estrategia de búqueda: *vaccine.ti. AND @PD>="20250817"<=20250831 18 records*

Document ID	Title	Inventor	Applicant Name
US 20250270656 A1	METHODS AND SYSTEMS FOR DEVELOPING PERSONALIZED VACCINE BY IDENTIFICATION AND PRIORITIZATION OF MUTATION-DERIVED NEOANTIGENS	Victor et al	Personal Genome Diagnostics Inc.
US 20250269009 A1	VACCINE COMPOSITION FOR NOVEL CORONAVIRUS INFECTION,HOU	Baidong	"RONGSEN BIOTECHNOLOGY (BEIJING) CO., LTD,INSTITUTE OF BIOPHYSICS, CHINESE ACADEMY OF SCIENCES"

US 20250257101 A1	Filovirus Consensus Antigens, Nucleic Acid Constructs and Vaccines Made Therefrom, and Methods of Using Same	Weiner; David B. et al.	The Trustees of the University of Pennsylvania,THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY,Inovio Pharmaceuticals, Inc.
US 20250259721 A1	DIGITAL VACCINE SYSTEM, METHOD AND DEVICE	Kaput; James et al.	VYDIANT, INC
US 20250255949 A1	STREPTOCOCCUS SUIS VACCINE COMPOSITION COMPRISING IMMUNOGENIC FUSION POLYPEPTIDES	Frosth; Sara et al.	Intervacc AB
US 20250255946 A1	LOW-DOSE NEOANTIGEN VACCINE THERAPY	Jooss; Karin et al.	Gritstone bio, Inc.
US 20250255954 A1	STABILIZED SPIKE PROTEIN AND METHOD OF USE THEREOF AS A CORONAVIRUS DISEASE 2019 (COVID-19) VACCINE	Wu; Yuanhan et al.	Wu; Yuanhan,Walker; Susanne,Kulp; Daniel,The Wistar Institute of Anatomy and Biology
US 20250255944 A1	IMMUNOACTIVATOR, VACCINE ADJUVANT, AND METHOD FOR INDUCING IMMUNITY	SUZUKI; Ryo et al.	TEIKYO UNIVERSITY
US 20250255948 A1	PNEUMOCOCCAL CONJUGATE VACCINES AND METHODS OF USE THEREOF	Buchwald; Ulrike K. et al.	Merck Sharp & Dohme LLC
US 20250255952 A1	SELF-AMPLIFYING mRNA VACCINE BASED ON Z7 GENOME	Bai; Fengwei et al.	Bai; Fengwei,Huang; Faqing
US 12383612 B2	Vaccine to protect a pig against Actinobacillus pleuropneumoniae	Witvliet; Maarten Hendrik et al.	Intervet Inc.

US 12383609 B2	Plasmodium sporozoite NPDP peptides as vaccine and target novel malaria vaccines and antibodies binding to	Lanzavecchia; Antonio et al.	INSTITUTE FOR RESEARCH IN BIOMEDICINE,SEATTLE CHILDREN'S HOSPITAL,SCHWEIZERISCHES TROPEN—UND PUBLIC HEALTH-INSTITUT
US 12383610 B2	Vaccine for protection against Streptococcus suis serotype 9, sequence type 16	Jacobs; Antonius Arnoldus Christiaan	Intervet Inc.
US 12383616 B2	Recombinant herpes zoster vaccine composition and application thereof	Shi; Li et al.	IMMUNE-PATH BIOTECHNOLOGY (SUZHOU) CO., LTD.
US 20250249090 A1	NEW FELINE HERPES VIRUS VACCINE	Visek; Callie Ann et al.	Boehringer Ingelheim Vetmedica GmbH
US 20250249088 A1	THERAPEUTIC AND VACCINE CANDIDATES AGAINST SARS-CoV-2	MUTHUMANI; Kar	GENEONE LIFE SCIENCE, INC.
US 20250249087 A1	CONSTRUCTION OF NOVEL HUMAN INFLUENZA VIRUS VACCINE AND APPLICATION	TAN; Yeping et al.	Wuhan JinYiTai Biological Co., Ltd.
US 12377140 B2	Multivalent pneumococcal vaccines	Besin; Gilles R. et al.	Affinivax, Inc.

Edición: Annia Ramos Rodríguez *aramos@finlay.edu.cu*
Randelys Molina Castro *rmolina@finlay.edu.*
Claudia Camejo Salas *ccamejo@finlay.edu.cu*
Yamira Puig Fernández *yamipuig@finlay.edu.cu*

FINLAY EDICIONES